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One of the major complications of minimal change nephrotic syndrome (MCNS) 
is hypercholesterolemia. In non-MCNS experimental rat models of NS, 
hypercholesterolemia is associated with abnormalities in hepatic cholesterol 
metabolism, and is postulated to be secondary to massive proteinuria. Our 
laboratory has established an IL-13 gene overexpression rat model of MCNS, a 
Th2 cytokine model similar to that in human disease, where hypercholesterolemia 
correlated significantly only with serum IL-13 levels, and appeared to precede the 
development of proteinuria. We therefore hypothesized that hypercholesterolemia 
in MCNS was primarily due to dysregulation of cholesterol homeostasis, 
mediated by the direct action of Th2 cytokines, and not solely a consequence 
secondary to the accompanying proteinuria. 
 
The aims of this study were firstly to profile the molecular events in the liver of 
the IL-13 transfected nephrotic rats using cDNA microarray to identify 
differentially expressed genes (DEGs); secondly to perform a comparative 
analysis of the gene expression profile of hepatic cholesterol metabolism at the 
onset of hypercholesterolemia in the pre-proteinuric phase (early event, termed as 
HC rats) and the nephrotic phase (late event); lastly to validate the in vivo results 
in rat primary hepatocyte culture. 
 
RNA from the liver of control and IL-13 transfected nephrotic rats were reverse 
transcribed and hybridized on Sentrix® BeadChip Array RatRef-12 v1. DEGs 
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were selected based on fold change ≥1.5 and FDR <0.05 and pathway analysis 
was performed using DAVID. Plasma IL-13, albumin, creatinine, total cholesterol 
and urine albumin excretion levels were assayed weekly. Hepatic cholesterol was 
extracted using hexane:isopropanol or Bligh-Dyer method, and quantified using 
enzymatic colorimetric assay or LC/MS respectively. Hepatocyte cholesterol 
efflux via ABCA1 and ABCG5 were measured using apoA-I and taurocholate as 
cholesterol acceptors respectively. The role of LXRa in IL-13-induced 
hypercholesterolemia was studied using LXRa-knockdown in rat primary 
hepatocytes. Gene and protein expressions of key molecules were studied using 
qPCR and Western blot respectively. 
 
Pathway analysis of DEGs identified ‘ABC transporters’ as the most relevant 
pathway in cholesterol metabolism, of which ABCG5 expression showed the 
greatest downregulation in the IL-13 transfected nephrotic rats, and was 
associated with HMGCR upregulation. 
 
Weekly biochemical profiling of our IL-13 transfected rats showed that plasma 
cholesterol was significantly elevated from Week 1 onwards and preceded the 
onset of significant proteinuria. Study of these HC rats (early event) showed 
reduced ABCG5, accompanied by downregulation of ABCA1, LXRa and RXRa. 
Moreover, LXRa correlated inversely with plasma cholesterol, suggesting the role 




IL-13-stimulated rat primary hepatocytes showed downregulation of HMGCR, 
LXRa, RXRa and ABCA1, accompanied by reduced ABCG5- and ABCA1-
mediated cholesterol efflux. Knockdown of LXRa in hepatocytes diminished 
T0901317-induced ABCG5 and ABCA1 expressions. 
 
In summary, the hypercholesterolemia observed in HC rats (early event) could be 
due to the downregulation of LXRa-ABCG5/ABCA1 pathway with reduced 
cholesterol efflux into bile canaliculi, resulting in increased intracellular free 
cholesterol. This could further inhibit hepatic uptake of cholesterol, leading to 
hypercholesterolemia. Late event hypercholesterolemia in the IL-13 transfected 
nephrotic rats could possibly be enhanced by the hepatic upregulation of HMGCR 
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Chapter 1 Introduction 
1.1. Nephrotic syndrome 
Nephrotic syndrome is characterized by massive proteinuria, hypoalbuminemia, 
edema and hypercholesterolemia. In children, idiopathic nephrotic syndrome 
(INS) is an important cause of morbidity amongst the childhood glomerular 
diseases both in Singapore and worldwide (Woo et al., 2010; Yap et al., 1990; 
Yap et al., 1989). 
 
1.1.1. Etiology of nephrotic syndrome 
The etiology of nephrotic syndrome is usually age-dependent, and can be 
attributed to a primary or secondary cause. Primary causes of nephrotic syndrome 
can be either immunological or genetic. 
 
Nephrotic syndrome presenting in the first three months of life is known as 
congenital nephrotic syndrome (CNS), and is primarily due to mutations in genes 
coding for podocyte slit diaphragm proteins such as podocin and nephrin, and 
transcriptional regulator in kidney development such as Wilms’ tumor 1. CNS can 
also be due to multi-systemic syndromes such as Pierson syndrome, as well as 
congenital infections such as syphilis or cytomegalovirus. 
 
Between the ages of 1 and 10 years, the majority of childhood nephrotic 
syndrome are idiopathic in nature. The proportion of secondary nephrotic 
syndrome due to underlying diseases such as systemic lupus erythematosus, 
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diabetic mellitus, viral infections (human immunodeficiency virus (HIV), 
hepatitis B and C), drug exposures and allergies, increases beyond the first decade 
of life (Gbadegesin and Smoyer, 2008). 
 
1.1.2. Classification and epidemiology of nephrotic syndrome 
Idiopathic nephrotic syndrome can be classified histologically into minimal 
change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS), 
membranoproliferative glomerulonephritis (MPGN), mesangial proliferative 
glomerulonephritis (MsPGN) and membranous nephropathy (MN). MCNS is the 
most common histologic variant among children with INS (ISKDC, 1978). 
 
The annual incidence of nephrotic syndrome in most Western countries is 
estimated to range between 2 to 7 cases per 100,000 children, and the prevalence 
is about 16 cases per 100,000 children (Niaudet, 2004). Ethnicity, race and gender 
play a role in the pathogenesis of the disease. The incidence of nephrotic 
syndrome was reported to be six times higher in Asian than European children in 
the United Kingdom (Sharples et al., 1985). Hispanic and black patients were 
more predisposed to steroid-resistant nephrotic syndrome than white patients 
(Ingulli and Tejani, 1991). A higher occurrence of nephrotic syndrome was 
observed in boys than in girls with a ratio of 2:1, but this disparity was less 




Although the overall incidence of nephrotic syndrome has remained unchanged 
over the years, the histological pattern may be changing, with the incidence of 
FSGS reported to be on the rise in children and adults (Srivastava et al., 1999). In 
Singapore, there has been a significant increase in MCNS over the past three 
decades in adults (Table 1) (Woo et al., 2010). Similarly in Singapore children, a 
renal biopsy study in children with steroid-dependent and steroid-resistant 
nephrotic syndrome also showed that MCNS was the most common histological 
pattern, although in this group of children, FSGS was also an important 
underlying cause of INS (Yap et al., 1989). 
 

















Minimal change nephrotic syndrome 18% 29% 30% <0.001 0.78 
Focal segmental glomerulosclerosis 10% 7% 13% <0.05 <0.03 
Focal global sclerosis 14% 19% 4% <0.001 <0.001 
Mesangial proliferative glomerulonephritis 33% 15% 8% <0.001 <0.02 
IgA nephritis 14% 17% 24% <0.002 <0.05 
Membranous nephropathy 8% 12% 19% <0.001 <0.04 
Crescenteric glomerulonephritis 1% <1% <1% 0.85 0.67 
Others 2% 1% 2% 0.86 0.1 
Total 100% 100% 100%   
 
 
1.1.3. Treatment for nephrotic syndrome 
Administration of prednisone, a corticosteroid, is usually initiated in all newly 
diagnosed cases of nephrotic syndrome to achieve remission, after allowing time 
for spontaneous remission of nephrotic syndrome and elimination of other 
underlying factors such as occult infections. The consensus treatment starts with a 
daily induction of 60mg/m2/day of prednisone for six weeks, followed by 
40mg/m2/day of prednisone on alternate days for another six weeks. Prednisone 
4 
 
may be stopped or slowly tapered over a variable period of time (Gipson et al., 
2009; Lombel et al., 2013). An estimated 80% of nephrotic children enter into 
remission with corticosteroids, but up to 70% experience frequent relapses or 
become dependent on steroids to remain in remission (Gbadegesin and Smoyer, 
2008; Koskimies et al., 1982).  
 
Based on response to corticosteroids, nephrotic patients are classified into having 
(i) steroid-sensitive nephrotic syndrome (SSNS), patients who respond to 
corticosteroids with complete remission; (ii) steroid-resistant nephrotic syndrome 
(SRNS), patients who fail to go into remission after eight weeks of corticosteroid 
therapy; (iii) frequently relapsing nephrotic syndrome (FRNS), patients who 
respond to corticosteroids with remission for several weeks upon discontinuation 
of therapy but later relapse four or more times in a year; (iv) steroid-dependent 
nephrotic syndrome (SDNS), patients who respond to corticosteroids with 
remission but relapse while still receiving treatment or within two weeks after 
discontinuation of treatment, hence requiring constant low-dosage of steroids to 
prevent relapse (Gbadegesin and Smoyer, 2008). 
 
In patients with FRNS and SDNS, steroid-sparing agents are often used to reduce 
the risk of relapse and lessen steroid-induced side effects, such as levamisole, 
cyclophosphamide, chlorambucil and cyclosporine. In patients with SRNS, 
intensive immunosuppressive treatments are used often in combination, such as 
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high-dose pulse methylprednisolone, cyclosporine, tacrolimus, mycophenolate 
mofetil and rituximab to achieve remission (Niaudet and Boyer, 2009). 
 
Prolonged courses of corticosteroid treatment and alternative immunosuppressive 
agents may result in adverse side effects such as growth retardation, behavior 
disturbances, obesity, hypertension, cataracts, osteopenia and nephrotoxicity 
(Niaudet, 2004). 
 
1.2. Hypercholesterolemia in nephrotic syndrome 
One of the major pathological complications of nephrotic syndrome is 
hypercholesterolemia, the elevation of cholesterol level in the blood.  
 
Although the majority of the children with nephrotic syndrome respond to 
corticosteroids, approximately 70% would experience one or more relapses 
(Gbadegesin and Smoyer, 2008; Koskimies et al., 1982). Children with FRNS 
will be exposed to prolonged periods of hypercholesterolemia. Similarly, in 
patients with SRNS, hypercholesterolemia is persistent (Merouani et al., 2003; 
Querfeld et al., 1988; Tsukahara et al., 1997). 
 
Prolonged hypercholesterolemia not only increases the risk of atherosclerosis 
development leading to cardiovascular morbidity and mortality in the long term 
(Ordonez et al., 1993; Querfeld, 1999), but also progressive glomerular damage 
leading to renal failure (Keane et al., 1991; Moorhead et al., 1982). Even during 
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remission of nephrotic syndrome with resolution of proteinuria, 
hypercholesterolemia can still remain unabated (Merouani et al., 2003; Strauss et 
al., 1987; Zilleruelo et al., 1984).  
 
Treatment with lipid-lowering medication is often indicated in addition to steroid 
therapy, as serum cholesterol can reach as high as 20mmol/l. Lipid-lowering 
agent statins is the first-line drugs to be prescribed to control the 
hypercholesterolemia in nephrotic syndrome (European Association for 
Cardiovascular et al., 2011). Alternative agents such as bile acid sequestrants, 
ezetimibe or nicotinic acid are used in patients who are unable to tolerate statins. 
These drugs target directly on cholesterol metabolism or prevent the absorption of 
cholesterol and bile acids. 
 
The therapeutic effect of statins is not consistent in nephrotic patients, with a 
study reporting negative results in using rosuvastatin (De Backer et al., 2003; 
Kong et al., 2013). Coupled with insufficient validation of the efficacy of 
alternative agents in statin-intolerant nephrotic patients, the use of these lipid-
lowering agents in managing the severe hypercholesterolemia often seen in 
children with nephrotic syndrome could not be firmly established. Therefore it is 
imperative to elucidate the molecular mechanism in the hypercholesterolemia of 
nephrotic syndrome in order to develop targeted therapy to control the high level 




1.2.1. Cholesterol metabolism 
Cholesterol is a type of lipid, more specifically a steroid. It is an essential 
structural component within the plasma membrane which serves to regulate 
membrane fluidity, and also an important precursor in the synthesis of steroid 
hormones, bile acids and vitamin D. 
 
Due to its involvement in various biological functions, cholesterol homeostasis is 
essential and maintained by a series of regulatory pathways that control the 
synthesis of endogenous cholesterol, absorption of dietary cholesterol, elimination 
of excess cholesterol, and transportation of cholesterol in the blood. Any 
imbalance in cholesterol homeostasis would result in health complications, such 
as cardiovascular diseases. 
 
1.2.1.1.Regulation of cholesterol synthesis 
The liver serves as a major site for cholesterol synthesis, which begins with the 
formation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) from acetyl-CoA and 
acetoacetyl-CoA in the cytosol (Figure 1). Reduction of HMG-CoA to 
mevalonate marks the irreversible step in cholesterol formation, catalyzed by 
HMG-CoA reductase (HMGCR). Subsequent conversion of mevalonate to 
cholesterol involves multiple steps catalyzed by a multitude of enzymes. 
 
The rate-limiting enzyme HMGCR is partly involved in the main regulation of 
cholesterol biosynthesis. It is negatively regulated by its own end product 
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cholesterol, whereby increased intracellular free cholesterols bind to the sterol-
sensing domain in HMGCR, activating it for proteolytic degradation (Kuwabara 
and Labouesse, 2002). Statins lower blood cholesterol level by inhibiting 
HMGCR activity. 
 
The transcription of HMGCR is regulated by sterol regulatory element binding 
transcription factor 2 (SREBF2), which is generally involved in cholesterol 
biosynthesis. It binds to a DNA sequence known as sterol regulatory element 
(SRE) within the promoter region of HMGCR, as well as other genes containing 
SRE, to activate transcription (Eberle et al., 2004). Another crucial gene regulated 
by SREBF2 is the LDL receptor (LDLR), which facilitates the uptake of 
circulatory cholesterols into the liver. 
 
SREBF2 is synthesized as an integral membrane protein in the rough endoplasmic 
reticulum (ER). When intracellular cholesterol level is high, SREBF2 binds to 
SREBF chaperone (SCAP), which in turn binds to Insig, an anchor protein 
holding the SCAP-SREBF2 complex in the ER membrane. 
 
The sterol-sensing domain within SCAP allows it to function as a cholesterol 
sensor, such that when cellular cholesterol level is low, SCAP changes 
conformation and releases Insig, allowing the SCAP-SREBF2 complex to migrate 
to Golgi apparatus. SREBF2 is then cleaved by two membrane-bound proteases, 
site-1 protease (S1P) and site-2 protease (S2P), to release the active SREBF2, 
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which migrates into the nucleus, binds SRE of target genes and promotes 
transcription. When cellular cholesterol level returns to normal or is high, nuclear 
SREBF2 is rapidly degraded and SREBF2 activation is inhibited by SCAP 
binding SREBF2 and the retention of SCAP-SREBF2 complex in the ER. 
 
Hence, the synthesis of endogenous cholesterol is mostly regulated by cholesterol 
itself through SREBF2, which in turn regulates the transcription of HMGCR and 




Figure 1: Regulation of cholesterol synthesis in the hepatocyte. 
SREBF2 regulates the transcription of HMGCR and LDLR, whereby HMGCR catalyzes the rate-
limiting step of HMG-CoA to mevalonate, and LDLR binds to LDL-cholesterol in the blood for 
endocytosis into the cell. ACAT2 esterifies intracellular free cholesterols to cholesteryl esters for 




1.2.1.2.Regulation of cholesterol elimination 
Significant elimination of excess cholesterol from the body takes place in the 
liver, and occurs mainly via two pathways (Figure 2). The first is the conversion 
of excess cholesterols to bile acids, which are then excreted into the bile duct. 
Cholesterol 7-alpha hydroxylase (CYP7A1) catalyzes the first and only rate-
limiting step in bile acid synthesis (Shefer et al., 1970). The second pathway 
involves the excretion of free cholesterols directly into the bile canaliculi (BC), 
facilitated by ATP-binding cassette, sub-family G, member 5 (ABCG5) and ATP-
binding cassette, sub-family G, member 8 (ABCG8). Both ABCG5 and ABCG8 
are half transporters that dimerize to form a functional transporter in the 
canalicular membrane of the hepatocyte (Graf et al., 2003). 
 
Extrahepatic cells such as macrophages remove surplus intracellular cholesterols 
via the membrane transporter ATP-binding cassette, sub-family A, member 1 
(ABCA1) into plasma high density lipoproteins (HDL) to be brought back to the 
liver for elimination, a process known as reverse cholesterol transport (RCT). 
However, ABCA1 in the liver is identified as the rate-limiting factor in the 
biogenesis of HDL. Hepatic ABCA1 mediates the efflux of cholesterols and 
phospholipids to lipid-poor apolipoproteins A-I, which combine to form plasma 
HDL (Fitzgerald et al., 2010; Lee and Parks, 2005). 
 
The transcription of ABCA1, ABCG5, ABCG8 and CYP7A1 are collectively 
regulated by liver X receptor (LXR), a transcription factor known to induce the 
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expression of genes involved in cholesterol catabolism, efflux and elimination, 
hence protecting the cells from cholesterol overload (Chiang et al., 2001; Repa et 
al., 2002; Schwartz et al., 2000). 
 
The accumulation of cellular oxysterols formed from excess cholesterols induces 
the activation of LXR, which functions as a sterol sensor (Lehmann et al., 1997). 
Upon activation, LXR recruits retinoid X receptor (RXR) to form an obligate 
heterodimer and binds to a regulatory DNA sequence known as LXR response 
element (LXRE) in the promoter region of target gene (Willy et al., 1995). 
 
There are two isoforms of LXR, of which the expression of LXR alpha (LXRa) is 
predominantly restricted to tissues known to play important roles in lipid 
metabolism such as the liver, kidney, intestine, adipose tissue, lung, spleen and 
macrophages, whereas LXR beta (LXRb) is ubiquitously expressed (Repa and 
Mangelsdorf, 2000; Teboul et al., 1995; Willy et al., 1995). 
 
Although these two isoforms are highly related, sharing almost 80% identity in 
the amino acid sequences in both their DNA- and ligand-binding domains, studies 
have shown that LXRa participates more actively in the regulation of hepatic 
cholesterol metabolism. When challenged with a high cholesterol diet, LXRa-
knockout mice were unable to maintain cholesterol homeostasis, consequently 
accumulating large amount of liver cholesterols with hypercholesterolemia. 
Despite the presence of intact LXRb in the liver of these mice, it was not able to 
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compensate for the absence of LXRa (Peet et al., 1998). Conversely, LXRb-
knockout mice with intact LXRa retained normal hepatic cholesterol metabolism 
and were able to adapt to cholesterol-rich diet (Alberti et al., 2001). LXRa is also 
more involved than LXRb in regulating LXR target gene expression as shown by 
LXRa binding LXRE in CYP7A1 with a substantially higher affinity than LXRb 
(Lehmann et al., 1997). When challenged with a high cholesterol diet, the 
expression of hepatic ABCG5/G8 was decreased in LXRa-knockout mice, 
whereas in LXRb-knockout mice, ABCG5/G8 expression was still maintained, 
demonstrating the sterol-induced upregulation of ABCG5/G8 required LXRa 
(Repa et al., 2002). Recently, Ma et al. reported that the maintenance of 
cholesterol efflux was predominantly mediated by the LXRa isoform but not 
LXRb (Ma et al., 2014). 
 
The greater specificity of LXRa response in cholesterol metabolism may be due to 
a greater amount of LXRa than LXRb in the liver (Repa and Mangelsdorf, 2000), 
and that LXRa essentially exhibits a higher activity than LXRb in activating its 
target genes (Peet et al., 1998). 
 
Hence, LXRa plays a more dominant role in preventing the accumulation of 
excess cholesterols within the cell by activating the transcription of genes which 





Figure 2: Regulation of cholesterol elimination in the hepatocyte. 
LXRa dimerizes with RXRa to initiate transcription of ABCA1, ABCG5, ABCG8 and CYP7A1. 
Basolateral ABCA1 transports cholesterols and phospholipids out of the hepatocyte to combine 
with apoA-I to form plasma HDL. Heterodimer ABCG5/G8 excretes excess cellular free 
cholesterols into the bile canaliculus (BC) for elimination. CYP7A1 catalyzes the rate-limiting 
step in bile formation involved in cholesterol degradation. 
 
1.2.1.3.Regulation of cholesterol transport 
Due to the hydrophobic nature of cholesterol, lipoprotein particles are utilized to 
facilitate cholesterol transport in the blood (Figure 3). A lipoprotein particle 
consists of a nonpolar core of cholesteryl esters and triglycerides surrounded by 
an amphipathic shell of cholesterols, phospholipids and apolipoproteins (apo) 
which are principal protein components that contain cell-targeting signals. 
 
Besides de novo synthesis of cholesterol, cells also obtain cholesterol via dietary 
means. Dietary cholesterols, cholesteryl esters and triglycerides are transported 
away from the intestine and enter into the bloodstream in the form of lipoprotein 
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complexes called chylomicrons (CM), which function to deliver dietary 
triglycerides to the adipose tissue and skeletal muscles, and dietary cholesterols to 
the liver. They first adhere to binding sites on the inner surface of blood 
capillaries in adipose tissue and skeletal muscles. ApoC-II on the shell of CM 
activates lipoprotein lipase (LPL) on the blood capillaries, which hydrolyzes the 
triglycerides within CM and releases monoacylglyercols and free fatty acids 
(FFA) into the cells. CM shrinks as its triglycerides are progressively being 
hydrolyzed until it is cholesterol-enriched. The remaining molecule, known as a 
chylomicron remnant (CMR), is taken up by the liver via remnant receptors. 
 
When triglycerides and cholesterols taken up by the liver are in excess, they are 
exported back into the blood in the form of very low density lipoprotein (VLDL), 
stabilized by apoB-100, apoC-II and apoE. Triglycerides in VLDL are hydrolyzed 
by LPL on capillary surfaces, giving rise to intermediate density lipoprotein (IDL) 
rich in cholesteryl esters. IDL can either be taken up by the liver for processing or 
converted to low density lipoprotein (LDL) by the removal of more triglycerides 
and all apolipoproteins, except apoB-100. 
 
LDL is the major carrier of cholesterol in the blood. Peripheral cells generally do 
not synthesize their own cholesterol, but obtain it from plasma LDL. The presence 
of LDLR on the surface of peripheral cells binds to apoB-100 on LDL, forming a 
LDL-LDLR complex which is taken up by the cell via receptor-mediated 
endocytosis. The endocytosed LDL-LDLR vesicle fuses with another vesicle, 
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giving rise to an acidified endosome and triggering the dissociation of LDL from 
LDLR. LDLR is recycled back to the plasma membrane intact. The endosome 
with the LDL fuses with lysosomes containing acid lipases that hydrolyze LDL to 
liberate the free cholesterols which are subsequently incorporated into the 
membrane. 
 
Excess free cholesterols within the cell activate acyl CoA:cholesterol 
acyltransferase (ACAT), which catalyzes the intracellular esterification of free 
cholesterols to cholesteryl esters for storage within cell. Two isoforms of ACAT 
have been identified – ACAT1 is expressed in most tissues, whereas ACAT2 
(Figure 1) is primarily expressed in the liver and intestine (Oelkers et al., 1998). 
 
Circulating HDL removes the excess cholesterols within peripheral cells by first 
extracting cholesterols from cell surface membrane via ABCA1, followed by 
converting them to cholesteryl esters through the action of lecithin cholesterol 
acyltransferase (LCAT), an enzyme activated by apoA-I on HDL. HDL transports 
the cholesterols back to the liver upon binding to scavenger receptor class B type I 
(SR-BI) for recycling or excretion from the body. The lipid-depleted HDL then 
dissociates from the liver and re-enters circulation (Voet and Voet, 2011). 
 
The maintenance of lipoprotein metabolism is essential for appropriate amount of 
lipids to be circulated within the body for cellular use and removal. Pathway 
defects in lipoprotein synthesis, processing, and clearance could lead to 
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accumulation of atherogenic lipids in plasma and endothelium. Hence, regulation 
of lipoprotein metabolism is crucial to preserve cholesterol homeostasis. 
 
 
Figure 3: Lipoprotein metabolism and transport. 
Different apolipoproteins in the lipoproteins are depicted with circles in different colors. CM 
transports dietary lipids from intestine into the bloodstream, and is hydrolyzed by LPL in the 
capillary surface to give CMR. The released FFA is taken up by adipose tissue and skeletal 
muscles. CMR is taken up into the liver via remnant receptor. Excess lipids in the liver are 
secreted into the blood as VLDL, which is hydrolyzed by LPL to release FFA to peripheral cells. 
The remaining cholesterol-enriched IDL is either taken up by the liver via LDLR or further 
hydrolyzed to give LDL. Cells obtain cholesterols from LDL via LDLR present on their 
membrane. Excess LDL return to the liver via LDLR. Circulating HDL removes excess 
cholesterols from peripheral cells via ABCA1 and LCAT and returns to the liver via SR-BI. 
Adapted and modified from reference (Berg et al., 2012). 
 
1.2.2. Characteristics of hypercholesterolemia in nephrotic syndrome 
The elevation of plasma total cholesterol, specifically LDL-cholesterol, is the 
major lipid abnormality in MCNS, although hypertriglyceridemia may occur as 
the disease progresses (Thabet et al., 1993b). In addition, recent studies have 
shown elevation of IDL, VLDL and triglycerides with variable levels of HDL in 
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the dyslipidemia of nephrotic syndrome (DK et al., 2014; Kaysen and de Sain-van 
der Velden, 1999; Vaziri, 2003). 
 
Composition within the plasma lipoproteins is also altered in nephrotic syndrome, 
where the ratios of cholesterols to triglycerides, free cholesterols to cholesteryl 
esters, and phospholipids to protein are significantly higher in nephrotic subjects 
(Gherardi et al., 1977). Apolipoproteins are also dysregulated, with apoB in 
VLDL and LDL, and apoC-III involved in inhibiting lipolysis of VLDL and 
chylomicrons, significantly elevated in patients (Kaysen, 1991; Warwick et al., 
1990; Warwick et al., 1991). 
 
1.2.3. Causes and current knowledge of hypercholesterolemia in nephrotic 
syndrome 
Till now, the pathogenesis of hypercholesterolemia in nephrotic syndrome is still 
unknown. Studies to elucidate the molecular mechanisms triggering 
hypercholesterolemia in nephrotic syndrome have been mostly carried out in the 
puromycin aminonucleoside nephrosis (PAN) model in rats, a commonly used 
model for MCNS. 
 
Although the pathogenesis of nephrotic hypercholesterolemia is incompletely 
understood, in the experimental PAN rat model of nephrotic syndrome, 
hypercholesterolemia has been shown to be associated with abnormalities in 
hepatic cholesterol metabolism which involves the dysregulation of crucial 
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enzymes and transporters participating in cholesterol metabolism (Liang and 
Vaziri, 2003). 
 
The mRNA and activity of hepatic HMGCR were markedly upregulated during 
the induction phase of nephrotic syndrome in PAN rats, but tapered down to 
baseline levels during the chronic phase of nephrotic syndrome (Vaziri and Liang, 
1995), without any significant difference in the mRNA, protein and activity of 
HMGCR when compared to controls (al-Shurbaji et al., 1998; Kim et al., 2007). 
In contrast, Han et al. reported an increase in protein expression of HMGCR in 
the PAN rats (Han et al., 2013). This transient but significant rise in HMGCR 
could contribute to increased synthesis of cholesterol and lead to the initiation and 
maintenance of hypercholesterolemia in nephrotic syndrome. 
 
Despite the presence of hypercholesterolemia, CYP7A1 in PAN rats did not show 
any rise in its mRNA, protein abundance and activity in both the induction and 
chronic phases of nephrotic syndrome (Liang et al., 1996; Thabet et al., 1993a). 
This was in contrast to rats with diet-induced hypercholesterolemia, whereby their 
CYP7A1 was upregulated in a feedback mechanism. Bile secretion was also 
unchanged in PAN nephrotic rats (Pahl et al., 1998). Hence, PAN-induced 
hypercholesterolemia could be associated with the absence of a compensatory rise 




To account for the different responses of HMGCR and CYP7A1 in PAN-induced 
hypercholesterolemia and diet-induced hypercholesterolemia, hepatic cellular 
cholesterol levels were measured, because HMGCR and CYP7A1 are regulated 
by free cholesterol level. Diet-induced hypercholesterolemia displayed a 16-fold 
increase in hepatic cholesterol content whereas there was no increase in hepatic 
cholesterol level in the PAN nephrotic rats despite severe hypercholesterolemia 
(al-Shurbaji et al., 1998; Kim et al., 2007; Liang et al., 1996; Vaziri and Liang, 
1995; Zhou et al., 2008), which led to the investigation of hepatic LDLR. Vaziri 
and Liang reported a gradual downregulation of LDLR protein in the course of 
PAN nephrosis in rats (Vaziri and Liang, 1996), hence explaining the normal 
hepatic cholesterol level. Decreased LDLR might lead to decreased clearance of 
plasma LDL, and thus contributing to hypercholesterolemia in nephrotic 
syndrome. However, al-Shurbaji et al. reported no significant difference in 
hepatic LDLR protein expression between the PAN nephrotic rats and controls 
(al-Shurbaji et al., 1998). 
 
Hepatic SREBF2 protein expression in the PAN nephrotic rats showed no change 
across the microsomal, cytoplasmic and nuclear compartments in the cell (Han et 
al., 2013; Kim et al., 2007), which could explain the normal levels of intracellular 





There was also diminished level of plasma LCAT coupled with increase in 
urinary LCAT and downregulation of SR-BI, of which the former is required for 
HDL-mediated clearance of cellular cholesterols in peripheral cells and SR-BI to 
facilitate hepatic uptake of HDL, hence resulting in reduced clearance of 
cholesterol (Vaziri et al., 2001). 
 
Upregulation of ACAT2 activity was observed in the livers of nephrotic rats 
(Vaziri and Liang, 2002), indicating that a greater amount of intracellular free 
cholesterols was being esterified to cholesteryl esters to be stored within the cells, 
decreasing the availability of free cholesterols to inhibit HMGCR, which could 
result in the transient upregulation of HMGCR leading to increased cholesterol 
synthesis (Vaziri and Liang, 1995). 
 
These abnormalities in enzymes and transporters in cholesterol metabolism 
observed in PAN rats were not entirely related or solely due to the degree of 
hypoalbuminemia, a conclusion drawn from studies comparing Nagase 
analbuminemic rats (NAR) and PAN rats. Both strains of rats had very low to 
absence of serum albumin and hypercholesterolemia but only PAN rats had 
proteinuria. Moreover, PAN rats exhibited a more severe hypercholesterolemia 
profile than NAR rats. Hence it was postulated that these abnormalities in hepatic 





By comparing the protein expression and activity of crucial factors involved in 
cholesterol metabolism in NAR and PAN rats, LDLR and LCAT were severely 
reduced in PAN rats but normal in NAR rats. Although both PAN and NAR rats 
displayed ACAT2 upregulation, the increase was mild in NAR rats and attributed 
to the increase in liver free cholesterol, as opposed to the fourfold increase in 
PAN rats. This drastic increase occurred in the presence of a significant reduction 
in liver free cholesterol, suggesting a primary maladaptive phenomenon in 
nephrotic syndrome. This comparison between NAR and PAN rats suggested a 
predominant role of proteinuria in the onset of hypercholesterolemia in MCNS 
(Liang and Vaziri, 2003; Vaziri and Liang, 2002). 
 
Two distinct hypotheses have been put forth to establish the relationship between 
proteinuria and dysregulated lipid metabolism in nephrotic syndrome. The first 
hypothesis states that proteinuria causes reduced serum oncotic pressure, which 
then directly stimulates albumin synthesis, along with synthesis of all other liver-
derived exported proteins, including lipoproteins (Jones et al., 1967; Marsh and 
Drabkin, 1960). The second postulates that the loss of a lipid regulatory protein 
during proteinuria causes the defective removal of lipids from the circulation, 
resulting in a cascade of events leading to dysregulation of the enzymes and 
receptors in cholesterol metabolism (Davies et al., 1990; Staprans et al., 1980; 




However, until now, the definitive contribution of increased synthesis and 
decreased catabolism to hypercholesterolemia in nephrotic syndrome, and their 
mechanistic relationship to proteinuria remains unresolved. 
 
The PAN rat model of MCNS is achieved by intravenous injection of puromycin 
aminonucleoside (PA), an analog of the antibiotic puromycin classified as a drug 
and toxin. Administration of PA induces nephrosis by causing direct damage to 
the podocytes, giving rise to glomerular lesions consistent with human nephrotic 
syndrome and coupled with proteinuria, hypercholesterolemia, hypoalbuminemia 
and edema (Ryan and Karnovsky, 1975; Vernier et al., 1959). Additionally, PA 
has been reported to cause increased reactive oxygen species in isolated rat 
hepatocytes by activating the enzyme protein kinase C, and inhibit endogenous 
protein degradation at the level of autophagic sequestration (Aoyagi et al., 2000; 
Kovacs et al., 1981). Hence, the hypercholesterolemia observed in PAN rats could 
also be attributed to the direct toxicity of PA on the hepatocytes. 
 
The proteinuria achieved from using PA is reported to be different from the 
proteinuria observed in MCNS patients (Chugh et al., 2012). This, coupled with 
the toxic nature of PA and its direct damage to podocytes, questions the 





The hypercholesterolemia observed in patients with MCNS is different and more 
extreme when compared to the hypercholesterolemia in other diseases with 
similar protein losses such as peritoneal dialysis and chronic nephropathy. 
Patients with MCNS relapses have extremely high serum cholesterol, typically 10 
to 20mmol/l, up to four times the normal cholesterol level (Hu et al., 2010; 
Querfeld et al., 1988) as compared to hypercholesterolemia in peritoneal dialysis 
in which serum cholesterol rarely exceeds 7mmol/l (Johansson et al., 2000). 
During MCNS remission, the extremely high cholesterol levels often rapidly fall 
to normal levels of about 3 to 5mmol/l, whereas hypercholesterolemia in other 
diseases with comparable protein losses is often sustained and chronic. Also, in 
some patients with MCNS, hypercholesterolemia has been observed to precede 
the development of proteinuria. These clinical observations suggest that 
proteinuria alone could not account for the onset of severe hypercholesterolemia 
in MCNS, and that some other mediators involved in the pathogenic mechanism 
of MCNS could potentially also induce the hypercholesterolemia seen in this 
disease. 
 
1.3. Minimal change nephrotic syndrome 
Minimal change nephrotic syndrome, also known as minimal change disease or 
lipoid nephrosis, is the most common cause of nephrotic syndrome in childhood, 
affecting close to 80% of nephrotic children, as compared to 20-30% of nephrotic 




The glomeruli in MCNS appears normal under light microscopy, but shows the 
effacement of podocyte foot processes with absence of electron-dense immune 
deposits under electron microscopy (Mathieson, 2007). This podocyte effacement 
represents a permeability defect in the glomerular filtration barrier and is shown 
to be associated with proteinuria in MCNS (Mundel and Reiser, 2010; Mundel 
and Shankland, 2002). However, the pathogenic mechanism of MCNS is still 
largely unknown. 
 
With a wide variety of immunological abnormalities being described in and 
associated with MCNS, including in vivo and in vitro observations, the hypothesis 
that immunological dysregulation is the cause of MCNS has long dominated the 
scientific literature for decades, with most studies focusing on T cell function. 
 
1.3.1. Minimal change nephrotic syndrome and the immune system 
Minimal change nephrotic syndrome was first postulated to be a disorder of T cell 
function by Shalhoub in 1974 when he hypothesized that an abnormal expansion 
of a clone of T cells produced a circulating factor that disrupted the glomerular 
basement membrane of the kidneys, leading to increased permeability to urinary 
proteins (Shalhoub, 1974). His postulate was based on clinical observations that 
(i) the disease remitted with measles infection, whereby the measles virus 
suppressed cell-mediated immunity, (ii) patients were highly susceptible to 
pneumococcal infection, whereby the hypothesized expansion of T cell clones 
suppressed the production of antibodies against pneumococcal infection, (iii) 
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disease remission was induced with corticosteroids and cyclophosphamide, both 
known to be inhibitors of T cells, and (iv) the occurrence of MCNS in Hodgkin’s 
lymphoma, a T cell lymphoproliferative disorder. 
 
The absence of immune complexes in the glomeruli of patients with MCNS, 
coupled with the lack of morphological changes in the kidney suggest that MCNS 
represents a generalized disorder of the immune system resulting in renal 
manifestations, rather than a specific disease of the kidney itself. The dysfunction 
in T cells seen in active MCNS has been demonstrated in many studies, including 
distinct T cell subset abnormalities in children with relapsing MCNS (Fiser et al., 
1991), and the significant increase in percentage of CD4+CD45RO+ and 
CD8+CD45RO+ memory T cell subsets in INS children (Yan et al., 1998). 
Abnormalities in serum immunoglobulins (Ig) also occurred during MCNS 
relapses characterized by depressed IgG and elevated IgE (Cheung et al., 2004; 
Yokoyama et al., 1987). 
 
Persistent stimulation of nuclear factor-kB (NF-kB), a crucial regulator of 
cytokine expression, within the peripheral blood mononuclear cells (PBMCs) 
during MCNS relapse could contribute to the immunologic abnormalities in 
MCNS (Sahali et al., 2001). Subtractive cDNA library from T cell-enriched 
PBMCs in MCNS patients during relapse and remission identified a number of 
differentially expressed transcripts involved in various tightly coordinated steps of 
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T cell activation during relapse, supporting MCNS as a T cell-mediated disease 
(Sahali et al., 2002). 
 
The mechanism by which T cell dysregulation could increase glomerular 
permeability causing proteinuria in MCNS has remained elusive. The absence of 
inflammation, infiltration of immune cells and deposition of immunoglobulin or 
complement in the glomerulus alludes to the role of a soluble circulating factor 
mediating proteinuria. Supernatant from T cells of patients with MCNS when 
injected into rats caused immediate proteinuria and podocyte foot process 
effacement (Garin and Boggs, 1987; Koyama et al., 1991; Tanaka et al., 1992). 
Also, the dysregulation of T cell function, often manifested as T cell expansion, is 
often associated with increased synthesis of several cytokines, suggesting the role 
of cytokines as circulating factors involved in MCNS (Araya et al., 2006). 
 
1.3.2. Minimal change nephrotic syndrome and Th2 cytokine bias 
The role of cytokines in MCNS is postulated to involve a T helper (Th) type 2 
(Th2) cytokine predominance (Mathieson, 2003). Th2 cytokines, mainly 
comprising of interleukin- (IL-) 4, IL-5 and IL-13, are secreted by CD4+ Th cells. 
Th2 cytokines are anti-inflammatory, stimulate B cells to produce antibodies, 
primarily IgE, IgA and IgG4, promote eosinophil proliferation, and are 




The close association between MCNS and atopy support the underlying Th2 
predominance in the disease. There have been several reports on patients who 
developed nephrotic syndrome following exposure to allergens such as pollen or 
bee stings (Florido et al., 1992; Wittig and Goldman, 1970). Furthermore, the 
incidence of atopy was reportedly higher in MCNS patients than in healthy 
subjects (Lin et al., 1990; Yap et al., 1983). Elevation of IgE was also observed in 
MCNS relapse (Cheung et al., 2004).  
 
The expression of IL-12 receptor b2 subunit, which is exclusively expressed by 
Th1 cells to facilitate IL-12 signaling, was downregulated in the T cell-enriched 
PBMCs of MCNS relapse, along with increased expression of Th2 transcriptional 
regulator c-Maf and histamine-releasing factor which triggers IL-13 production 
by basophils (Sahali et al., 2002). Together with a lack of IL-12 production during 
MCNS relapse (Stefanovic et al., 1998), Th1 phenotype was suggested to be 
depressed, with the activated T cells of MCNS committed to a Th2 phenotype. IL-
4 was also found to be upregulated in the PBMCs from patients with MCNS, and 
this was associated with increased B-cell expression of the type II IgE receptor 
and high IgE production (Cho et al., 1999). 
 
Our laboratory was the first to demonstrate that IL-13 was upregulated in CD4+ 
and CD8+ T cells in patients with MCNS relapse (Yap et al., 1999). Moreover, 
the percentage of CD3+ cells producing IL-13 was significantly higher in children 
with nephrotic relapse, also correlating with the elevated serum IgE levels 
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observed during the active phase of the disease (Cheung et al., 2004). Our 
findings were consistent with the study of Kimata et al. which showed the 
importance of IL-13 in the spontaneous production of IgE and IgG4 by PBMCs in 
the nephrotic patients (Kimata et al., 1995). Furthermore, we were able to 
demonstrate that genetic polymorphisms in the 3’ untranslated region (3’UTR) of 
the IL-13 gene correlated with long-term outcome of MCNS in Singapore Chinese 
children, rather than disease susceptibility (Wei et al., 2005). These findings are 
consistent with the well-recognized association between MCNS and Hodgkin’s 
disease, where IL-13 is known to be an autocrine growth factor for the Reed-
Sternberg cell in Hodgkin’s lymphoma, being highly expressed in both the Reed- 
Sternberg cells in biopsy samples and tumor cell lines (Kapp et al., 1999; 
Skinnider et al., 2001; Skinnider et al., 2002). 
 
Our laboratory overexpressed IL-13 gene in rats, which subsequently developed 
proteinuria, hypoalbuminemia, edema and hypercholesterolemia, associated with 
minor abnormalities on light microscopy, and podocyte foot process effacement 
with downregulation of nephrin, podocin and dystroglycan (Lai et al., 2007), 
consistent with a possible role of IL-13 in MCNS. In addition, in this model of 
minimal change-like nephropathy, serum IL-13 level correlated with serum 
cholesterol, but not with serum albumin or urine albumin excretion, suggesting an 




1.4. Research hypothesis and scope of thesis 
The current hypothesis regarding the pathogenesis of nephrotic 
hypercholesterolemia is mainly derived from the PAN model of nephrotic 
syndrome in rats, where PA directly damages podocytes, without involvement of 
the immune system. On the other hand, our IL-13 gene overexpression rat model 
reflects more closely to the immunological Th2 cytokine pathogenesis of human 
MCNS, and is a more appropriate model to study the pathogenesis of 
hypercholesterolemia associated with the disease. 
 
We hypothesize that in relapse of MCNS, hypercholesterolemia is primarily due 
to dysregulation of cholesterol homeostasis, mediated by the direct action of Th2 
cytokines like IL-13, on pathways regulating cholesterol synthesis, elimination or 
transport, and not solely a consequence secondary to the accompanying 





Figure 4: Hypothesis of Th2 cytokine bias model of MCNS leading to nephrotic 
hypercholesterolemia. 
Following an immunological trigger, T cells release Th2 cytokines such as IL-13, which directly 
act on the liver to dysregulate pathways regulating cholesterol synthesis, elimination or transport, 
resulting in the hypercholesterolemia seen in MCNS. 
 
1.4.1. Aims of study 
To study the hypothesis that hypercholesterolemia in MCNS is primarily due to 
cytokine dysregulation, we propose to firstly establish the role of Th2 cytokines in 
regulating cholesterol homeostasis in the IL-13 gene overexpression rat model of 
MCNS prior to the onset of proteinuria, and subsequently to validate this pathway 
in a rat primary hepatocyte cell culture system. 
 
The main objectives will be accomplished by: 
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1. Profiling the genes involved in the pathways of cholesterol metabolism in 
the liver of the IL-13 transfected nephrotic rats using cDNA microarray 
and identify the differentially expressed genes (DEGs). 
a. Subsequent functional clustering and pathway analysis using 
Database for Annotation, Visualization and Integrated Discovery 
(DAVID) will be performed to characterize the link between IL-13 
and hepatic cholesterol metabolism in the IL-13 transfected 
nephrotic rats. 
b. The microarray results will be validated using quantitative real-
time polymerase chain reaction (qPCR). 
2. Conducting a timeline experiment to determine if hypercholesterolemia 
preceded the onset of proteinuria in this cytokine-induced model of MCNS 
by studying plasma cholesterol and urine albumin excretion level at 
weekly intervals following IL-13 transfection of the rat. 
3. Performing a comparative analysis of the gene expression profile of the 
pathways of hepatic cholesterol metabolism between the IL-13 transfected 
rats at the onset of hypercholesterolemia in the pre-proteinuric phase 
(early event) and the nephrotic phase (late event). 
a. qPCR will be performed to determine if the DEGs identified from 
the liver microarray profile in the late event could also be involved 
in the early event. 
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b. Protein detection methods such as Western bot and ELISA will be 
used to correlate and validate the qPCR data of the pathways of 
cholesterol metabolism in the early event. 
4. Validating the findings of cholesterol dysregulation from both the early 
and late events in the IL-13 transfected rats in an in vitro IL-13-
stimulated rat primary hepatocyte cell culture system. 
a. Gene and protein expressions of the molecules involved in the 
dysregulated cholesterol metabolic pathway(s) identified in the IL-
13 gene overexpression rat model of MCNS will be studied in the 
hepatocytes following IL-13 stimulation. 
b. Intracellular cholesterol level will be measured in the hepatocytes. 
c. Cholesterol transport across the cells will be assayed using apoA-I 
and taurocholate. 
d. Functional studies using siRNA-transfected rat hepatocytes to 
knock down target molecules will be performed to delineate the 
molecular mechanism of IL-13-induced hypercholesterolemia. 
 
Understanding the molecular mechanism of hypercholesterolemia associated with 
INS in children has important implications especially in the steroid-dependent and 
steroid-resistant child, as they tend to have prolonged hypercholesterolemia, 
which in the long term will result in significant atherosclerotic disease. Lowering 
cholesterol level during childhood may reduce the risk for atherosclerotic changes 
and serious cardiovascular and cerebrovascular disease in young adulthood. In 
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addition, hyperlipidemia has also been associated with progression of chronic 
kidney disease due to its effects on inflammatory and fibrogenic pathways. A 
better understanding of the etiology of the pathogenesis of hypercholesterolemia 
is thus important, so that novel molecules can be developed to tackle this 
complication of nephrotic syndrome, given that statins may have severe side 
effects when used in combination with drugs normally used to treat nephrotic 




Chapter 2 Materials and methods 
2.1. IL-13 gene overexpression rat model of MCNS 
All animal studies were approved by the Institutional Animal Care and Use 
Committee of the National University of Singapore. Six-week-old female Wistar 
rats weighing between 100g to 200g were used. Induction of MCNS in rats by IL-
13 gene overexpression has been published (Lai et al., 2007). 
 
The complete experimental protocol is illustrated in Figure 5. Prior to blood 
collection and electroporation, the rats were housed in metabolic cages for a 24-
hour urine collection and the volume of urine recorded. After subjecting the rats 
to inhalational isoflurane with oxygen, 1ml of blood was drawn from the ventral 
artery of the tail into a heparinized tube using a 23G needle. 
 
Electroporation of the rats was carried out every week over a period of 10 weeks 
with 200μg of endotoxin-free and purified plasmid DNA injected into their 
quadriceps. An electric current consisting of six pulses of 20 milliseconds each at 
160V was generated using the “Electro Square Porator ECM830” (BTX 
Technologies Inc., NY, USA) and delivered though the 10mm 2-Needle Array™ 
tip (BTX Technologies Inc., NY, USA) connected to a 2-Needle Array™ 
electrode (BTX Technologies Inc., NY, USA). Treatment rats received 
mammalian expression plasmid pCI cloned with rat IL-13 gene (pCI-IL-13), 




Both urine and blood collected were centrifuged at 3000rpm for 10 minutes to 
remove debris and obtain plasma respectively. Plasma IL-13, albumin, creatinine, 
total cholesterol and urine albumin excretion levels were assayed regularly. 
 
To study the treatment rats in the nephrotic state (termed as ‘late event’), the rats 
were euthanized at Week 10 by overdose of anesthetic (75mg/kg of ketamine and 
10mg/kg of xylazine) via intraperitoneal injection, followed by blood collection 
via cardiac puncture. The liver was immediately removed, cut into small pieces 
and frozen in liquid nitrogen, then stored at -80°C until processed. 
 
To study the rats which developed hypercholesterolemia in the pre-proteinuric 
phase (termed as ‘early event’), a subgroup of treatment rats were euthanized as 
soon as their plasma total cholesterol levels increased to 1.5 times more than their 
baseline value at the start of the experiment, without the development of 
proteinuria. This sacrificial process could vary between Week 1 to Week 10. 
Blood and liver were collected as described above. Additional measurements 
were carried out for plasma triglycerides, HDL-cholesterol and LDL-cholesterol 





Figure 5: Experimental protocol for animal work. 
The y-axis represents the order of events that occurred weekly as indicated by the x-axis. 24-hour 
urine was first collected (U), followed by the drawing of tail blood (B) and electroporation was 
carried out last (E). No electroporation was done on rats that were to be sacrificed (S). Rats were 
sacrificed at Week 10 to study the late event in nephrotic syndrome (solid gray cross). HC rats 
were sacrificed as soon as their plasma total cholesterol levels increased to 1.5 times more than 
their Week 0 value, without the development of proteinuria (early event) (gray crosses with dotted 
filling and lines). 
 
2.2. Plasma IL-13 
Plasma level of rat IL-13 was measured using a commercially available solid 
phase sandwich Enzyme Linked Immuno Sorbent Assay (ELISA) kit (Invitrogen, 
CA, USA), in which monoclonal antibody specific for rat IL-13 had been coated 
onto the wells of the microtiter strips provided. Briefly, 50μl of standards ranging 
from 7.8pg/ml to 500pg/ml, positive controls and rat plasma samples were 
pipetted into the wells, followed by the addition of 150μl of biotinylated 
secondary monoclonal antibody. Plasma from the IL-13 transfected rats was 




After incubation at room temperature for 2 hours, the wells were washed with 
wash buffer provided to remove excess biotinylated antibody. Following a 30-
minute incubation with 100μl of streptavidin-peroxidase enzyme, the wells were 
washed and then incubated with 100μl of stabilized chromogen substrate, which 
upon reacting with the bound enzyme, produced a color signal directly 
proportional to the amount of IL-13 bound. After a 30-minute incubation in the 
dark, 100μl of stop solution was added and the final absorbance was measured at 
wavelength 450nm using a microplate reader (Bio-Rad Laboratories, Inc., CA, 
USA). The concentration of IL-13 in the samples was determined from the 
standard curve, factoring in the dilution. 
 
2.3. Plasma total cholesterol 
Plasma total cholesterol level was determined by an enzymatic colorimetric 
endpoint method (Allain et al., 1974) using a commercial kit (Randox 
Laboratories, Antrim, UK). Briefly, 10μl of reagent blank consisting of 0.9% w/v 
sodium chloride (NaCl) in distilled water, standard and samples were each added 
to 1ml of Reagent R1. After incubation at room temperature for 10 minutes, 200μl 
of reaction mixture was transferred into the wells of a microplate in duplicate and 
absorbance was read at 490nm using a microplate reader (Bio-Rad Laboratories, 
Inc., CA, USA) against reagent blank. Sample concentration of total cholesterol 
was determined by multiplying the absorbance ratio of sample ൫Asample൯ and 
standard ሺAstandardሻ with the concentration of the standard provided by the 




2.4. Plasma HDL-cholesterol 
Plasma HDL-cholesterol level was determined by an enzymatic clearance assay 
(Izawa et al., 1997) using a commercial kit (Randox Laboratories, Antrim, UK). 
Briefly, 15μl of reagent blank consisting of 0.9% w/v NaCl in distilled water, 
standard and samples were each added to 900μl of Enzyme Reagent 1 in a 1cm 
cuvette and mixed. After incubation at 37°C for 5 minutes, 300μl of Enzyme 
Reagent 2 was added immediately, mixed and incubated for exactly 30 seconds 
before reading the initial absorbance A1 at 600nm using Spectronic® GENESYS™ 
5 spectrophotometer (Thermo Electron Corporation, WI, USA) against reagent 
blank. Final absorbance A2 was read immediately after a further incubation of 150 
seconds at 600nm against reagent blank. Sample concentration of HDL-
cholesterol was determined by multiplying the absorbance ratio of the sample 
difference ൫A2‐A1൯ and the standard ሺAstandardሻ with the concentration of the 
standard provided by the manufacturer ቀ A2‐A1Astandard ൈ 	concentration of standardቁ. 
 
2.5. Plasma triglycerides 
Plasma triglyceride level was determined by an enzymatic endpoint method 
(Jacobs and Vandemark, 1960; Koditschek and Umbreit, 1969; Tietz et al., 1990; 
Trinder, 1969) using a commercial kit (Randox Laboratories, Antrim, UK). 
Briefly, 5μl of reagent blank consisting of 0.9% w/v NaCl in distilled water, 
standard and samples were each added to 500μl of Reagent R1. After incubation 
at room temperature for 10 minutes, 200μl of reaction mixture was transferred 
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into the wells of a microplate in duplicate and absorbance was read at 500nm 
using Infinite M1000 microplate reader (Tecan, Mannedorf, Switzerland) against 
reagent blank. Sample concentration of triglycerides was determined by 
multiplying the absorbance ratio of sample ൫Asample൯ and standard ሺAstandardሻ with 
the concentration of the standard provided by the manufacturer 
ቀ AsampleAstandard ൈ	concentration of standardቁ. 
 
2.6. Plasma LDL-cholesterol 
Plasma LDL-cholesterol concentration was calculated using the formula of 
Friedewald et al. (Friedewald et al., 1972), which is the most often used formula 
in clinical practice and considered acceptable for patients' classification 
(Tremblay et al., 2004). 
 
The concentration of   plasma LDL-cholesterol in mmol/l is obtained using fasted 
blood samples from plasma total cholesterol ሺCTCሻ, plasma HDL-cholesterol 
ሺCHDLሻ and plasma triglycerides ሺCTGሻ, and calculated with the formula 
൫CTC‐CHDL‐ CTG 2.2⁄ ൯. 
 
2.7. Plasma albumin 
Plasma albumin level was determined by the bromocresol green (BCG) method 
using a commercial kit (Randox Laboratories, Antrim, UK). Briefly, 5μl of 
reagent blank consisting of 0.9% w/v NaCl in distilled water, standards and 
samples were each added to 1.5ml of BCG reagent and mixed. After incubation at 
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room temperature for 5 minutes, 200μl of reaction mixture was transferred into 
the wells of a microplate in duplicate and absorbance was read at 600nm using a 
microplate reader (Bio-Rad Laboratories, Inc., CA, USA) against reagent blank. 
Sample concentration of albumin was determined by multiplying the absorbance 
ratio of sample ൫Asample൯ and standard ሺAstandardሻ with the concentration of the 
standard provided in the kit ቀ AsampleAstandard ൈ	concentration of standardቁ. 
 
2.8. Plasma creatinine 
Plasma creatinine was determined by the alkaline picrate method (Archibald, 
1962). Creatinine in alkaline solution reacts with picrate to form a colored 
complex, which is directly proportional to the creatinine concentration. Briefly, 
100μl of distilled water as blank, standards of 0.5, 1, 3, 10mg/dl and samples were 
each added to a mixture containing 100μl of distilled water, 100μl of 5% w/v 
sodium tungstate in distilled water and 100μl of 2/3N sulphuric acid, and 
incubated at room temperature for 10 minutes. After centrifuging the mixture at 
6000rpm for 2 minutes, 100μl of supernatant was transferred into the wells of a 
microplate in duplicate, followed by the sequential addition of 20μl of saturated 
aqueous picric acid and 30μl of 1N aqueous sodium hydroxide (NaOH). 
Incubation was carried out at room temperature for 20 minutes. The absorbance of 
the colored complex formed was read at 490nm using a microplate reader (Bio-
Rad Laboratories, Inc., CA, USA). Sample concentration of creatinine was 




2.9. Urine albumin ELISA 
A direct sandwich ELISA system was developed to detect the concentration of rat 
albumin in 24-hour urine samples (Crowther, 2001). Wells were coated with 
100μl of 21.65μg/ml (total protein) rabbit antiserum to rat albumin antibody (MP 
Biomedicals, CA, USA) and 50μl of 0.965μg/ml (total protein) horseradish 
peroxidase (HRP)-conjugated sheep polyclonal antibody to rat albumin secondary 
antibody (MP Biomedicals, CA, USA) was used as the detecting antibody. o-
Diphenylenediamine (OPD) (MP Biomedicals, CA, USA) in pH 5.0 citrate buffer 
was used as the substrate for color development. Rat albumin standards (MP 
Biomedicals, CA, USA) of known concentrations were included in each assay. 
Each sample was measured in triplicate. Endpoint absorbance was read at 490nm 
by a microplate reader (Bio-Rad Laboratories, Inc., CA, USA). The total amount 
of albumin excreted in a 24-hour urine sample was derived by multiplying the 
concentration of albumin obtained from the standard curve (mg/ml) and the 
volume of urine collected for 24 hours (ml) (Appendix 2.1). 
 
2.10. RNA extraction 
Extraction of total RNA from rat liver tissue was carried out by first 
homogenizing 300mg of liver in 3ml of TRIzol® Reagent using Heidolph Diax 
600 homogenizer (Heidolph, Schwabach, Germany). For adherent monolayer cell 
culture in 6-well plate, 500µl of TRIzol® Reagent was used to lyse cells directly 




The homogenized and lysed sample in TRIzol® Reagent was incubated at room 
temperature for 5 minutes to permit complete dissociation of the nucleoprotein 
complexes. Two hundred µl of chloroform (Thermo Fisher Scientific Inc., MA, 
USA) was added for every 1ml of TRIzol® Reagent used and the mixture was 
shaken vigorously for 15 seconds, followed by incubation at room temperature for 
3 minutes. After centrifugation at 12,000g at 4°C for 15 minutes, the mixture was 
separated into a lower red phenol-chloroform phase, an interphase and an upper 
colorless aqueous phase. The aqueous phase, which contained the RNA, was 
carefully removed and transferred into a clean microfuge tube. Five hundred µl of 
isopropanol (Thermo Fisher Scientific Inc., MA, USA) was added to precipitate 
the RNA for every 1ml of TRIzol® Reagent used initially. The mixture was mixed 
by inverting repeatedly and incubated at room temperature for 10 minutes, 
followed by centrifugation at 12000g at 4°C for 10 minutes. After discarding 
supernatant, the RNA pellet was washed with 1ml of 75% ethanol (Merck, NJ, 
USA) for every 1ml of TRIzol® Reagent used initially. The sample was briefly 
vortexed and centrifuged at 7500g at 4°C for 5 minutes. After decanting ethanol, 
the RNA pellet was air-dried and dissolved in RNase-free water (Qiagen GmbH, 
Hilden, Germany). Concentration of RNA yield was measured using NanoDrop 
1000 Spectrophotometer (NanoDrop products, Thermo Scientific, DE, USA). 
 
2.11. RNA purification and cleanup 
Liver tissue RNA was first isolated using TRIzol® Reagent method as described 
in 2.10, and further purified using RNeasy Mini Kit (Qiagen GmbH, Hilden, 
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Germany) according to manufacturer’s protocol for microarray experiment 
(Appendix 2.2). Concentration and purity ratio A260/A280 of liver tissue RNA 
were measured using NanoDrop 1000 Spectrophotometer (NanoDrop products, 
Thermo Scientific, DE, USA). 
 
2.12. RNA quantification and quality analysis 
The samples were processed using Agilent RNA 6000 Nano Kit (Agilent 
Technologies, Waldbronn, Germany) according to manufacturer’s protocol, 
followed by measuring the concentration of RNA in samples and checking their 
RNA quality using Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, 
Germany) before using them for microarray (Appendix 2.3). Purity of the RNA 
was checked using the ratio A260/A280, and its integrity was measured by the 
ratio 28S/18S and RNA Integrity Number (RIN). 
 
2.13. RNA amplification for microarray analysis using Illumina® TotalPrep 
RNA Amplification Kit 
 
2.13.1. Reverse transcription to synthesize first strand cDNA 
All liver RNA samples were reconstituted to 300ng in a final volume of 11µl with 
nuclease-free water. Reverse Transcription Master Mix, consisting of 1µl of T7 
oligo(dT) primer, 2µl of 10X first strand buffer, 4µl of dNTP mix, 1µl of RNase 
inhibitor and 1µl of ArrayScript™, was added to each RNA sample and incubated 




2.13.2. Second strand cDNA synthesis 
Second Strand Master Mix, consisting of 63µl of nuclease-free water, 10µl of 
10X second strand buffer, 4µl of dNTP mix, 2µl of DNA polymerase and 1µl of 
RNase H, was added to the first strand cDNA sample and incubated at 16°C for 2 
hours. The double-stranded cDNA sample obtained was briefly put on ice before 
proceeding immediately to cDNA purification. 
 
2.13.3. cDNA purification 
The cDNA was transferred into a 1.5ml microfuge tube containing 250µl of 
cDNA Binding Buffer. The mixture was then transferred to a cDNA Filter 
Cartridge and centrifuged at 10,000g for 1 minute. This was followed by washing 
with 500µl of Wash Buffer and centrifuged at 10,000g for 1 minute. The cDNA 
Filter Cartridge was then transferred to a cDNA Elution Tube and 10µl of 55°C 
nuclease-free water was added to the center of the cDNA Filter Cartridge, 
incubated at room temperature for 2 minutes and centrifuged at 10,000g for 1.5 
minutes. An additional 9µl of 55°C nuclease-free water was added to the center of 
the cDNA Filter Cartridge and centrifuged at 10,000g for 2 minutes in the same 
cDNA Elution Tube to collect the purified double-stranded cDNA. 
 
2.13.4. In vitro transcription to synthesize cRNA 
In vitro Transcription Master Mix, consisting of 2.5µl of T7 10X Reaction Buffer, 
2.5µl of T7 Enzyme Mix and 2.5µl of Biotin-16-UTP, was added to the purified 
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cDNA sample and mixed, and incubated at 37°C for 14 hours. The reaction was 
stopped by adding 75µl of nuclease-free water to the newly synthesized cRNA 
sample to bring the final volume to 100µl, before proceeding to cRNA 
purification. 
 
2.13.5. cRNA purification 
cRNA was transferred into a clean 1.5ml microfuge tube containing 350µl of 
cRNA Binding Buffer, followed by 250µl of 100% ethanol and mixed. The 
mixture was passed through a cRNA Filter Cartridge by centrifugation at 10,000g 
for 1 minute and washed with 650µl of Wash Buffer by centrifugation at 10,000g 
for 1 minute. An additional spin was carried out to remove trace amount of Wash 
Buffer. After transferring cRNA Filter Cartridge to a cRNA Collection Tube for 
cRNA elution, 50µl of 55°C nuclease-free water was added to the center of the 
cRNA Filter Cartridge, incubated at room temperature for 2 minutes and 
centrifuged at 10,000g for 1.5 minutes. An additional 30µl of 55°C nuclease-free 
water was added to the center of the cRNA Filter Cartridge and centrifuged at 
10,000g for 1.5 minutes in the cRNA Collection Tube to collect the purified 
cRNA. 
 
The concentration of purified cRNA was measured using NanoDrop 1000 
Spectrophotometer (NanoDrop products, Thermo Scientific, DE, USA). Samples 





2.13.6. cRNA hybridization and array scanning 
Hybridization of 750ng cRNA was carried out for 18 hours on Sentrix® BeadChip 
Array RatRef-12 v1 (Illumina®, CA, USA) according to the manufacturer’s 
protocol (Appendix 2.4). Array washing was performed followed by blocking, 
streptavidin-Cy3 detection and scanning with BeadArray™ Reader (Illumina®, 
CA, USA) using scan factor 1.5, PMT 531. 
 
2.14. Microarray analysis 
The raw intensity values of the array were extracted with background subtraction 
via BeadStudio (Illumina®, CA, USA) for analysis. The raw data was pre-
processed to correct unreliable intensities for each array. The intensities with 
detection p-values greater than 0.05 were considered as unreliable and replaced by 
the intensity with detection p-value equal to 0.05. The pre-processed data was 
normalized by the Cross-Correlation method (Chua et al., 2006). Differentially 
expressed genes (DEGs) were selected based on fold change of at least 1.5 and 
false discovery rate (FDR) less than 0.05. Biological functional clustering and 
pathway analysis were carried out on the DEGs using a bioinformatics resource 
Database for Annotation, Visualization, and Integrated Discovery (DAVID) 




2.15. Plasmid DNA standard curve 
Plasmid DNA standard curves were generated for copy number quantification of 
target genes in sample. Conventional PCR was first carried out with rat liver 
cDNA using specific primer sequences (Table 2). Thermal cycling conditions for 
Taq polymerase-amplification consisted of 1 cycle of 95°C for 5 minutes, 
followed by 35 cycles of 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 
30 seconds, and a final extension of 72°C for 7 minutes. 
 
TA cloning reaction mixture was prepared with 3µl of Taq polymerase-amplified 
PCR product, 1µl of water, 1µl of salt solution and 1µl of pCR™ 2.1-TOPO® 
plasmid vector using the TOPO® TA Cloning® Kit (Invitrogen, Life 
Technologies, CA, USA), and incubated at room temperature for 15 minutes.  
 
Transformation was carried out by adding 4µl of the cloning reaction mixture to a 
tube of OneShot® TOP10 Chemically Competent E. coli cells (Invitrogen, Life 
Technologies, CA, USA) and incubated on ice for 20 minutes, before being 
subjected to heat shock in a 42°C water bath for 30 seconds. The mixture was 
then incubated on ice for 2 minutes, followed by the addition of 250µl of SOC 
medium and shaking at 250rpm at 37°C for 1 hour. 
 
One hundred µl of the transformation mixture was spread on a pre-warmed Luria-
Bertani (LB) agar plate containing 100µg/ml of ampicillin (Sigma-Aldrich, MO, 
USA) and 40µg/ml of 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) 
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(Promega, WI, USA) for blue/white colony screening. The plate was incubated 
overnight at 37°C. 
 
White colonies representing successful transformation of E. coli cells with cloned 
vector were selected and cultured in LB broth containing 100µg/ml of ampicillin 
with shaking at 250rpm overnight at 37°C. After centrifuging at 6000g at 4°C for 
15 minutes, E. coli cell pellet was lysed and plasmids were extracted and purified 
using QIAprep® Spin Miniprep Kit (Qiagen GmbH, Hilden, Germany) according 
to manufacturer’s protocol. The concentration of the eluted plasmid was measured 
using NanoDrop 1000 Spectrophotometer (NanoDrop products, Thermo 
Scientific, DE, USA). Presence of insert was confirmed by EcoRI (New England 
BioLabs Inc., MA, USA) restriction digestion and agarose gel electrophoresis. 
 
A 10X serial dilution was done to obtain a series of plasmid standards with copy 
numbers ranging from 109 to 100. Plasmid standards were run in triplicate in 
qPCR using LightCycler® 480 SYBR Green I Master reagent kit (Roche, 
Mannheim, Germany) with LightCycler® 480 Instrument machine (Roche, 
Mannheim, Germany). 
 
The crossing threshold point (Ct) of plasmid standards was plotted against its 
copy number in the plasmid standard curve. A perfect amplification reaction 
produces a plasmid standard curve with a slope gradient of -3.33 and an efficiency 
of 2. Upon determining the Ct of an unknown sample, LightCycler® 480 Basic 
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Software provides the concentration of target DNA in the unknown sample using 
the plasmid standard curve (LightCycler® 480 Instrument Operator’s Manual). 
 
Table 2: Nucleotide sequence of primers for the respective genes of interest in rat liver.  
Gene GeneBank accession Primer Nucleotide sequence 5’ – 3’ 
Product 
size/bp 
b-actin NM_031144 Forward Reverse 
5’-GCCCTAGACTTCGAGC-3’ 
5’-CTTTACGGATGTCAACGT-3’ 217 
ABCA1 NM_178095 Forward Reverse 
5’-AGACGGGCCTTCGGTGACAA-3’ 
5’-GCTGAAGACCAGGGCGATGC-3’ 282 
ABCG5 NM_053754 Forward Reverse 
5’-CACTTGTGCTGCTTGGTATG-3’ 
5’-ATTGGGTTATTTGGCACAGA-3’ 247 
ACAT2 NM_153728 Forward Reverse 
5’-GAGTCGAGAACCCTTCAG-3’ 
5’-GAAGGAAGTAGAGTTCCACCA-3’ 184 
CYP7A1 NM_012942 Forward Reverse 
5’-TGCCACCACTACATGATATTGA-3’ 
5’-CCAGCTATGTGAACACCC-3’ 210 
HMGCR NM_013134 Forward Reverse 
5’-CTGGTAGCATAGGAGGC-3’ 
5’-CACACAATTCGGGCAAG-3’ 301 
IL-4Ra NM_133380 Forward Reverse 
5’-TCCACCCAATAGACCGT-3’ 
5’-GCAATCAAGTTTGCGTTC-3’ 266 
IL-13Ra1 NM_145789 Forward Reverse 
5’-TTGGCACAACCTGAGCT-3’ 
5’-TGCACGAATAAGGCACC-3’ 330 
IL-13Ra2 NM_133538 Forward Reverse 
5’-GGAATGCTGGGAAGGT-3’ 
5’-AGTTTAGCAGAGCGTCT-3’ 190 
LDLR NM_175762 Forward Reverse 
5’-CAAGATCAAGAAAGGGGGTT-3’ 
5’-CTGCTTCTCATCCTCCAAAA-3’ 193 
LXRa NM_031627 Forward Reverse 
5’-GCGAGGGCTGCAAGGGATTC-3’ 
5’-TTGGGGACACCGATGTGGCT-3’ 240 
RXRa NM_012805 Forward Reverse 
5’-CTCGGCTCTCCTCTGGGCTC-3’ 
5’-GCTGCTCACGGGGTTCATGG-3’ 201 







2.16. Quantitative real-time PCR 
One µg of RNA was reverse transcribed to single-stranded cDNA using Maxima® 
First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific, Thermo 
Fisher Scientific, PA, USA) according to manufacturer’s protocol. 
 
The qPCR was performed in a final volume of 10µl reaction mixture containing 
1µM each of the forward and reverse primers, 1µl of PCR-grade water, 5µl of 
LightCycler 480 SYBR Green I Master mix (Roche, Mannheim, Germany) and 
2µl of single-stranded cDNA, and run in LightCycler® 480 Instrument machine 
(Roche, Mannheim, Germany). Thermal cycling conditions consisted of an initial 
pre-incubation at 95°C for 10 minutes, followed by 40 cycles of 95°C for 5 
seconds, 62°C for 10 seconds and 72°C for 15 seconds, and lastly melting curve 
analysis was carried out before cooling to 40°C. 
 
All samples were run in duplicate and target gene copy number for each sample 
was determined from the respective plasmid standard curve. Target gene 
expression was expressed as a ratio against the housekeeping gene b-actin. 
 
2.17. Western blot 
For Western blot analysis, liver tissue and cultured cells were homogenized and 
lysed in RIPA buffer with phosphatase and protease inhibitors (Pierce Thermo 
Scientific, IL, USA). Lysed samples were rotated at 4°C for 15 minutes, followed 
by centrifugation at 13,000g at 4°C for 10 minutes. The supernatant was 
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transferred into a clean 1.5ml microfuge tube, and protein concentration was 
measured based on Lowry method (Lowry et al., 1951). 
 
Lysates containing equal amount of protein were fractionated on 5% and 8% Tris-
glycine polyacrylamide gel at 100V for 2 hours and transferred to 0.45µm 
nitrocellulose membrane (Bio-Rad Laboratories, Inc., Munich, Germany). The 
membrane was blocked using 5% nonfat milk (Bio-Rad Laboratories, Inc., CA, 
USA) in 1X Tris-buffered saline (TBS) and 0.05% Tween 20 (TBST) at room 
temperature for 1 hour. After a 5-minute wash in TBST, the membrane was 
probed with the following primary antibodies at 4°C overnight: mouse anti-
ABCA1 (1:5000) (Millipore, CA, USA), rabbit anti-IL-4Ra (1:1000) (Santa Cruz 
Biotechnology Inc., CA, USA), mouse anti-IL-13Ra2 (1:1000) (Santa Cruz 
Biotechnology Inc., CA, USA), rabbit anti-LXRa (1:4000) (Sigma-Aldrich, MO, 
USA), rabbit anti-pSTAT6 (1:5000) (Santa Cruz Biotechnology Inc., CA, USA) 
and rabbit anti-STAT6 (1:5000) (Santa Cruz Biotechnology Inc., CA, USA). 
Antibody against GAPDH (1:20,000) (Sigma-Aldrich, MO, USA) served as the 
loading control. 
 
After 3 washes in TBST for 5 minutes, membrane was incubated in 2.5% nonfat 
milk in TBST containing HRP-linked secondary antibodies for 1 hour. After 5 
washes in TBST for 5 minutes, the membrane was developed by 
chemiluminescent detection using Luminata™ Forte Western HRP Substrate 
(Millipore, MA, USA) and protein bands quantified using ImageJ software 
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(National Institute of Health, MD, USA). Target protein expression was expressed 
as an index of the GAPDH. 
 
2.18. Hepatocyte isolation and culture 
Hepatocytes were harvested from the liver of male Wistar rats (kind gift from 
Professor Hanry Yu, National University of Singapore, Singapore) weighing 
between 250g to 300g by a two-step in situ collagenase perfusion method (Seglen, 
1976). Routinely, 200 to 300 million cells were isolated with viability above 85% 
as determined by trypan blue exclusion assay. 
 
Freshly isolated rat hepatocytes were seeded at a density of 1.2 million cells on 
type I collagen-coated 6-well plates (Iwaki® Cell Biology, Japan) in Williams’ 
Medium E (Sigma-Aldrich, MO, USA) supplemented with 1g/l of bovine serum 
albumin (BSA) (Sigma-Aldrich, MO, USA), 0.292g/l of L-glutamine (Gibco®, 
Life Technologies, CA, USA), 0.5g/l of insulin (Sigma-Aldrich, MO, USA), 5nM 
of dexamethasone (Sigma-Aldrich, MO, USA), 50ng/ml of linoleic acid (Sigma-
Aldrich, MO, USA), 100units/ml of penicillin and 100µg/ml of streptomycin 
(Gibco®, Life Technologies, CA, USA). The cultures were incubated at 37°C and 
5% CO2 in a humidified atmosphere. After cell attachment for 3 hours, the 
medium was replaced with fresh Williams’ Medium E, and subsequently culture 
medium was changed every 24 hours. Cells were photographed using an Olympus 
IX70 microscope equipped with the cell-F software (Soft imaging Software 




After overnight incubation, hepatocyte cell cultures were stimulated with 25ng/ml 
of recombinant rat IL-13 (R&D Systems, MN, USA) for 2 to 48 hours. Cells were 
observed daily to ensure the absence of bacterial and fungi contamination. 
 
2.19. Cholesterol quantification in rat liver tissue 
Cholesterol in rat liver was extracted according to a modified Bligh and Dyer 
lipid extraction method (Bligh and Dyer, 1959; Shui et al., 2011). One hundred 
mg of rat liver tissue was homogenized in 1ml of ice-cold 1X Phosphate-buffered 
saline (PBS). The homogenized sample was vortexed for 15 seconds, before 
transferring 100µl of the homogenate into a clean 2ml microfuge tube. After 
adding 900µl of ice-cold chloroform:methanol (1:2), the tube was vortexed for 15 
seconds and incubated on ice for 15 minutes in the dark, with intermittent 
vortexing during incubation. Three hundred µl of ice-cold chloroform and 300µl 
of ice-cold water were added to the mixture. The mixture was vortexed for 15 
seconds and incubated on ice for 1 minute and repeated. After centrifuging at 
9000rpm at 4°C for 2 minutes, the lower organic phase was transferred into a 
clean 1.5ml microfuge tube and dried under Savant SPD1010 SpeedVac 
Concentrator (Thermo Scientific, PA, USA). The dried lipid film was 
reconstituted in chloroform:methanol (1:1). Quantification of free cholesterol and 
cholesteryl esters were carried out using liquid chromatography/mass 
spectrometry (LC/MS), a collaboration with Professor Markus Wenk (National 
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University of Singapore, Singapore), and normalized against the mass of rat liver 
tissue used. 
 
2.20. Cholesterol quantification in hepatocyte cell culture 
Cholesterol in hepatocytes was extracted using the hexane:isopropanol method 
(Robinet et al., 2010). Culture medium was removed and cells were washed twice 
with 1X PBS, followed by the addition of 1ml of hexane:isopropanol (3:2). After 
incubation at room temperature for 5 minutes, the solvent extract was transferred 
to a clean 1.5ml microfuge tube and vacuum dried using Savant SPD1010 
SpeedVac Concentrator (Thermo Scientific, PA, USA). The dried lipid film was 
dissolved in 1ml of isopropanol:NP-40 (Pierce Thermo Scientific, IL, USA) (9:1) 
and quantified using enzymatic colorimetric endpoint method as described in 2.3. 
 
After cholesterol extraction, residual solvent remaining in the well was 
evaporated at room temperature. Protein from the same well was dissolved by 
adding 1.4ml of 0.2N NaOH. The plate was incubated at 37°C for 3 hours, 
followed by rocking at room temperature for 5 minutes. Protein lysate was 
transferred to a clean microfuge tube and protein concentration was measured 
using Lowry method. 
 
2.21. Cholesterol efflux assay 
This experiment was based on reported journal by Low et al. (Low et al., 2012). 
After seeding the hepatocytes and incubating at 37°C and 5% CO2 in a humidified 
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atmosphere for 3 hours, the cells were labeled with 1µCi/ml of [3H]-cholesterol 
(PerkinElmer, MA, USA) for 24 hours in culture medium containing 5% of fetal 
bovine serum (FBS). The cells were washed twice with 1X PBS, followed by 
treatment with 25ng/ml of IL-13 for 24 hours. The cells were washed twice with 
1X PBS and [3H]-cholesterol efflux was initiated by adding either 5µg/ml of 
apoA-I (cholesterol acceptor for ABCA1) (Sigma, MO, USA) for 24 hours or 
10mM of taurocholate (cholesterol acceptor for ABCG5) (Sigma, MO, USA) for 
30 minutes in serum-free culture medium. Culture medium was centrifuged at 
14,000rpm for 10 minutes to remove cellular debris. Cells were frozen at -20°C 
for 30 minutes, followed by thawing and addition of 500µl of water, in which 
cells were scraped and homogenized. One hundred µl of centrifuged culture 
medium and homogenized cell lysate were aliquoted into separate scintillation 
vials followed by adding 5ml of scintillation liquid. Radioactivity in the vial was 
counted using the scintillation machine (Wallac WinSpectral 1414 Liquid 
Scintillation Counter, Turku, Finland). Efflux of [3H]-cholesterol was calculated 
as the percentage of counts in the culture medium to the counts in both the culture 
medium and cells ቀ ሾ3Hሿ-cholesterol in mediumሾ3Hሿ-cholesterol in medium	+	ሾ3Hሿ-cholesterol in cell 	ൈ 100%ቁ. 
 
2.22. ABCG5 ELISA 
Concentration of ABCG5 in rat liver and rat primary hepatocyte cell culture were 
measured using a commercial ELISA kit (MyBioSource, Inc., CA, USA), in 
which antibody specific for rat ABCG5 had been pre-coated onto the wells of the 
microplate. Briefly, 100μl of standards ranging from 25pg/ml to 1600pg/ml and 
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samples were pipetted into the wells in duplicate, followed by incubation for 2 
hours. All incubation steps were carried out at 37°C. After removing unbound 
substances, 100μl of biotin-conjugated antibody specific for rat ABCG5 was 
added and incubated for 1 hour. The wells were washed to remove excess 
biotinylated antibody and then incubated with 100μl of avidin-conjugated HRP 
for 1 hour. After washing to remove unbound avidin-HRP complex, 100μl of 
substrate solution was added, which upon reacting with the bound HRP, produced 
a color signal which developed in proportion to the amount of ABCG5 bound in 
the initial step. Color development was halted with the stop solution and 
absorbance was measured at wavelengths 450nm and 540nm using microplate 
reader Infinite® M1000 microplate reader (Tecan, Mannedorf, Switzerland). Final 
absorbance value was derived after subtracting readings at 540nm from readings 
at 450nm. The concentration of ABCG5 in the sample was determined from the 
standard curve using its final absorbance value, and multiplied by its dilution 
factor. Samples from rat liver and cultured rat hepatocytes were diluted 2000X 
and 200X respectively. 
 
2.23. Hematoxylin and eosin staining 
The liver tissue structure of control and HC rats was stained with hematoxylin and 
eosin (H&E) to look for histological abnormality and lipid droplets. Paraffin-
embedded liver tissue was cut into 7µm sections and mounted onto a slide. 
Sections were first dewaxed and rehydrated through alcohol, by going through 
incubation with 2 changes of Clearene (Leica Biosystems Richmond, Inc., IL, 
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USA) for 5 minutes each, 3 changes of absolute ethanol (Fisher Scientific, MA, 
USA) for 1 minute each, followed by 90% ethanol for 1 minute, 70% ethanol for 
1 minute and 50% ethanol for 1 minute. The sections were washed in distilled 
water before staining with Shandon™ hematoxylin (Thermo Fisher Scientific 
Inc., MA, USA) for 5 minutes. After washing in distilled water, 0.25% acid 
alcohol was used to differentiate the section, and then submerged in aqueous 
ammonia. The sections were lastly stained with eosin (Fisher Scientific, MA, 
USA). The sections were dehydrated and cleared by going through incubation 
with 95% ethanol for 1 minute and 3 changes of absolute ethanol for 1 minute 
each, followed by 2 changes of Clearene for 1 minute each and a final incubation 
with Clearene for 5 minutes. The sections were then mounted with cover slip 
using Permount™ mounting medium (Thermo Fisher Scientific Inc., MA, USA) 
and viewed under Olympus BX51 light microscope (Olympus, Tokyo, Japan). 
 
2.24. Transfection of cultured hepatocytes with siRNA 
Freshly isolated hepatocytes were seeded at a cell density of 0.6 million cells per 
well on a type I collagen-coated 6-well plate. Culture medium was replaced with 
fresh medium after 3 hours of cell attachment, followed by an overnight 
incubation at 37°C and 5% CO2 in a humidified atmosphere. 
 
The cells were transfected with ON-TARGETplus rat LXRa small interfering 
RNA (siRNA) SMARTpool or ON-TARGETplus non-targeting control pool (GE 
Dharmacon, CO, USA) as negative control at a final concentration of 50nM by 
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using DharmaFECT 1 Transfection Reagent (GE Dharmacon, CO, USA) 
according to manufacturer’s protocol (DharmaFECT™ Transfection Reagents – 
siRNA Transfection Protocol) for 24 hours. The target sequences of the pool of 
LXRa siRNAs were as follows: (1) GCUCAAGCCACAUCGGUGU; (2) 
GAGUGUCGCCUUCGCAAAU; (3) GAGACAUCGCGGAGGUACA; and (4) 
CGUCCACAGAAGCGGAAAA. 
 
Briefly, the sequence specific siRNA and transfection reagent were separately 
diluted in serum-free and antibiotic-free culture medium and incubated at room 
temperature for 5 minutes. After adding the diluted siRNA into the diluted 
transfection reagent, the mixture was further incubated for 20 minutes to allow 
complex formation. siRNA-transfection agent complex was gently added to the 
cultured cells and incubated at 37°C and 5% CO2 in a humidified atmosphere for 
24 hours. The cells were then treated with 5µM of LXRa agonist T0901317 
(Sigma-Aldrich, MO, USA) for another 24 hours, following which the cells were 
harvested for qPCR and Western blot analyses. 
 
Gene knockdown percentage efficiency was calculated according to 
manufacturer’s protocol (Demonstration of a ΔΔCq Calculation Method to 




2.25. Statistical analysis 
Statistical analysis was performed using SPSS software (IBM SPSS Statistics for 
Windows, Version 22.0, Armonk, NY, USA). All values were expressed as mean 
± standard error mean (SEM). Differences between control and IL-13 transfected 
rats were determined using the non-parametric Mann-Whitney test, where p-value 
< 0.05 was considered significant. Statistical analysis on paired samples in the 
cell culture work was carried out using the non-parametric Wilcoxon signed-rank 
test, where p-value < 0.05 was considered significant. The strength of the 
association between two variables was measured using Spearman's rank 
correlation coefficient (r), where results were considered to be statistically 





Chapter 3 Delineating the molecular mechanism of IL-13-induced 
hypercholesterolemia in the nephrotic rat 
 
3.1. Introduction 
Hypercholesterolemia is one of the major pathological manifestations of MCNS, 
the most common cause of childhood INS. MCNS patients with multiple relapses 
or steroid-resistance will be exposed to prolonged periods of 
hypercholesterolemia, thus increasing the risk of atherosclerosis leading to 
cardiovascular and cerebrovascular diseases. 
 
Previous studies on PAN rats suggested that the mechanism of nephrotic 
hypercholesterolemia is related to dysregulation of cholesterol metabolism in the 
liver triggered by the proteinuria (Liang and Vaziri, 2003). However, till now, the 
exact mechanistic pathway has not been elucidated. 
 
Following our discovery of the upregulation of IL-13 mRNA in CD4+ and CD8+ 
T cells in patients with MCNS relapse, we went on to establish an experimental 
model of MCNS, with the overexpression of IL-13 gene in rats by weekly 
injecting a mammalian plasmid construct that contained rat IL-13 gene into rat 
thigh muscle followed by electroporation for ten weeks (Lai et al., 2007). 
Histological examination of the renal tissue at the end of ten weeks showed no 
significant glomerular pathology on light microscopy, however, on electron 
microscopy, podocyte foot process effacement was seen in the glomeruli from rats 
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transfected with the IL-13 gene, similar to MCNS. Our preliminary biochemical 
studies showed an elevation of serum cholesterol level consistently observed in all 
rats transfected with the IL-13 gene as compared to control, as well as edema, 
proteinuria and hypoalbuminemia. In addition, only the level of serum 
cholesterol, but not serum albumin or urine albumin excretion levels, correlated 
significantly with the serum IL-13 level, suggesting an association between IL-13 
and hypercholesterolemia. 
 
Studies have also shown the presence of IL-13 receptor subunits in the liver, as 
well as the ability of IL-13 to signal through these receptors in the hepatocytes to 
trigger downstream processing (Akaiwa et al., 2001; Stanya et al., 2013), 
indicating the possible direct involvement of IL-13 acting on the liver. 
 
We therefore hypothesized that IL-13 was able to act on the liver, in turn causing 
hepatic cholesterol dysregulation, thereby inducing hypercholesterolemia in the 




3.2. Aim of chapter 
In this chapter, we aimed to examine the molecular mechanism of IL-13-induced 
hypercholesterolemia in the livers of the IL-13 transfected nephrotic rats at Week 
10, representing the ‘late event’ of MCNS. The objectives of this chapter are to: 
1. Profile the molecular expression events involved in the liver of the IL-13 
gene overexpression rat model of MCNS using cDNA microarray and 
identify the DEGs in these IL-13 transfected nephrotic rats. 
2. Perform functional clustering and pathway analysis using DAVID to 
characterize the link between IL-13 and hepatic cholesterol metabolism in 
the IL-13 transfected nephrotic rats. 





3.3.1. Phenotype of rats used for microarray analysis 
The serum IL-13 level of the IL-13 transfected nephrotic rats was significantly 
elevated as compared to control rats (Table 3). The IL-13 transfected nephrotic 
rats also displayed elevated serum cholesterol and urine albumin excretion, and 
decreased serum albumin classical of nephrotic syndrome. No significant 
difference was observed for serum creatinine and liver mass. The complete profile 
for every rat is shown in Appendix 3.1. 
 
Table 3: Profile of control and IL-13 transfected nephrotic rats used in cDNA microarray. 
 Control rats (n=3) 
IL-13 transfected nephrotic rats  
(n=6) p-value 
Serum IL-13 
(pg/ml) 0 ± 0 717 ± 305 0.018 
Serum albumin 
(g/l) 45.3 ± 5.9 27.1 ± 1.7 0.020 
Serum cholesterol 
(mmol/l) 1.79 ± 0.09 6.00 ± 0.77 0.020 
Serum creatinine 
(µmol/l) 81.6 ± 7.2 71.6 ± 5.0 0.517 
Urine albumin excretion 
(µg/24hour) 270 ± 64 5825 ± 1539 0.020 
Liver mass 
(g) 12.3 ± 0.2 16.4 ± 1.5 0.121 
 
3.3.2. Liver RNA transcriptional profile of IL-13 transfected nephrotic rats 
The RNA transcriptional profile in the livers of the IL-13 transfected nephrotic 
rats was determined using genome-wide gene expression microarray analysis. 
This identified 499 DEGs (fold change ≥ 1.5 and FDR < 0.05) out of the 22,523 
genes analyzed, when compared to control rats. Of the 499 DEGs, 274 (54.9%) 
were downregulated (with a maximum fold change of 7.39) and 225 (45.1%) were 
upregulated (with a maximum fold change of 18.01). The expression levels of the 
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DEGs are indicated by a color scale from low (green) to high (red) (Figure 6). The 
lists of downregulated and upregulated DEGs are available in Appendix 3.2 and 
Appendix 3.3 respectively. 
 
 
Figure 6: Heatmap of the 499 DEGs. 
The data are presented in a matrix format, such that each row represents individual genes and 
column representing each rat. The expression level of the 499 DEGs is indicated using a log2-
transformed scale colored bar from low (green) to high (red), with black representing median 
expression. C indicates biological replicate for control rats and J indicates biological replicate for 
IL-13 transfected nephrotic rats. 
 
Nine crucial genes that are well established to significantly affect cholesterol 
metabolism from pathways involving cholesterol biosynthesis, elimination and 
transport were selected to validate the microarray results by qPCR. Except for 
RXRa and ABCA1, there was good agreement between the microarray data and 
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the qPCR data, with qPCR confirming the up- or downregulation of each gene. 
The fold change was also of a comparable magnitude to the microarray data 
(Figure 7). 
 
Microarray analysis showed increased expression of genes involved in both 
cholesterol synthesis and degradation, and decreased expression of genes involved 
in cholesterol transport (Figure 7). Of the nine genes validated on qPCR, ABCG5 
and HMGCR showed significant dysregulation in the livers of IL-13 transfected 
nephrotic rats as compared to control rats. 
 
 
Figure 7: Validation of microarray results using qPCR. 
Nine genes involved in cholesterol metabolism were selected and analyzed using qPCR to confirm 
the microarray results. Downregulated genes were arbitrarily assigned a negative value. For qPCR, 
gene expression levels were normalized against housekeeping gene b-actin and fold change was 
calculated using the 2ΔΔCt method, where ΔΔCt was converted to an absolute value. Results were 
presented as fold change ± SEM. Asterisk (*) indicates significant difference, with p-value < 0.05, 
between the ΔCt values of control (n=7) and IL-13 transfected nephrotic (n=7) rats. The 
transcriptional profiles observed were nearly similar between microarray and qPCR, except for 




3.3.3. Functional annotation clustering and pathway analyses of DEGs 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
v6.7 was used to understand the biological meaning behind the list of 499 DEGs. 
The list of DEGs was submitted to the Functional Annotation Tool in DAVID and 
analyzed with the functional annotation clustering and pathway options. The top 
ten clusters were selected from the functional annotation clustering analysis of the 
499 DEGs based on enrichment score, whereby a higher enrichment score 
indicated closer agreement among the biological processes of the genes (Table 4). 
Functional annotation clustering showed that these DEGs were principally related 
to cofactor binding involving redox reaction, lipid and drug metabolisms, RNA 
processing, C-acyltransferase, CoA hydrolase and antioxidant activities, and were 
involved in cellular components such as peroxisome and mitochondrial matrix. 
 
Table 4: Functional annotation clusters of the 499 DEGs with enrichment score. 
Functional annotation cluster Enrichment score 
Redox reactions involving NAD/NADP 3.33 
Lipid metabolism 2.97 
mRNA processing and metabolic processes 2.80 
C-acyltransferase activity 2.29 
Peroxisome 2.28 
Mitochondrial matrix 2.18 
Intracellular organelle lumen 2.17 
Antioxidant activity 2.10 
Acyl-CoA hydrolase activity 1.86 
Drug metabolism 1.83 
 
The DAVID analysis tool was also used to identify putative pathways occurring 
in the livers of the IL-13 transfected nephrotic rats, using the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway database. The 499 DEGs were mapped 
67 
 
to 19 pathways (Table 5), of which ‘Fatty acid metabolism’, ‘ABC transporters’, 
‘Valine, leucine and isoleucine degradation’, ‘Spliceosome’ and ‘Fatty acid 
elongation in mitochondria’ were the top five pathways which still showed 
significant p-values after using the multiple testing correction technique 
Benjamini provided by DAVID. 
 
Because we were interested to identify key molecular events and investigate 
biological signaling pathways involved in cholesterol dysregulation in the livers 
of IL-13 transfected nephrotic rats, we chose to focus on ‘ABC transporters’, 
which was the second most significant pathway mapped out by KEGG, as the 
genes involved in the first pathway ‘Fatty acid metabolism’ were distinctively 
different from those involved in cholesterol metabolism. 
 
The genes involved in the ‘ABC transporters’ pathway are summarized in Table 
6, and the description of their functions was obtained from the NCBI Reference 
Sequence Database (RefSeq) (Pruitt et al., 2007). ABCG5 showed the greatest 
decrease in gene expression level in the ‘ABC transporters’ pathway, with a fold 





Table 5: KEGG pathway analysis of the 499 DEGs. 
KEGG_ID Term p-value Fold enrichment 
Benjamini 
p-value Genes 
rno00071 Fatty acid 
metabolism 
1.26E-06 8.76 < 0.001 RGD1562373, Peci, 
Adh6, Adh1, Acsl4, 
Acat2, Hadha, Hadhb, 
Acadm, Adh4 
rno02010 ABC transporters 1.51E-04 6.69 0.011 Abcc8, Abcc3, Abcd2, 
Abcb9, Abcg3, Abcg4, 
Abcg5, Abca6 
rno00280 Valine, leucine and 
isoleucine 
degradation 
2.02E-04 6.40 0.010 RGD1562373, Auh, 
Hmgcs2, Acat2, Hadha, 
Hadhb, Mcee, Acadm 
rno03040 Spliceosome 3.85E-04 3.65 0.014 Isy1, Thoc1, U2surp, 
Ppih, Prpf38b, Sfrs5, 
Prpf3, LOC682323, 
Snrpa, Rbm8a, Cdc40, 
LOC306428 
rno00062 Fatty acid 
elongation in 
mitochondria 
9.79E-04 18.39 0.028 Mecr, Ppt1, Hadha, Hadhb 
rno03320 PPAR signaling 
pathway 
2.86E-03 4.14 0.067 Scd, RGD1562373, Pck1, 
Rxrb, Acsl4, Hmgcs2, 
Fabp7, Acadm 
rno01040 Biosynthesis of 
unsaturated fatty 
acids 
3.57E-03 7.66 0.072 Scd, RGD1562373, 
Acot5, Hadha, Acot2 
rno00020 Citrate cycle (TCA 
cycle) 




2.04E-02 6.69 0.284 Cndp1, Srm, Hadha, 
Acadm 
rno00980 Metabolism of 
xenobiotics by 
cytochrome P450 
2.23E-02 3.68 0.281 Gsta4, Adh6, Adh1, Yc2, 
LOC687840, Cyp2c22, 
Adh4 
rno00590 Arachidonic acid 
metabolism 
4.00E-02 3.15 0.418 Ptgds2, Pla2g4a, Cyp4f37, 
Cbr1, Gpx2, Cyp2c22 









5.84E-02 4.46 0.466 Acat2, Hadha, Mcee, 
Acadm 
rno00270 Cysteine and 
methionine 
metabolism 
6.74E-02 4.20 0.493 Adi1, Ahcy, Srm, Bhmt 
rno00830 Retinol metabolism 7.43E-02 3.12 0.505 Dhrs4, Adh6, Adh1, 
Cyp2c22, Adh4 
rno04620 Toll-like receptor 
signaling pathway 
9.54E-02 2.45 0.577 Map2k6, Ikbke, Rac1, 
Ripk1, Irf7, Stat1 
rno04142 Lysosome 9.59E-02 2.20 0.559 Manba, Naglu, Ppt1, Ctsb, 
Abcb9, Slc17a5, Slc11a1 










Gene description Gene function Fold change 
Abcg5 NM_053754 ATP-binding cassette, sub-family G (WHITE), member 5 
Limit intestinal absorption and promote biliary excretion of sterols. Mainly 
expressed in intestine and liver. -6.00 
Abcd2 NM_033352 ATP-binding cassette, sub-family D (ALD), member 2 
Peroxisomal import and homeostasis of fatty acids and/or fatty acyl-CoAs in the 
organelle (Fourcade et al., 2009). -2.00 
Abca6 XM_001081607 ATP-binding cassette, sub-family A (ABC1), member 6 Macrophage lipid homeostasis and intracellular lipid transport (Gai et al., 2013). -1.68 
Abcg4 NM_001106816 ATP-binding cassette, sub-family G (WHITE), member 4 
Cholesterol transport and controls platelet production, atherosclerosis, and 
thrombosis. Highly expressed in megakaryocyte progenitors and brain (Westerterp 
et al., 2014). 
1.58 
Abcg3 NM_001128311 ATP-binding cassette, subfamily G (WHITE), member 3 
Transport of specific peptides or hydrophobic compounds from lymphocytes. 
Highly expressed in thymus and spleen. 1.97 
Abcb9 NM_022238 ATP-binding cassette, sub-family B (MDR/TAP), member 9 
Multi-drug resistance and translocation of peptides from cytosol into lysosomal 
lumen.  2.21 
Abcc8 NM_013039 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 
Multi-drug resistance and modulator of ATP-sensitive potassium channels and 
insulin release.  3.38 
Abcc3 NM_080581 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 







Hypercholesterolemia, one of the pathological manifestations in MCNS, is a 
cause of concern in patients who frequently relapse or are steroid-resistant, as this 
is a highly significant risk factor for development of atherosclerosis leading to 
early onset cardiovascular and cerebrovascular complications. It is therefore 
imperative to elucidate the exact molecular mechanism of nephrotic 
hypercholesterolemia, which till now is still controversial. 
 
Most of the data on nephrotic hypercholesterolemia are derived from studying 
PAN rats, an established model for nephrotic syndrome. In this model, 
hypercholesterolemia is triggered upon PA-induced damage to the kidneys 
resulting in heavy proteinuria and hypoalbuminemia. The PAN model is a toxic 
model, unlike human MCNS which appears to be associated with Th2 cytokine 
immune dysregulation, consistent with Shalhoub hypothesis (Shalhoub, 1974). 
 
Our IL-13 gene overexpression rat model of MCNS showed that high levels of 
circulating IL-13 in the serum were able to induce nephrosis in the rats (Lai et al., 
2007). This closely mirrors the hypothesis that immune dysregulation with a Th2 
cytokine bias may be involved in human MCNS. This is therefore a more 





Microarray analysis was carried out to analyze the possible molecular 
mechanisms involved in cholesterol metabolism in the livers of the IL-13 
transfected nephrotic rats. Using a fold change of at least 1.5 and FDR less than 
0.05, 499 DEGs were selected. This list of DEGs was analyzed using the 
functional annotation clustering tool provided by DAVID in order to group highly 
similar annotation terms into clusters, thus giving a more focused biological 
interpretation (Huang da et al., 2009). The top ten clusters generated 
predominantly showed a liver profile involving cellular components with 
metabolic processes. 
 
Nephrotic hypercholesterolemia has always been associated with dysregulated 
metabolic activities in the liver, and this was reflected in the top three clusters. 
Enzymatic redox reactions involving crucial coenzymes, nicotinamide adenine 
dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), 
were ranked as the top cluster. NAD and NADP serve as electron carriers in a 
variety of enzymatic reactions, and are used extensively in biosynthetic pathways 
such as cholesterol synthesis, rather than catabolic pathways. 
 
The second top cluster, lipid metabolism, indicated dysregulation of lipid 
metabolism in the liver, whereby lipid generally encompasses cholesterol, 
triglycerides and fatty acids. The third top cluster, which was mRNA processing 
and metabolic activities, suggested dysregulated mRNA synthesis which could in 
72 
 
turn lead to dysregulated protein synthesis of crucial enzymes and transporters in 
cholesterol metabolism, possibly contributing towards hypercholesterolemia. 
 
Mitochondrial matrix and peroxisomes were among the top cellular components 
in which the DEGs were involved in. Peroxisomes are small organelles which 
contain a variety of enzymes involved in a variety of metabolic processes 
including free radical detoxification, lipid catabolism and biosynthesis, and 
hydrogen peroxide metabolism. Mitochondrial matrix, the site of tissue 
respiration, contains the enzymes for the tricarboxylic acid cycle and, in some 
organisms, the enzymes involved in fatty acid oxidation. They are known to house 
numerous cellular metabolic processes. 
 
Using the KEGG pathway analysis tool, the DEGs were mapped to 19 different 
pathways, of which the second most significant pathway ‘ABC transporters’ was 
the most relevant to cholesterol metabolism, and might be involved in the 
pathogenesis of hypercholesterolemia in the IL-13 transfected nephrotic rats. Of 
the eight DEGs involved in the ‘ABC transporters’ pathway, ABCG5 expression 
showed the greatest downregulation. 
 
qPCR validation of crucial genes involved in cholesterol metabolism identified 
HMGCR as one of the upregulated genes, and this could explain the increased 
synthesis of cholesterol, as HMGCR controls the first rate-limiting step in the 
synthesis of cholesterol. In the PAN rat model of nephrotic syndrome, significant 
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but transient upregulation of hepatic HMGCR expression and activity was also 
observed, of which the hypercholesterolemia was attributed to this transient 
upregulation (Vaziri and Liang, 1995). However, pathway analysis could not 
demonstrate any significant involvement of HMGCR in the molecular pathogenic 
mechanism of hypercholesterolemia in IL-13 transfected nephrotic rats. 
 
Downregulation of cholesterol transporters, LDLR and ABCG5, could suggest 
defective clearance of cholesterol from the circulation and from the liver into bile 
respectively. However our microarray data in the IL-13 transfected nephrotic rats 
showed that only ABCG5 was significantly downregulated, and this was validated 
by qPCR. ABCG5 is highly involved in biliary cholesterol transport in the liver. It 
is essentially a half-transporter, belonging to the family of ATP-binding cassette 
(ABC) transporters, which are transmembrane proteins that transport various 
substrates such as lipids, sterols and drugs across cellular membranes by utilizing 
energy from adenosine triphosphate (ATP) hydrolysis. A fully functional 
transporter is formed when ABCG5 binds to ABCG8, limiting intestinal sterol 
absorption and promoting hepatic biliary excretion of sterols. 
 
Since the discovery that mutation in ABCG5 and/or ABCG8 can lead to 
sitosterolemia, a rare autosomal recessive lipid metabolic disease whereby 
patients exhibit hyperabsorption and marked reduction in biliary excretion of 
dietary sterols but have normal biliary excretion of phospholipids, emerging 
evidence is suggesting the specific involvement of ABCG5 and ABCG8 in the 
74 
 
transport and regulation of cholesterol metabolism (Berge et al., 2000; Miettinen, 
1980). Sitosterolemia patients are often hypercholesterolemic, which leads to the 
development of cholesterol deposits in the skin and tendons known as xanthomas, 
as well as in the arteries, leading to accelerated atherosclerosis and eventually 
premature coronary heart disease (Bhattacharyya and Connor, 1974; Miettinen, 
1980; Salen et al., 1989). 
 
Disruption of either ABCG5 or ABCG8 in mice resulted in increased intestinal 
absorption and decreased biliary excretion of cholesterols (Yu et al., 2002a; Yu et 
al., 2004). Overexpression of human ABCG5 and ABCG8 in ABCG5/G8-
knockout mice led to reduced absorption and increased secretion of dietary 
cholesterol (Wu et al., 2004; Yu et al., 2005). Similarly, the overexpression of 
ABCG5 and ABCG8 in mice caused a selective increase in cholesterol excretion 
into bile (Yu et al., 2002b). 
 
Evidence have shown that ABCG5 and ABCG8 are obligate heterodimers, only 
dimerizing with each other and not with other half-transporters from the G family 
of ATP transporters such as ABCG1, ABCG2 and ABCG4. They are also 
dependent on one another for transport out of endoplasmic reticulum to be 
expressed on membrane surface (Graf et al., 2003). The transporter is highly 
expressed in the liver and intestine, specifically located on the apical surface of 
hepatocyte facing the bile canaliculi and brush border membrane of enterocyte 
(Graf et al., 2003; Klett et al., 2004). ABCG5/G8 consists of two transmembrane 
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domains that contain the translocation site for specific substrates such as 
cholesterol or plant sterol, and two cytoplasmic nucleotide binding domains that 
hydrolyze ATP to drive the transport process (Holland and Blight, 1999). 
 
ABCG5 and ABCG8 genes are located adjacent to each other in a head-to-head 
orientation on chromosome 2 and are encoded on opposite strands, with their 
initiation codons separated by a 144bp intergenic region (Berge et al., 2000; Lu et 
al., 2001). This intergenic region not only serves as a bidirectional promoter, but 
also contains binding sites for GATA transcription factor, NF-kB, hepatocyte 
nuclear factor 4 alpha (HNF4a) and liver receptor homolog-1 (LRH-1) (Freeman 
et al., 2004; Remaley et al., 2002; Sumi et al., 2007). 
 
A very prominent and well-established transcriptional regulator of ABCG5 is 
LXR, which is highly involved in cholesterol degradation (Repa et al., 2002). The 
LXRE within the intergenic region of ABCG5 and ABCG8 genes has only been 
recently identified (Back et al., 2013). LXR activation increases the transcription 
of ABCG5 and ABCG8 in the liver. Consistently, activation of LXR fails to 
increase biliary cholesterol excretion in ABCG5/G8-knockout mice (Yu et al., 
2003). Similarly, hepatic ABCG5/G8 expression was decreased in the LXRa-
knockout mice when challenged with a high cholesterol diet, demonstrating that 
sterol-induced upregulation of ABCG5/G8 requires LXRa, whereas the 
expression of ABCG5/G8 was still maintained and comparable to wild-type mice 




Although there were no significant changes in LXRa and RXRa expression levels 
in our microarray data, their downstream target gene ABCG5 was drastically 
downregulated, which could lead to a decrease in biliary excretion of hepatic 
cholesterols. Hence, excess cholesterols in the circulation might not be cleared as 
efficiently, mounting to the hypercholesterolemia observed in the IL-13 
transfected nephrotic rats. 
 
In summary, the pathogenesis of hypercholesterolemia in the IL-13 transfected 
nephrotic rats with MCNS could be due to the downregulation of ABCG5 which 
is associated with decreased hepatic clearance of cholesterol into bile, and 
upregulation of HMGCR, associated with increased synthesis of cholesterol. 
Upregulation of gene expression of cholesterol degradation enzymes shown in our 
microarray, although not significant on qPCR, could indicate a possible feedback 
mechanism consequent to the increased plasma cholesterol.  
 
The next chapter will investigate the initial molecular mechanism (early event 
prior to the development of proteinuria) that could have resulted in the 
dysregulated transcriptional profile seen in the hypercholesterolemic nephrotic 
rats (late event), in particular the role of ABCG5 and HMGCR.  
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Chapter 4 Delineating the initial molecular mechanism of 




Patients with MCNS relapses have extremely high serum cholesterol, typically 10 
to 20mmol/l, up to four times the normal cholesterol level (Hu et al., 2010; 
Querfeld et al., 1988), compared to other diseases with similar urinary protein 
losses such as patients on peritoneal dialysis whose protein losses can reach a 
similar range as nephrotic patients, yet serum total cholesterol level rarely exceeds 
7mmol/l (Johansson et al., 2000). Moreover, hypercholesterolemia has been 
observed to precede the development of proteinuria in some of these children with 
MCNS following a viral infection.  
 
This observation, together with the extreme serum total cholesterol increase 
during the disease phase and rapid drop to normality in remission, suggests that 
proteinuria could not be the sole trigger for hypercholesterolemia in MCNS as 
purported in the PAN rats, and that some other mediators could potentially 
contribute to the hypercholesterolemia seen in this disease. 
 
Our IL-13 gene overexpressed rat model demonstrated features consistent with 
MCNS, namely marked proteinuria, hypoalbuminemia, edema and 
hypercholesterolemia, as well as podocyte foot process effacement. Additionally, 
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a significant correlation was established between serum IL-13 and serum 
cholesterol in these IL-13 transfected nephrotic rats, but not with serum albumin 
or urine albumin excretion level (Lai et al., 2007). 
 
We therefore hypothesized that the hypercholesterolemia in our IL-13 gene 
overexpression rat model of minimal change-like nephropathy was not solely 
secondary to the marked proteinuria, but could be due to increased level of plasma 





4.2. Aims of chapter 
The aims of this chapter are to: 
1. Investigate if hypercholesterolemia preceded the onset of proteinuria in 
our IL-13 gene overexpression rat model of MCNS by studying the 
biochemical profile at weekly intervals following IL-13 transfection of the 
rat. 
2. Perform a comparative analysis of the gene expression profile of the 
pathways of hepatic cholesterol metabolism between the IL-13 transfected 
rats at the onset of hypercholesterolemia in the pre-proteinuric phase 
(early event) and the nephrotic phase (late event), in particular the role of 
the DEGs identified from the microarray profile of the IL-13 transfected 
nephrotic rats in the late event, namely ABCG5 and HMGCR. 
3. Investigate the plasma and liver lipid profiles and hepatic protein 
expressions of the selected DEGs during the early event of the IL-13 





4.3.1. Relationship of IL-13 to the development of hypercholesterolemia and 
proteinuria in IL-13 transfected rats from Week 0 to Week 10 
Plasma IL-13 was significantly elevated as early as Day 1 after the first 
electroporation of pCI-IL-13, and remained significantly higher in the IL-13 
transfected rats compared to control rats throughout the entire experiment until 
Week 10 (Figure 8) (Appendix 4.1). 
 
 
Figure 8: Weekly plasma IL-13 profile. 
Plasma IL-13 was significantly elevated in the IL-13 transfected rats compared to control rats from 
Day 1 to Week 10. ^ denotes p-value < 0.005, * denotes p-value < 0.001. 
 
As shown in Figure 9, in the IL-13 transfected rats, plasma cholesterol was 
significantly higher than controls from Week 1 onwards and preceded the onset of 
significant proteinuria which occurred at Week 10 (Figure 10) (Appendix 4.2 and 




Figure 9: Weekly plasma cholesterol profile. 
Plasma cholesterol was significantly elevated from Week 1 onwards in the IL-13 transfected rats 
compared to control rats. * denotes p-value < 0.02. 
 
 
Figure 10: Weekly urine albumin excretion profile. 
Urine albumin excretion was significantly elevated at Week 10 in the IL-13 transfected rats 




4.3.2. Phenotype of HC rats 
In order to investigate the pathogenesis of hypercholesterolemia in the absence of 
proteinuria upon IL-13 transfection, HC rats which developed 
hypercholesterolemia in the pre-proteinuric phase (termed as ‘early event’) were 
sacrificed as soon as their plasma total cholesterol levels were 1.5 times above 
their baseline values at the start of the experiment at Week 0. 
 
The HC rats showed significant elevation in plasma IL-13, plasma total 
cholesterol and liver mass compared to controls. In addition, the plasma creatinine 
was significantly lower in this group of rats. Plasma albumin and urine albumin 
excretion did not differ significantly between the control rats and HC rats (Table 
7) (Appendix 4.4). 
 
Table 7: Profile of control and HC rats. 







(pg/ml) 21 ± 3 (10-36) 1219 ± 290 (112-4420) < 0.001 
Plasma total cholesterol 
(mmol/l) 1.84 ± 0.05 (1.60-2.03) 2.97 ± 0.22 (2.14-5.07) < 0.001 
Plasma albumin 
(g/l) 37.1 ± 1.5 (31.0-44.2) 40.1 ± 1.3 (31.8-48.5) 0.101 
Plasma creatinine 
(µmol/l) 95.9 ± 5.0 (70.5-116.9) 81.4 ± 3.7 (55.3-105.7) 0.029 
Urine albumin excretion 
(µg/24hour) 254 ± 39 (133-436) 308 ± 40 (104-645) 0.421 
Body mass 
(g) 257 ± 12 (196-311) 248 ± 7 (208-289) 0.474 
Liver mass 




Plasma lipid profiling was carried out on a subgroup within the HC rats after 
overnight fasting. They exhibited significantly elevated levels of plasma LDL-
cholesterol and HDL-cholesterol, without any difference in plasma triglycerides 
when compared to controls. There was no significant difference in the liver 
cholesterol levels between control and HC rats (Table 8) (Appendix 4.5 and 
Appendix 4.6). H&E staining carried out on the rat liver section did not show any 
gross abnormality in both control and HC rats, nor were there lipid droplets 
observed in the HC rats (Figure 11). 
 
Table 8: Plasma lipid profile and liver cholesterol profile of control and HC rats. 
Results are shown as mean ± SEM with the range of values for each parameter in parentheses. 
Plasma Control rats (n=6) 
HC rats 
(n=5) p-value 
Total cholesterol (mmol/l) 1.85 ± 0.07 (1.60-2.03) 2.60 ± 0.24 (2.14-3.30) 0.006 
LDL-cholesterol (mmol/l) 1.11 ± 0.09 (0.81-1.41) 1.68 ± 0.18 (1.33-2.30) 0.011 
HDL-cholesterol (mmol/l) 0.47 ± 0.05 (0.32-0.64) 0.69 ± 0.07 (0.52-0.90) 0.045 
Triglycerides (mmol/l) 0.59 ± 0.12 (0.39-1.18) 0.51 ± 0.06 (0.31-0.62) 0.855 
Liver Control rats (n=9) 
HC rats 
(n=15) p-value 
Total cholesterol (mg/g liver) 1.00 ± 0.07 (0.77-1.46) 0.92 ± 0.03 (0.71-1.17) 0.493 
Free cholesterol (mg/g liver) 0.82 ± 0.06 (0.66-1.19) 0.74 ± 0.03 (0.62-0.94) 0.221 






Figure 11: H&E staining of rat liver. 
H&E staining of the livers of control rats (C) (n=3) and HC rats (HC) (n=3). Images were taken at 
40X magnification. 
 
4.3.3. Comparative analysis of gene expression profile and protein 
expression in HC rats 
To establish the presence of IL-13 receptors in the liver, hepatic gene expressions 
of IL-13 receptor subunits, IL-4Ra, IL-13Ra1 and IL-13Ra2, were studied. Only 
IL-13Ra2 showed significant upregulation in the HC rats (Figure 12). Moreover, 
there was an increase in the protein level for IL-13Ra2, similar to its gene 





Figure 12: Hepatic mRNA expressions of IL-13 receptor subunits in HC rats. 
No significant difference was observed in the hepatic mRNA expressions of IL-4Ra and IL-13Ra1 
between the HC rats (n=15) and control rats (n=9). Hepatic IL-13Ra2 mRNA level was 
significantly elevated in HC rats compared to controls. 
 
 
Figure 13: Hepatic protein expressions of IL-4Ra and IL-13Ra2 in HC rats. 
Representative Western blot image of IL-4Ra and IL-13Ra2 in control (C) and HC rats (HC) with 
GAPDH as loading control (A). No significant difference in hepatic protein expressions of IL-4Ra 
and IL-13Ra2 was observed between the HC rats (n=13) and control rats (n=9) (B).  
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The nine genes selected for microarray validation by qPCR in the IL-13 
transfected nephrotic rats in Chapter 3 were further investigated in the HC rats. 
ABCG5 was the only gene that showed consistent downregulation in both the 
microarray data and HC rats. HMGCR transcription was significantly upregulated 
in microarray data but showed a non-significant downregulation in HC rats. 
Significant downregulation of LXRa, RXRa, ABCA1 and ACAT2 was only 
detected in the HC rats, and not in the nephrotic rats (Figure 14) (Appendix 4.7). 
 
 
Figure 14: Hepatic mRNA expressions of cholesterol metabolic genes in HC rats. 
The nine genes selected for microarray validation by qPCR in the IL-13 transfected nephrotic rats 
were investigated in the HC rats (n=15) and controls (n=9). The gene expression index for LDLR 




The protein expression of ABCG5 in the liver of HC rats was subsequently 
validated using ELISA, and this showed a significant downregulation as 
compared to controls (Figure 15) (Appendix 4.8). 
 
 
Figure 15: Hepatic protein concentration of ABCG5 in HC rats. 
Hepatic protein concentration of ABCG5 was significantly decreased in the HC rats (n=15) as 
compared to control rats (n=9). 
 
Using Western blot analysis, the protein expression of ABCA1 in the liver of HC 
rats was significantly reduced compared to control rats (Figure 16). Although 
there was no significant difference between the hepatic protein expression of 
LXRa in the HC rats compared to controls (Figure 17), a significant correlation 
was established between hepatic protein level of LXRa and plasma total 





Figure 16: Hepatic protein expression of ABCA1 in HC rats. 
Representative Western blot image of ABCA1 in control (C) and HC rats (HC) with GAPDH as 
loading control (A). Hepatic protein expression of ABCA1 was significantly downregulated in HC 





Figure 17: Hepatic protein expression of LXRa in HC rats. 
Representative Western blot image of LXRa in control (C) and HC rats (HC) with GAPDH as 
loading control (A). No significant difference in hepatic protein expression of LXRa was observed 




Figure 18: Correlation between hepatic protein expression of LXRa and plasma total 




The overexpression of IL-13 in rats was carried out by in vivo electroporation of 
pCI-IL-13 as reported previously by Lai et al. (Lai et al., 2007). Successful 
intramuscular electroporation of pCI-IL-13 was confirmed by the consistent 
significant elevation of plasma IL-13 in the IL-13 transfected rats as compared to 
control rats throughout the entire experiment. 
 
The longitudinal biochemistry profiling of the IL-13 transfected rats from Week 0 
to Week 10 showed that plasma cholesterol was significantly elevated by Week 1, 
whereas proteinuria was only significantly elevated at Week 10, demonstrating 
that the development of hypercholesterolemia preceded the onset of proteinuria. 
This observation was consistent with our hypothesis that the hypercholesterolemia 
in our IL-13 overexpression rat model of minimal change-like nephropathy is not 
solely secondary to the marked proteinuria, but could be related to the increased 
level of plasma IL-13 acting on hepatic pathways of cholesterol metabolism. 
 
In order to investigate the molecular mechanism of IL-13-induced 
hypercholesterolemia prior to the onset of significant proteinuria, that is, the 
‘early event’, a subgroup of IL-13 transfected rats, termed HC rats, were 
sacrificed as soon as their plasma total cholesterol levels were 1.5 times above 
their baseline values at the start of the experiment at Week 0, without the 
development of proteinuria. These hypercholesterolemic HC rats had significantly 
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heavier liver masses, suggestive of a more active or dysregulated metabolism 
occurring in the liver as compared to control rats. 
 
Fasting plasma lipid profiling was carried out on a subgroup within the HC rats, 
and this showed that both plasma LDL-cholesterol and HDL-cholesterol were 
significantly elevated, but not plasma triglycerides. Therefore, the hyperlipidemia 
in our IL-13 transfected rat model was consistent with that seen in human MCNS, 
with elevated levels of plasma LDL-cholesterol being the major lipid abnormality. 
The exact nature of plasma HDL-cholesterol in nephrotic syndrome has not yet 
been confirmed, and reported to be variable by different authors. However, 
upregulation of plasma HDL-cholesterol has also been shown in patients with 
nephrotic syndrome and PAN rats (Adigun et al., 1999; Liang and Vaziri, 1999; 
Michaeli et al., 1981; Oetliker et al., 1980), similar to our IL-13 transfected rats. 
 
Our HC rats did not demonstrate significant hypertriglyceridemia, as this has been 
described mainly in overtly nephrotic rats, probably secondary to the massive 
proteinuria. In a recent landmark study by Clement et al., plasma angiopoietin-
like 4 (ANGPTL4) has been identified as the molecular link between proteinuria 
and hypertriglyceridemia (Clement et al., 2014). These authors have shown that 
the increase in ANGPTL4 in circulation in response to nephrotic range proteinuria 
induced hypertriglyceridemia. ANGPTL4 is a known inactivator of LPL, a crucial 
enzyme that breaks down triglycerides to free fatty acids (FFAs) resulting in FFA 
uptake in the adipose tissue, heart and skeletal muscles. Inhibition of LPL by 
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ANGPTL4 thus results in the development of hypertriglyceridemia. However, the 
investigators have not been able to demonstrate any relationship between 
ANGPTL4 and the marked hypercholesterolemia seen in nephrotic syndrome. 
 
In order to determine if the elevated plasma cholesterol was due to increased 
hepatic synthesis as the liver is the major organ regulating cholesterol production, 
we went on to examine the liver cholesterol profile in the IL-13 transfected HC 
rats. Liver total cholesterol, cholesteryl esters and free cholesterol in the HC rats 
were not significantly different from the control rats, similar to that observed in 
PAN rats (Kim et al., 2007; Zhou et al., 2008). H&E staining also did not show 
any accumulation of large amounts of lipid droplets within the liver, when 
compared to control rats. This suggested that the severe hypercholesterolemia 
following IL-13 transfection in our HC rats was more likely a result of defective 
hepatic clearance of cholesterol from the circulation into the bile ducts rather than 
due to increased hepatic synthesis. 
 
The gene and protein expressions of the IL-13 receptor subunits were detected in 
the liver of HC rats, with IL-13Ra2 gene expression showing significant 
upregulation, indicating that circulatory IL-13 was able to act on the liver to 
trigger downstream intracellular event. We therefore proceeded to investigate in 
the HC rats, the nine crucial genes identified from the microarray profile in 
Chapter 3, that are well established to significantly affect cholesterol metabolism 




Although the IL-13 transfected nephrotic rats demonstrated significant increase in 
HMGCR mRNA level, we could not show any significant difference in HMGCR 
between HC and control rats. This was consistent with our finding of 
downregulation of ACAT2 gene expression, an enzyme important in the 
conversion of excess hepatic free cholesterols to cholesteryl esters for storage, as 
the liver cholesterol in the HC rats was not elevated, despite the high plasma 
cholesterol level. In contrast, the hypercholesterolemia in PAN rats has been 
attributed to the upregulation of hepatic HMGCR and ACAT2 expression and 
enzymatic activity (Vaziri and Liang, 2002; Vaziri and Liang, 1995). Therefore, 
the mechanism triggering hypercholesterolemia in our IL-13 transfected rat model 
of nephrotic syndrome during the ‘early event’ prior to onset of proteinuria was 
different from that in PAN rats. Dysregulation of HMGCR appeared to be a late 
event in our IL-13 transfected rat model, with upregulation occurring only when 
the rats developed frank nephrosis. 
 
Both gene and protein expressions for ABCG5 were significantly downregulated 
in the HC rats, consistent with the ABCG5 downregulation observed in the IL-13 
transfected nephrotic rats representing the late event. ABCG5 is crucial in the 
elimination of excess cellular free cholesterols into bile. The downregulation of 
ABCG5 could impede effective removal of cholesterol within the liver, leading to 
the buildup of intracellular cholesterols. This in turn could prevent the further 
uptake of excess circulatory cholesterols, leading to the significant elevation of 
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plasma LDL-cholesterol observed in the HC rats. Therefore, downregulation of 
ABCG5 could be one of the key elements in initiating and subsequently 
maintaining hypercholesterolemia in the IL-13 transfected rats. 
 
Both gene and protein expressions of ABCA1 were significantly downregulated 
in the HC rats. ABCA1 is a full transporter protein belonging to the ABC 
transporter superfamily, and is essentially involved in two main functions, of 
which is cell-dependent. Hepatic ABCA1 is involved in the biogenesis of HDL in 
the liver by mediating the efflux of cellular cholesterols and phospholipids to 
plasma apoA-I, whereas excess cellular cholesterols in peripheral cells are 
removed via ABCA1 into HDL to be transported back to the liver for either 
recycling or disposal from the body as bile, a process known as reverse 
cholesterol transport (RCT) (Lee and Parks, 2005). The study by Brunham et al. 
showed that knockout of the hepatic ABCA1 resulted in reduced plasma HDL-
cholesterol level and accelerated atherosclerosis (Brunham et al., 2009). Hence, 
ABCA1 is believed to be anti-atherogenic. 
 
Although hepatic ABCA1 was downregulated in our HC rats, this was not 
accompanied by a decrease in plasma HDL-cholesterol level, which was instead 
significantly elevated. Significant elevation of plasma HDL was also reported in 
other experimental rat models of nephrotic syndrome such as those induced by 
PA, adriamycin and passive Heymann nephritis (Kaysen et al., 1995; Liang and 
Vaziri, 1999). The biogenesis of plasma HDL does not depend solely on hepatic 
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ABCA1 and is multifaceted, involving also apoA-I, whose hepatic synthesis has 
been shown to be increased, along with decreased catabolism in experimental 
nephrosis (Liang and Vaziri, 1999; Marshall et al., 1990). High levels of plasma 
HDL could also be due to decreased availability of hepatic SR-BI (Brundert et al., 
2005; Kozarsky et al., 1997), which was also observed in the PAN nephrotic rats, 
coupled with significant increase in plasma HDL (Liang and Vaziri, 1999; Vaziri 
et al., 2011). 
 
The gene expression of LXRa, a major and prominent regulator for both ABCA1 
and ABCG5, was also significantly downregulated in the HC rats. Although we 
were unable to demonstrate any change in the LXRa protein level, we were able 
to demonstrate a significant inverse correlation between LXRa protein level and 
plasma total cholesterol in the HC rats, suggesting the regulatory role of LXRa in 
cholesterol metabolism. In addition, we found that levels of cognate LXRa target 
genes, ABCA1 and ABCG5, as well as the gene expression of RXRa, the obligate 
LXRa binding partner, were decreased during the early event of IL-13 transfection 
in the rats. Previous studies have reported that cytokines, such as IL-1b and TNF-
a, were able to suppress LXRa gene expression and activity (Ruan et al., 2004; 
Wang et al., 2005). It is therefore possible that IL-13 could be involved in the 
suppression of LXRa, which in turn downregulates its target genes ABCA1 and 
ABCG5, leading to the hypercholesterolemia seen in the IL-13 transfected rat 




In summary, we have shown that the elevation of plasma total cholesterol level 
preceded the onset of proteinuria in our IL-13 transfected rats. The study of the 
HC rats (early event) displayed significant reduction of ABCG5 gene and protein 
expressions, similar to that in the IL-13 transfected nephrotic rats. This was 
accompanied with the downregulation of ABCA1, and their transcriptional 
regulator LXRa and its obligate binding partner RXRa. Moreover, LXRa protein 
expression correlated inversely with plasma total cholesterol level, suggesting the 
possible role of LXRa-ABCG5/ABCA1 pathway in the initiation of 
hypercholesterolemia following IL-13 transfection. 
 
The next chapter will investigate the direct effect of IL-13 on the liver, using an in 
vitro rat primary hepatocyte cell culture incubated with IL-13 in order to validate 
these findings from our HC rats.  
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Chapter 5 Mechanism of IL-13-mediated cholesterol 




Cholesterol homeostasis is essential due to the involvement of cholesterol 
molecule in several biological processes such as the synthesis of steroid 
hormones, regulation of cell membrane fluidity and production of bile salts to 
emulsify dietary fats. 
 
The liver is central to the regulation of cholesterol homeostasis, which is 
maintained by a series of regulatory pathways that control the hepatic synthesis of 
endogenous cholesterol and elimination of excess cholesterol into the bile 
canaliculi. In addition, the liver synthesizes various lipoproteins involved in 
transporting cholesterol and lipids throughout the body. Any imbalance in 
cholesterol homeostasis would result in health complications, such as 
hypercholesterolemia, a risk factor for cardiovascular diseases. 
 
In the weekly biochemical profiling of our IL-13 transfected rats, 
hypercholesterolemia was shown to precede the development of proteinuria, 
depicting the early event upon IL-13 transfection. Hypercholesterolemia was 
sustained till the rats developed significant proteinuria and nephrotic syndrome, 
representing the late event following continuous IL-13 transfection. At this time 
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point, there was also a significant direct correlation between serum IL-13 and 
serum cholesterol levels in the IL-13 transfected rats. However, no relationship 
was seen between serum IL-13 and urinary albumin excretion or serum albumin 
levels. These observations strongly suggested that the hypercholesterolemia seen 
in our IL-13 transfected rats could be due to IL-13-induced dysregulation of 
cholesterol metabolism in the liver, and was not solely secondary to marked 
proteinuria. 
 
In the previous chapters, liver microarray profile of the IL-13 transfected 
nephrotic rats (late event) demonstrated severe downregulation of ABCG5 gene 
expression. Pathway analysis of the DEGs also identified ‘ABC transporters’ 
pathway to be the top most relevant pathway of cholesterol metabolism in our IL-
13 transfected nephrotic rats, suggesting the possible involvement of ABC 
transporters such as ABCG5 in the genesis of hypercholesterolemia. ABCG5 and 
its obligate binding partner ABCG8 are important for cholesterol excretion, 
secreting excess intracellular free cholesterols directly into the bile canaliculi. The 
disruption of ABCG5 could lead to increased hepatic cholesterol levels, thereby 
inhibiting the further uptake of circulatory cholesterols into the liver, eventually 
resulting in increased plasma cholesterol level. 
 
Our studies on the early event following IL-13 transfection in rats (HC rats) 
showed that the expression of ABCG5 was similarly reduced. These HC rats had 
high plasma cholesterol level but normal urine albumin excretion level. Therefore, 
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the consistent feature of ABCG5 downregulation found in both the early and late 
events in our IL-13 transfected rat model suggested a possible role for ABCG5 
both in initiating and sustaining the hypercholesterolemia seen in this model of 
minimal change-like nephropathy. 
 
On the other hand, the other cholesterol metabolic genes investigated did not 
show similar consistency between both the early and late events following IL-13 
transfection. In the late event where the IL-13 transfected rats had developed both 
hypercholesterolemia and proteinuria, increased gene expression of HMGCR was 
seen. On the contrary, HMGCR gene expression was not increased in the HC rats 
which developed hypercholesterolemia prior to onset of proteinuria, but instead 
was downregulated albeit insignificant statistically. The HC rats also showed 
downregulation of gene expressions of ABCA1, LXRa and RXRa, a finding not 
observed in the late event in the nephrotic rats. 
 
We therefore hypothesized that the hypercholesterolemia seen in our IL-13 
transfected rats prior to the onset of proteinuria could be due to the IL-13-induced 
dysregulation of cholesterol metabolism in the liver. The hypercholesterolemia 
could possibly be further enhanced by another stimulus during the late events, 





5.2. Aim of chapter 
The aim of this chapter is to investigate the direct effect of IL-13 on cholesterol 
homeostasis in the liver, by using an in vitro rat primary hepatocyte cell culture 
system, in order to validate the findings of cholesterol dysregulation from both the 
early and late events in the IL-13 transfected rats. Specifically, the objectives of 
this chapter are to: 
1. Validate the gene expression profile of IL-13 transfected nephrotic rats 
and HC rats in the IL-13-stimulated hepatocytes. 
2. Study the gene and protein expressions of molecules (LXRa, ABCA1 and 
ABCG5) involved in the cholesterol metabolic pathway(s) following IL-
13 stimulation. 
3. Determine intracellular cholesterol level in IL-13-stimulated hepatocytes. 
4. Assay [3H]-cholesterol transport in the IL-13-stimulated hepatocytes using 
apoA-I and taurocholate, which induces cholesterol efflux via ABCA1 and 
ABCG5 respectively. 
5. Perform functional studies using LXRa siRNA-transfected rat hepatocytes 
and investigate the effect of LXRa-knockdown on its downstream targets 





5.3.1. Establishing rat primary hepatocyte cell culture for IL-13 stimulation 
To study the direct effect of IL-13 on cholesterol metabolism in the liver, we first 
established the hepatocyte cell culture system. Primary hepatocytes were isolated 
from rat liver, followed by seeding and culturing them on a collagen-coated 
surface. Cells were observed under light microscope after seeding to ensure 
optimal confluency for re-establishment of cell polarity and cell-cell contact. The 
hepatocytes displayed a cuboidal morphology after a 3-hour incubation (Figure 
19A). 
 
After overnight incubation, the cells changed from the cuboidal morphology into 
a polygonal shape with extensive cell-cell contact and bile canaliculi network 
formation defined as the interconnecting bright translucent belts around each cell 
(Figure 19B). Cells were stimulated with 25ng/ml of IL-13 after overnight 
incubation. Similar cell morphology appearance was seen in IL-13-stimulated 
cultures at both 24-hour (Figure 19E) and 48-hour (Figure 19F) post-stimulation 
as compared to unstimulated cultures (Figure 19C and Figure 19D respectively). 
Hepatocytes still maintained their polygonal morphology with extensive cell-cell 
contact and bile canaliculi network formation in both unstimulated and IL-13-
stimulated cultured hepatocytes till 48-hour post-stimulation. The cells did not 





Figure 19: Morphology of cultured rat primary hepatocytes. 
Images of rat primary hepatocytes after 4 hours of seeding (A), overnight incubation (B), 24 hours 
in unstimulated condition (C), 48 hours in unstimulated condition (D), 24-hour stimulation with 





5.3.2. Comparative analysis of gene and protein expression profiles in rat 
primary hepatocyte cell culture 
Both IL-4Ra (Figure 20A) and IL-13Ra1 (Figure 20B) gene expressions were not 
significantly different between IL-13-stimulated and unstimulated hepatocytes 
(Appendix 5.1). However, gene expression of IL-13Ra2 was increased and protein 
expression of phosphorylated signal transducer and activator of transcription 6 
(pSTAT6) was detected in IL-13-stimulated cultures but reduced and undetected 
respectively in unstimulated cells (Figure 21), demonstrating and verifying the 




Figure 20: mRNA expression of IL-4Ra and IL-13Ra1 in IL-13-stimulated hepatocytes. 
No significant difference was observed for IL-4Ra (A) and IL-13Ra1 expressions (B) in 






Figure 21: Representative images of IL-13Ra2 and pSTAT6 expression in IL-13-stimulated 
hepatocytes. 
Representative gel image of IL-13Ra2 mRNA expression at 24-hour (24H) and 48-hour (48H) in 
unstimulated (I) and 25ng/ml of IL-13-stimulated hepatocytes (II). Expression of b-actin was 
shown as a housekeeping gene (A). Representative Western blot image of pSTAT6 protein 
expression at 24H and 48H in unstimulated (I) and 25ng/ml of IL-13-stimulated hepatocytes (II). 
Expression of STAT6 and GAPDH were shown for normalization and loading control respectively 
(B). 
 
The nine genes selected for microarray validation by qPCR in the IL-13 
transfected nephrotic rats in Chapter 3 were further investigated in the IL-13-
stimulated rat primary hepatocyte cell culture. These genes were grouped into 
those involved in cholesterol synthesis (Figure 22), elimination (Figure 23) and 
transport (Figure 24).  
 
Of the genes involved in cholesterol synthesis, there was no difference in gene 
expression of SREBF2 in IL-13-stimulated hepatocytes compared to unstimulated 
cultures (Figure 22A). On the other hand, gene expression of HMGCR was 
significantly downregulated in the IL-13-stimulated hepatocytes compared to 
unstimulated hepatocytes (Figure 22B), whereas gene expression of ACAT2 was 
significantly upregulated in the IL-13-stimulated hepatocytes compared to 





Figure 22: mRNA expression of genes involved in cholesterol synthesis in IL-13-stimulated 
hepatocytes. 
No significant difference was observed for SREBF2 expression (A), whereas HMGCR (B) and 
ACAT2 expressions (C) were significantly downregulated and upregulated respectively in 
hepatocytes stimulated with 25ng/ml of IL-13 for 24 hours as compared to unstimulated 
hepatocytes (n=5). 
 
Gene expressions of LXRa (Figure 23A), RXRa (Figure 23B) and CYP7A1 (Figure 
23C), which are involved in the cholesterol elimination pathway, demonstrated 





Figure 23: mRNA expression of genes involved in cholesterol elimination in IL-13-stimulated 
hepatocytes. 
Expression levels for LXRa (A), RXRa (B) and CYP7A1 (C) were significantly downregulated in 
hepatocytes stimulated with 25ng/ml of IL-13 for 24 hours as compared to unstimulated 
hepatocytes (n=5). 
 
Of the genes involved in cholesterol transport, there was no significant difference 
in gene expression of LDLR in the IL-13-stimulated hepatocytes compared to 
unstimulated cultures (Figure 24A). Following IL-13 stimulation, ABCA1 gene 
expression was significantly reduced (Figure 24B). However, the gene expression 
of ABCG5 was significantly increased in the IL-13-stimulated hepatocytes 





Figure 24: mRNA expression of genes involved in cholesterol transport in IL-13-stimulated 
hepatocytes. 
No significant difference was observed for LDLR expression (A), whereas ABCA1 (B) and 
ABCG5 expressions (C) were significantly downregulated and upregulated respectively in 
hepatocytes stimulated with 25ng/ml of IL-13 for 24 hours as compared to unstimulated 
hepatocytes (n=5). 
 
Western blot analysis showed significant downregulation for ABCA1 protein 
expression (Figure 25A and Figure 25B) in the IL-13-stimulated hepatocytes 
compared to controls, whereas no difference was detected for LXRa protein level 
(Figure 25A and Figure 25C). Protein concentration of ABCG5 measured using 
ELISA was not significantly different between IL-13-stimulated hepatocytes 





Figure 25: Protein levels of ABCA1, LXRa and ABCG5 in IL-13-stimulated hepatocytes. 
Representative Western blot image of ABCA1 and LXRa at 24-hour in unstimulated hepatocytes 
(I) and 25ng/ml of IL-13-stimulated hepatocytes (II), with GAPDH as loading control (A). 
Western blot and densitometric analyses showed a decrease in ABCA1 protein expression (B) and 
no change in LXRa protein level (C) in IL-13-stimulated hepatocytes as compared to unstimulated 
cells (n=6). ELISA did not detect any difference in ABCG5 protein concentration between IL-13-




5.3.3. Temporal expressions of LXRa and its target genes 
We next investigated the temporal gene expressions of LXRa, RXRa, ABCA1 and 
ABCG5 following IL-13 stimulation. These genes were significantly 
downregulated in the early events following IL-13 transfection in rats (HC rats). 
 
Gene expressions of LXRa (Figure 26A) and RXRa (Figure 26B) were 
significantly downregulated as early as 2-hour post-IL-13-stimulation compared 
to unstimulated hepatocytes, and was sustained till 24-hour post-stimulation. 
Gene expression of ABCA1 showed significant decrease 6-hour post-stimulation 
(Figure 26C), while CYP7A1 only showed significant decrease in gene expression 
24-hour post-stimulation (Figure 26E). Although there was significant increase in 
ABCG5 gene expression in the IL-13-stimulated hepatocytes throughout the 
temporal experiment, its expression showed a progressive decrease in the 






Figure 26: Temporal response curve of LXRa, RXRa, ABCA1, ABCG5 and CYP7A1 
expression following IL-13 stimulation in hepatocytes. 
Rat hepatocytes were cultured with 25ng/ml of IL-13 and harvested at various time points as 
indicated for gene expression detection (n=5). * indicates p-value < 0.05. 
 
5.3.4. Effect of IL-13 on [3H]-cholesterol efflux and intracellular cholesterol 
level 
The induction of [3H]-cholesterol efflux using apoA-I in culture medium was 
measured in the cultured hepatocytes after incubation with IL-13. ApoA-I-
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meditated cholesterol efflux in the IL-13-stimulated hepatocytes was significantly 
reduced when compared to unstimulated hepatocytes (Figure 27). Incubation with 
IL-13 also demonstrated significant decrease in [3H]-cholesterol efflux in the rat 
hepatocytes when bile acid taurocholate was used as the cholesterol acceptor in 
the culture medium (Figure 28). However, IL-13 stimulation of hepatocytes did 
not result in a change in intracellular total cholesterol levels as compared to 
unstimulated cells (Figure 29) (Appendix 5.4). 
 
 
Figure 27: Reduction in apoA-I-mediated [3H]-cholesterol efflux in IL-13-stimulated 
hepatocytes. 
Following 24 hours of [3H]-cholesterol labeling, cultured rat hepatocytes were stimulated for 24 
hours with 25ng/ml of IL-13. Cholesterol efflux was assayed with the addition of 5µg/ml of apoA-





Figure 28: Reduction in taurocholate-mediated [3H]-cholesterol efflux in IL-13-stimulated 
hepatocytes. 
Following 24 hours of [3H]-cholesterol labeling, cultured rat hepatocytes were stimulated for 24 
hours with 25ng/ml of IL-13. Cholesterol efflux was assayed by incubating 10mM of taurocholate 
in culture medium for another 30 minutes (n=10). 
 
 
Figure 29: No difference in intracellular cholesterol level between IL-13-stimulated and 
unstimulated hepatocytes. 
Cultured rat hepatocytes were incubated with 25ng/ml of IL-13 for 24 hours, followed by 
extraction of intracellular cholesterol using hexane:isopropanol. Concentration of cholesterol was 




5.3.5. Validation of LXRa regulation on ABCA1 and ABCG5 
To verify whether LXRa regulated ABCA1 and ABCG5 expressions, we used 
siRNA to knock down LXRa in our rat primary hepatocyte cell culture, and 
stimulated the culture with T0901317, followed by examining the gene expression 
of LXRa and its target genes ABCA1 and ABCG5. T0901317 is a well-established 
synthetic agonist for LXRa activity and known to induce LXRa target genes.   
Following incubation with LXRa siRNA, we achieved a significant and 
reproducible gene silencing of LXRa in rat primary hepatocytes under both 
unstimulated and T0901317-stimulated conditions, achieving a gene knockdown 
percentage efficiency of 78.6% ± 3.8% and 80.0% ± 2.7% respectively, as 
compared to cells incubated with non-targeting control siRNA (NTC) (Figure 30). 
LXRa protein level was similarly downregulated in the LXRa-knockdown 
hepatocytes under both unstimulated and T0901317-stimulated conditions, 
although insignificant due to small sample size, thus validating its gene 





Figure 30: LXRa siRNA-mediated silencing of LXRa gene expression in hepatocytes in the 
absence and presence of T0901317. 
Hepatocytes were first incubated with either 50nM of non-targeting control siRNA (NTC) or 
50nM of LXRa siRNA for 24 hours, followed by the absence or presence of 5µM of T0901317 




Figure 31: LXRa siRNA-mediated silencing of LXRa protein expression in hepatocytes in 
the absence and presence of T0901317. 
Hepatocytes were first incubated with either 50nM of NTC or 50nM of LXRa siRNA for 24 hours, 
followed by the absence or presence of 5µM of T0901317 (T) for another 24 hours (n=2 or 3). 
Representative Western blot image of LXRa in NTC- and LXRa siRNA-transfected hepatocytes, 
in the absence and presence of T0901317, with GAPDH as loading control (A). Decreased protein 
expression of LXRa was observed in LXRa siRNA-transfected hepatocytes in the absence and 
presence of T0901317 (B). 
 
Following LXRa siRNA transfection in hepatocytes, gene expressions of ABCA1 
(Figure 32) and ABCG5 (Figure 33) were reduced compared to cells transfected 
with NTC, although this did not reach statistical significance. 
 
To further clarify whether the regulation of ABCA1 and ABCG5 expressions was 
dependent on LXRa, we next examined the effect of LXRa-knockdown on 
T0901317-induced ABCA1 and ABCG5 expressions. Stimulation of NTC-
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transfected hepatocytes with T0901317 resulted in a significant increase in gene 
expression levels of both ABCA1 (Figure 32) and ABCG5 (Figure 33) compared 
to unstimulated NTC-transfected cells, indicative of successful activation of 
LXRa. T0901317-induced mRNA expressions of ABCA1 (Figure 32) and ABCG5 
(Figure 33) in the LXRa-knockdown hepatocytes were significantly reduced when 
compared to NTC-transfected cells stimulated with T0901317. 
 
Validating its mRNA expression, increase in ABCA1 protein level was observed 
in T0901317-stimulated NTC-transfected hepatocytes compared to unstimulated 
NTC-transfected cells. Protein levels of ABCA1 were downregulated, although 
not significant due to small sample size, in the LXRa-knockdown hepatocytes 
compared to NTC-transfected cells, under both unstimulated and T0901317-





Figure 32: Effect of LXRa siRNA on T0901317-induced ABCA1 gene expression level in 
hepatocytes. 
Hepatocytes were first incubated with either 50nM of NTC or 50nM of LXRa siRNA for 24 hours, 
followed by the absence or presence of 5µM of T0901317 (T) for another 24 hours (n=5). 
 
 
Figure 33: Effect of LXRa siRNA on T0901317-induced ABCG5 gene expression level in 
hepatocytes. 
Hepatocytes were first incubated with either 50nM of NTC or 50nM of LXRa siRNA for 24 hours, 





Figure 34: Effect of LXRa siRNA on T0901317-induced ABCA1 protein level in hepatocytes. 
Hepatocytes were first incubated with either 50nM of NTC or 50nM of LXRa siRNA for 24 hours, 
followed by the absence or presence of 5µM of T0901317 (T) for another 24 hours (n=2 or 3). 
Representative Western blot image of ABCA1 in NTC- and LXRa siRNA-transfected 
hepatocytes, in the absence and presence of T0901317, with GAPDH as loading control (A). 
Decreased protein expression of ABCA1 was seen in LXRa siRNA-transfected hepatocytes in the 






The hepatocyte is the major cell type involved in cholesterol regulatory pathways 
in the liver. Therefore rat primary hepatocyte cell culture was used in this chapter 
to study the direct effect of IL-13 in order to validate the findings of cholesterol 
dysregulation in the early and late events in the IL-13 transfected rats. 
 
Hepatocytes are highly polarized cells, and many of its liver-specific functions 
such as metabolite uptake, transport and excretion are highly dependent on cell 
polarity (Coleman and Roma, 2000; Treyer and Musch, 2013). The basolateral 
membrane in contact with the blood vessels contains transporter proteins 
responsible for the uptake of substrates to be metabolized within the cell. The 
apical membranes of adjoining hepatocytes form the bile canaliculi which contain 
export proteins to excrete free cholesterols and bile into the canaliculi after 
cellular cholesterol degradation (Tuschl et al., 2009). 
 
Membrane polarity is lost during the isolation of hepatocytes. It is therefore 
imperative to re-establish their polarity for long-term functional maintenance in 
vitro. In this study, our rat primary hepatocyte cell culture achieved and 
maintained a functional polygonal shape with extensive cell-cell contacts and bile 
canaliculi network formation after overnight incubation and throughout the 48-




The non-change in IL-13 receptor subunits IL-4Ra and IL-13Ra1 gene 
expressions in our IL-13-stimulated rat hepatocyte culture was consistent with the 
results in our HC rats. This was also similar to the findings by David et al. in 
human keratinocyte cell line HaCaT, where no change was seen in the mRNA 
expressions of IL-4Ra and IL-13Ra1 following incubation with IL-13 from 2 to 24 
hours (David et al., 2001). However, gene expression of IL-13Ra2 was 
upregulated and protein expression of pSTAT6 was only detected in IL-13-
stimulated hepatocytes, demonstrating the occurrence of intracellular IL-13 
signaling. This result was consistent with studies in monocytes, splenocytes and 
keratinocytes which have shown that IL-13 induced the expression of IL-13Ra2 
and triggered phosphorylation of STAT6 (Daines et al., 2006; David et al., 2001; 
Hebenstreit et al., 2006; Hershey, 2003). 
 
The mRNA expression profile of the nine cholesterol metabolic genes selected for 
microarray validation by qPCR in the IL-13 transfected nephrotic rats in Chapter 
3 were investigated in the IL-13-stimulated rat primary hepatocyte cell culture. 
 
With regards to the genes associated with cholesterol synthesis, we found a 
significant downregulation of gene expression of HMGCR in IL-13-stimulated 
hepatocytes, however transcription level of SREBF2 was not different from 
unstimulated cells. SREBF2 is a transcriptional regulator of HMGCR and LDLR, 
and upon activation induces cholesterol synthesis. Therefore, the significant 
downregulation of HMGCR expression in IL-13-stimulated hepatocytes could not 
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be due to SREBF2 downregulation, but rather a direct effect of IL-13 or elevated 
cellular free cholesterol level. In our hepatocyte culture system, ACAT2, an 
enzyme which converts free cholesterols into cholesteryl esters for storage within 
the hepatocytes, was significantly upregulated in the presence of IL-13 
incubation. ACAT2 is increased upon excess free cholesterols within the cell. 
Hence, the upregulation of ACAT2 observed in IL-13-stimulated hepatocytes 
could either be a feedback mechanism or a direct effect of IL-13. The measured 
intracellular total cholesterol level was not significantly different between IL-13-
stimulated hepatocytes and unstimulated cells. However, intracellular free 
cholesterol level was not measured, which could clarify if HMGCR and ACAT2 
were affected directly by IL-13 or were the result of the homeostatic response to 
an increased amount of intracellular free cholesterols. 
 
The cholesterol metabolic genes involved in the degradation of cholesterol, 
namely LXRa, RXRa and CYP7A1, were all significantly downregulated in the 
hepatocytes stimulated with IL-13. Obligate heterodimer LXRa and RXRa 
regulates the mRNA expression of CYP7A1. Downregulation of cholesterol 
degradation genes could lead to the accumulation of cholesterols in the cell, 
which in turn could downregulate cholesterol synthesis via HMGCR and increase 
cholesterol storage via ACAT2. 
 
IL-13 stimulation in the hepatocytes did not alter LDLR gene expression, which is 
involved in the hepatic uptake of circulatory cholesterols. This non-change in 
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LDLR level was in sync with the non-change in SREBF2 level. On the other hand, 
ABCA1 gene expression was downregulated following IL-13 stimulation. The 
significant downregulation in ABCA1 protein expression validated its gene 
expression level. Although there was significant elevation in ABCG5 mRNA 
transcription level early following IL-13 stimulation of hepatocytes, its protein 
expression was not different from unstimulated cells. The temporal experiment on 
ABCG5 gene expression levels showed that there was a progressive decrease in 
the difference between IL-13-stimulated and unstimulated hepatocytes over time. 
This together with the downregulation of ABCA1 gene and protein expressions, 
was associated with downregulation of LXRa, a known regulator of ABCA1 and 
ABCG5. Moreover, our HC rats also showed downregulation of gene expressions 
of LXRa, RXRa, ABCA1 and ABCG5 as well as protein expressions of ABCA1 
and ABCG5. The association between these genes was also demonstrated in the 
temporal experiment which showed that gene expressions of LXRa and RXRa 
were downregulated as early as 2 hours after IL-13 stimulation in the hepatocytes, 
whereas their target genes ABCA1 and CYP7A1 only showed significant 
downregulation after 6 hours and 24 hours respectively. 
 
The roles of ABCA1 and ABCG5 in IL-13-induced cholesterol efflux were 
examined in our rat primary hepatocyte culture, whereby the presence of specific 
cholesterol acceptor in the culture medium activates specific membrane 
transporter for cholesterol efflux. To initiate cholesterol efflux via ABCA1, 
cholesterol acceptor apoA-I is required in the culture medium (Kim et al., 2012; 
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Li et al., 2010; Schwartz et al., 2000; Wang et al., 2000), while bile salt 
taurocholate is used as the cholesterol acceptor for ABCG5 (Johnson et al., 2010; 
Tachibana et al., 2007; Vrins et al., 2007). 
 
IL-13-stimulated hepatocytes exhibited a significant decrease in the percentage of 
apoA-I-mediated cholesterol efflux as compared to unstimulated cells. This 
reduction in cholesterol efflux by hepatic ABCA1 into apoA-I could be due to the 
downregulation in both gene and protein expressions of ABCA1 in the IL-13-
stimulated hepatocytes. Decreased hepatic ABCA1 has been linked to inefficient 
clearance of excess cholesterol in peripheral cells, especially macrophages, which 
could lead to foam cell formation and eventually atherosclerotic lesions. 
 
Studies have demonstrated that the presence of bile salts as cholesterol acceptor 
was essential for ABCG5/G8 specific cholesterol efflux in cell models, and that 
other commonly known cholesterol acceptors such as apoA-I and HDL were not 
able to increase efflux via ABCG5/G8 (Tachibana et al., 2007; Vrins et al., 2007). 
Biologically, taurocholate is one of the major bile salts in mammalian bile, hence 
was used as cholesterol acceptor to induce cholesterol efflux in order to 
investigate ABCG5-mediated transport in the IL-13-stimulated hepatocytes. We 
have shown that the percentage of taurocholate-mediated cholesterol efflux was 
significantly reduced in IL-13-stimulated hepatocytes, suggesting that the efflux 
of cholesterol via ABCG5 could be reduced or impaired. ABCG5 represents one 
of the major pathways for cholesterol removal in the liver. Downregulation of 
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ABCG5-mediated cholesterol efflux hinders the effective clearance of cellular 
cholesterols within the liver. This could lead to hepatic intracellular cholesterol 
buildup, of which excess free cholesterols could downregulate the cholesterol 
biosynthetic enzyme HMGCR and activate ACAT2, as seen in the HMGCR 
downregulation and ACAT2 upregulation in the IL-13-stimulated hepatocytes. 
 
We went on to confirm the regulatory effect of LXRa on ABCA1 and ABCG5 
expressions in our rat primary hepatocyte culture by using LXRa siRNA to knock 
down LXRa. Both gene and protein expressions of LXRa were successfully 
reduced upon LXRa siRNA transfection in our cultured rat hepatocytes under 
both T0901317-stimulated and unstimulated conditions. T0901317 is a well- 
established synthetic agonist of LXRa activity known to induce the transcription 
of LXRa target genes (Schultz et al., 2000). Stimulation of hepatocytes with 
T0901317 was able to significantly increase the expressions of ABCA1 and 
ABCG5 compared to unstimulated cells. Moreover, the significant decrease in 
ABCA1 and ABCG5 expressions in LXRa-knockdown hepatocytes compared to 
NTC-transfected cells in the presence of T0901317 demonstrated the direct 
regulation of LXRa on ABCA1 and ABCG5. 
 
In summary, IL-13-stimulated hepatocytes showed a gene expression profile 
consistent with reduced cholesterol synthesis, degradation and efflux with 
downregulation of LXRa, RXRa and ABCA1 expression. Although there was 
significant increase in ABCG5 gene expression in the IL-13-stimulated 
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hepatocytes throughout the temporal experiment, its gene expression showed a 
progressive decrease in the difference between stimulated and unstimulated 
cultures over time. In addition, ABCG5 protein expression showed similar levels 
in both IL-13-stimulated and unstimulated hepatocytes. Moreover, the reduced 
cholesterol efflux using apoA-I and taurocholate indicated that both efflux 
transporters ABCA1 and ABCG5 were functionally reduced, of which ABCA1 
showed consistent downregulation in its gene and protein expressions. The effect 
of LXRa-knockdown on T0901317-induced hepatocytes confirmed that LXRa 
directly regulated both ABCA1 and ABCG5 gene expressions, and that its 
downregulation could lead to the decrease in ABCA1 and ABCG5, hence 
reducing the efflux of hepatic cholesterol in vivo. How these events could lead to 






Chapter 6 Conclusion and future directions 
6.1. Conclusion 
In this study, we have elucidated distinct molecular mechanisms of 
hypercholesterolemia associated with our IL-13 transfected rats in the early (in the 
absence of proteinuria) and late (in the presence of proteinuria) events. 
 
The molecular signature of the hypercholesterolemia associated with IL-13 
transfected nephrotic rats (late event) is defined by DEGs highly involved in 
metabolism requiring NAD and NADP, characteristic of synthesis instead of 
catabolism. Pathway analysis of the DEGs identified ‘ABC transporters’ as the 
most relevant pathway in cholesterol metabolism, of which ABCG5 expression 
showed the greatest downregulation validated by qPCR, suggesting possible 
involvement of ABC transporters in the genesis of hypercholesterolemia seen in 
the IL-13 transfected nephrotic rats. Profiling of crucial cholesterol metabolic 
genes in these rats also showed HMGCR to be significantly upregulated. 
 
In order to determine if the cause of the dysregulation of ABCG5 and HMGCR 
was due to IL-13 transfection in the rats or secondary to proteinuria, we went on 
to study the liver molecular profile and protein expression of the cholesterol 
metabolic genes in the early phase of our IL-13 transfection rat model when 
hypercholesterolemia was first demonstrated, prior to the development of 
proteinuria (HC rats). The HC rats displayed reduction of ABCG5 expression, 
similar to that in the IL-13 transfected nephrotic rats. This was accompanied by 
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downregulation of ABCA1, and their transcriptional regulator LXRa and its 
obligate binding partner RXRa. Moreover, a significant inverse correlation was 
observed between hepatic LXRa protein level and plasma total cholesterol in the 
HC rats, suggesting the possible role of LXRa-ABCG5/ABCA1 pathway in the 
initiation of hypercholesterolemia following IL-13 transfection. 
 
In order to validate the role of this pathway in the genesis of hypercholesterolemia 
seen early in IL-13 transfected rats, we then investigated the expression profile of 
cholesterol metabolic genes in an IL-13-stimulated rat primary hepatocyte cell 
culture system and compared this to the molecular signatures seen in the early and 
late events in the IL-13 transfected rats. 
 
Gene expressions of SREBF2 and LDLR were not significantly different from 
controls across the IL-13 transfected nephrotic rats, HC rats, as well as in the IL-
13-stimulated hepatocytes. SREBF2 is a transcriptional regulator of HMGCR and 
LDLR. This could suggest that SREBF2-regulated cholesterol biosynthesis and 
LDLR-mediated cholesterol import do not play a major role in the 
hypercholesterolemia of IL-13-induced MCNS. 
 
We have demonstrated significantly increased gene expression of HMGCR only 
in the liver of IL-13 transfected nephrotic rats, but not early in the genesis of 
hypercholesterolemia prior to development of proteinuria in the HC rats. This 
finding was validated in our IL-13-stimulated rat hepatocytes where gene 
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expression of HMGCR was significantly downregulated compared to 
unstimulated hepatocytes. To determine whether the downregulation of HMGCR 
mRNA expression was secondary to an increased amount of hepatic intracellular 
cholesterols, we measured total cholesterol level in our IL-13-stimulated rat 
hepatocytes. However, there was no significant difference in the total cholesterol 
level between hepatocytes incubated with and without IL-13. This result was 
consistent with that observed in the HC rats, which also did not show any change 
in the liver total cholesterol level when compared to control rats. Further studies 
will have to be performed to determine the hepatic intracellular total cholesterol 
level at 48-hour post-IL-13-stimulation, as a 24-hour IL-13 incubation might be 
relatively short to detect any changes in the cholesterol concentration within the 
hepatocytes. In addition, the level of free cholesterols should be measured in our 
IL-13-stimulated hepatocytes, as it is the presence of excess free cholesterols 
binding to the sterol-sensing domain in HMGCR that results in its proteolytic 
degradation (Kuwabara and Labouesse, 2002). 
 
These results suggested that HMGCR did not have a primary role in the initial 
genesis of hypercholesterolemia in the IL-13 transfected rats, but upregulation of 
HMGCR was a late event phenomenon that perpetuates the hypercholesterolemia 
in nephrotic syndrome. HMGCR controls the rate-limiting step in the synthesis of 
endogenous cholesterol. The discrepant findings in HMGCR gene expression 
between the early and late events therefore suggest that hypercholesterolemia 
could possibly be further enhanced by another stimulus during the late event 
129 
 
upregulating HMGCR gene expression, namely the development of proteinuria.   
This finding is in contrast to the PAN rats with nephrotic syndrome, where studies 
have suggested that the transient increase in HMGCR was important in the 
initiation of hypercholesterolemia secondary to proteinuria (Vaziri and Liang, 
1995). 
 
The gene expression of ACAT2 was significantly upregulated in the cultured 
hepatocytes following IL-13 stimulation. The role of ACAT2 in the hepatocyte is 
to convert free cholesterols into cholesteryl esters for storage within the cell. An 
increase in ACAT2 enzyme activity therefore occurs in the presence of excess 
intracellular free cholesterols. Vaziri and Liang have attributed part of the 
hypercholesterolemia in PAN rats to the increase in ACAT2, whereby its increase 
could have led to a reduction in hepatic intracellular free cholesterol level. The 
decrease in free cholesterol level in turn could activate hepatic SREBF2 and its 
downstream targets, HMGCR and LDLR, to synthesize more cholesterols, and 
eventually diminishing the hepatic uptake of circulatory cholesterols, resulting in 
hypercholesterolemia in the PAN rats (Vaziri and Liang, 2002). However this 
theory was not substantiated in our IL-13-stimulated hepatocytes as the initial 
upregulation of ACAT2 occurred in association with HMGCR downregulation and 
normal levels of SREBF2. Furthermore, in the early event during the genesis of 
hypercholesterolemia in HC rats, ACAT2 gene expression was not upregulated, 
but was in fact significantly downregulated. Even in the IL-13 transfected 
nephrotic rats (late event), ACAT2 gene expression was not upregulated. Hence, 
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the upregulation of ACAT2 observed in IL-13-stimulated hepatocytes could either 
be a direct effect of IL-13 or secondary to a feedback mechanism following 
accumulation of hepatic free cholesterols. 
 
Gene expression of LXRa was significantly downregulated in the IL-13-
stimulated hepatocytes as compared to unstimulated condition, and this 
downregulation occurred as early as after 2 hours of IL-13 incubation, suggesting 
a direct effect of IL-13 on the regulation of LXRa expression. Expression of 
RXRa, the obligate binding partner of LXRa, also showed a similar temporal 
downregulation trend as LXRa. The decrease in both LXRa and RXRa was 
consistent with the decrease in the hepatic LXRa and RXRa expressions in HC 
rats. Moreover, protein expression of LXRa was unchanged in the IL-13-
stimulated hepatocytes, similar to the observation in HC rats. 
 
Gene expression of ABCA1, a target gene of LXRa, was significantly 
downregulated in hepatocytes stimulated with IL-13 as compared to controls, and 
this downregulation became significant after 6 hours of IL-13 incubation, and 
occurred after significant downregulation of LXRa. Protein expression of ABCA1 
was also significantly reduced in the IL-13-stimulated hepatocytes. These findings 
suggested that IL-13 first induced the downregulation of LXRa, which 
subsequently resulted in downregulation of ABCA1. Similarly, expression of 
ABCA1 was significantly downregulated in the HC rats but no change was seen in 
the IL-13 transfected nephrotic rats, again consistent with the concept that the 
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LXRa-ABCG5/ABCA1 pathway is activated early in the genesis of 
hypercholesterolemia, following IL-13 transfection. The downregulation of 
hepatic ABCA1 in our IL-13 transfected rats was not accompanied by a decrease 
in plasma HDL-cholesterol level. This could be because the biogenesis of plasma 
HDL is multifactorial involving other molecules such as SR-BI and apoA-I. 
 
Gene expression of CYP7A1, a key enzyme involved in cholesterol degradation, 
was significantly downregulated in the IL-13-stimulated hepatocytes. 
Downregulation of CYP7A1 causes the accumulation of cholesterols within the 
cell. Its temporal expression profile showed significant decrease only after 24 
hours of IL-13 incubation. The downregulation of CYP7A1 was not seen in both 
IL-13 transfected nephrotic rats and HC rats. As CYP7A1 is also a target gene of 
LXRa, this further supports the hypothesis that IL-13 acts on LXRa, which 
subsequently results in the downregulation of its target gene CYP7A1. 
 
Although the gene expression of ABCG5 in IL-13-stimulated hepatocytes was 
significantly upregulated, this ABCG5 upregulation could not account for the 
reduction in taurocholate-mediated cholesterol efflux seen in our hepatocyte cell 
culture system, since taurocholate is known to activate cholesterol efflux via 
ABCG5/G8. In addition, the temporal expression of ABCG5 showed a decreasing 
difference between IL-13-stimulated hepatocytes and unstimulated cells with 
time, suggesting a non-significant difference might be observed at a time point 
later than 24-hour. This was corroborated in the HC rats, where both gene and 
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protein expressions of ABCG5 were significantly downregulated, and this ABCG5 
gene downregulation was sustained in the IL-13 transfected nephrotic rats. 
 
In conclusion, the hypercholesterolemia observed early in the IL-13-induced rat 
model of MCNS (HC rats) could be due to IL-13-induced downregulation of 
LXRa, which subsequently led to the reduction in ABCA1 and ABCG5. The 
downregulation of hepatic ABCG5 could lead to reduced cholesterol efflux into 
bile canaliculi and hence inefficient removal of excess free cholesterols within the 
hepatocytes, bringing about an increased amount of intracellular cholesterols. 
Increased hepatic cholesterol level could inhibit the further uptake of circulatory 
cholesterols into the liver for excretion, leading to the hypercholesterolemia as 
seen in our IL-13 transfected rats. Late event hypercholesterolemia seen in our IL-
13 transfected nephrotic rats could possibly be maintained by the continuous 
downregulation of ABCG5 and upregulation of HMGCR secondary to the gross 
proteinuria (Figure 35). 
 
Our study has elucidated the gene molecular profile involved in the IL-13-induced 
hypercholesterolemia in the HC rats. Hence, to effectively bring down the 
elevated level of cholesterol to homeostatic level, targeted therapy could be 
developed to ameliorate the dysregulation of enzymes, transporters and/or 




Figure 35: Proposed mechanism of hepatic cholesterol dysregulation in the IL-13-mediated 
hypercholesterolemia. 
Plasma IL-13 was elevated upon IL-13 transfection in the rat (A). In the early event (pre-
proteinuric phase) (B), the increased circulatory IL-13 could act directly on the liver through IL-13 
receptor binding, resulting in decreased LXRa expression (1), and the subsequent downregulation 
of its target genes ABCA1 (2) and ABCG5 (4). Reduction in ABCA1 decreases the amount of 
plasma HDL being synthesized (3). Decreased hepatic ABCG5 leads to reduced cholesterol efflux 
into bile canaliculi (BC) (5), and hence inefficient removal of excess cholesterols within the 
hepatocyte, bringing about an increased amount of intracellular free cholesterols (6). This could 
inhibit the further uptake of circulatory cholesterols into the liver for excretion, leading to the 
hypercholesterolemia as seen in our IL-13 transfected rats (C). In the late event (D), the 
development of nephrotic range proteinuria resulted in the upregulation of HMGCR (7), and 
together with the continuous downregulation of ABCG5 (4), perpetuated the hypercholesterolemia 





6.2. Future directions 
In order to prove that IL-13 has a direct downregulatory effect on LXRa, we will 
be performing antibody inhibitory experiments on the IL-13 receptor subunits in 
the cultured hepatocyte system, prior to incubation with IL-13. When IL-13 
receptors are sufficiently blocked, IL-13 can no longer bind effectively to its 
receptors to trigger downstream signaling. The non-change in LXRa gene 
expression would prove the direct effect of IL-13 on LXRa. 
 
To confirm the effect of IL-13 on the expression of genes regulated by LXRa, we 
will perform transfection studies in cultured hepatocytes using LXRa response 
element (LXRE)-luciferase vector construct. Since IL-13 downregulates LXRa, 
which in turn downregulates its target genes ABCA1 and ABCG5, the activity of 
LXRE-linked luciferase should be significantly suppressed upon IL-13 
stimulation, implying that IL-13 is able to suppress the expression of LXRE-
regulated transcription in hepatocytes. 
 
To determine whether the loss of LXRa is the sole factor responsible for the IL-
13-mediated reduction in LXRE-driven gene transcription, we will cotransfect 
LXRa expression plasmid together with LXRE-linked luciferase plasmid construct 
in hepatocytes followed by IL-13 stimulation. Cotransfection experiment should 
show an increase in the LXRE-linked luciferase activity compared with 
hepatocytes transfected with only LXRE-linked luciferase plasmid construct in 




We could also overexpress LXRa in our IL-13 gene overexpression rat model of 
MCNS and observe if LXRa overexpression could prevent the lipid abnormalities 
observed in our IL-13 transfected rat model. 
 
Upon establishing the molecular mechanism of IL-13-induced dysregulation of 
LXRa in the rat model of MCNS, validation of this pathway will also be carried 
out on human primary hepatocytes. 
 
Although the regulation of cholesterol metabolism, such as production of 
endogenous cholesterol, mainly occurs in the liver, the intestine is also highly 
involved in regulating cholesterol metabolism. Intestinal cells also have very high 
expression levels of ABCG5/G8 (Lee et al., 2001), functioning to stimulate sterol 
secretion into the intestinal lumen for excretion. Transfection of IL-13 in the rats 
could result not only in downregulation of ABCG5/G8 in the hepatocytes but also 
in the intestinal cells, and could conceivably result in increased uptake of dietary 
cholesterol into the circulation resulting in hypercholesterolemia. Therefore, we 
propose to conduct IL-13 stimulation experiments on human intestinal cell culture 
model system such as Caco-2 and HT-29, as well as primary human intestinal 




Finally to confirm that the free cholesterol secreted into the bile is indeed 
decreased after IL-13 transfection of the rats, we will also be measuring the bile 
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Appendix 2.1: Protocol for rat urine albumin ELISA 
Preparation of reagents 
 0.1M sodium carbonate buffer, pH 9.6 
0.2M sodium carbonate (Na2CO3)    8ml 
0.2M sodium bicarbonate (NaHCO3)    17ml 
ddH2O        25ml 
 0.2M sodium carbonate (Na2CO3) 
Sodium carbonate (Na2CO3)     21.2g 
ddH2O        1000ml 
 0.2M sodium bicarbonate (NaHCO3) 
Sodium bicarbonate (NaHCO3)     16.8g 
ddH2O        1000ml 
 Blocking solution 
BSA        0.5g 
Tween 20        25μl 
1X PBS        50ml 
 Diluent for standards and samples 
1X PBS        500ml 
Tween 20        250μl 
 OPD substrate 
Phosphate-citrate buffer, pH 5.0     6ml 
OPD        300μl 
30% H2O2 (Only add H2O2 just before use.)   3μl 
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 Phosphate-citrate buffer, pH 5.0 
0.1M citrate buffer      24.3ml 
0.2M phosphate buffer      25.7ml 
ddH2O        50ml 
 0.1M citrate buffer 
Citric acid        3.84g 
ddH2O        200ml 
 0.2M phosphate buffer 
Na2HPO4 (anhydrous)      5.68g 
ddH2O        200ml 
 
Preparation of standards 
 Dilute rat albumin stock solution of 20mg/ml to a working solution of 
2μg/ml: 
1. Add 10μl rat albumin stock solution to 990μl diluent to get 200μg/ml 
solution. 
2. Add 50μl 200μg/ml solution to 4950μl diluent to get 2μg/ml solution. 
 Make a 2X serial dilution from the 2μg/ml solution to obtain standard 
concentrations in ng/ml of 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625. 
 
Preparation of samples 
 Dilute urine samples sequentially: 
1. First dilute centrifuged urine samples 1/10 by adding 50μl urine 
sample to 450μl diluent. 
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2. Dilute the above diluted urine sample between 1/5 and 1/100 as shown 
in table below: 
Second dilution 
(Final dilution) 
Volume from first dilution / μl Volume of diluent / μl 
1/5 (1/50) 40 160 
1/10 (1/100) 20 180 
1/20 (1/200) 15 285 
1/30 (1/300) 15 435 
1/40 (1/400) 15 585 
1/50 (1/500) 15 735 
1/60 (1/600) 15 885 
1/70 (1/700) 15 1035 
1/80 (1/800) 15 1185 
1/90 (1/900) 15 1335 
1/100 (1/1000) 15 1485 
 
Procedure 
1. Coat 96-well EIA/RIA Clear Flat Bottom Polystyrene High Bind 
Microplate (Corning Inc., MA, USA) with 100μl rabbit antiserum to rat 
albumin diluted 1/2000 in 0.1M sodium carbonate buffer, pH 9.6. Incubate 
at 4°C overnight. 
2. Aspirate coating antibody and wash microplate thrice with 1X PBS using a 
microplate washer (Tecan, Mannedorf, Switzerland).  
3. Block wells with 100μl blocking solution at room temperature for 45 
minutes. 
4. Discard blocking solution without washing. 
5. Add 50μl of diluent as blank, standards and diluted urine samples to each 
well in triplicate. Incubate at 37°C for 2 hours. 
6. Aspirate and wash plate thrice with 1X PBS using microplate washer.  
7. Incubate wells with 50μl HRP-conjugated sheep polyclonal antibody to rat 
albumin diluted 1/20000 in blocking solution at 37°C for 1 hour.  
8. Aspirate and wash plate 4 times with 1X PBS. 
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9. Add 50μl OPD substrate in each well and incubate in darkness for color 
development at room temperature for 10 minutes. 
10. Stop reaction with 60μl 4.5N sulphuric acid and mix gently. Incubate for 5 
minutes. 
11. Read absorbance at 490nm using microplate reader. 
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Appendix 2.2: Protocol for RNA purification and cleanup (RNeasy Mini 
Handbook, 4th Edition, 09/2010) 
 
Preparation of reagents 
 Buffer RPE is supplied as a concentrate. Before using it for the first time, 
add 4 volumes of absolute ethanol as indicated on the bottle to obtain a 
Buffer RPE working solution. 
 Prepare DNase I stock solution before using the RNase-Free DNase Set for 
the first time. Dissolve the lyophilized DNase I (1500 Kunitz units) by 
injecting 550µl of the RNase-free water provided using RNase-free needle 
and syringe. Mix gently by inverting the vial. Do not vortex. Aliquot the 
stock solution into single-use volume and store at -20°C. Do not refreeze 
aliquots after thawing. 
 
Procedure 
1. Adjust the sample to a final volume of 100µl with RNase-free water.  
2. Add 350µl Buffer RLT and mix well. 
3. Add 250µl absolute ethanol to the mixture and mix well by pipetting.  
4. Transfer the entire 700µl mixture to an RNeasy Mini spin column placed 
in a 2ml collection tube supplied. Centrifuge at 13000rpm for 15 seconds. 
Discard flow-through. 
5. Add 350µl Buffer RW1 to the spin column. Centrifuge at 13000rpm for 15 
seconds. Discard flow-through. 
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6. Add 10µl DNase I stock solution to 70µl Buffer RDD. Mix by gently 
inverting the tube and centrifuge briefly to collect residual liquid from the 
sides of the tube. 
7. Add the 80µl DNase I incubation mix directly to the spin column 
membrane and incubate at room temperature for 15 minutes. 
8. Add 350µl Buffer RW1 to the spin column. Centrifuge at 13000rpm for 15 
seconds. Discard flow-through. 
9. Add 500µl Buffer RPE to the spin column. Centrifuge at 13000rpm for 15 
seconds. Discard flow-through. 
10. Add 500µl Buffer RPE to the spin column. Centrifuge at 13000rpm for 2 
minutes. 
11. Place the spin column in a new 2ml collection tube supplied and discard 
the old collection tube with flow-through. Centrifuge at 13000rpm for 1 
minute. 
12. Place the spin column in a new 1.5ml collection tube supplied. Add 30µl 
RNase-free water directly to the spin column membrane. Centrifuge at 
13000rpm for 1 minute to elute the RNA. 
13. Repeat step 12 using the eluate from step 12 to obtain a higher RNA 




Appendix 2.3: Protocol for RNA quantification and quality analysis 
(Agilent RNA 6000 Nano Kit Quick Start Guide, Edition 04/2007) 
 
Preparation of reagents and equipment 
 Adjust purified liver tissue RNA sample concentration to 150ng/µl using 
RNase-free water. 
 Heat denature all RNA samples to minimize secondary structure and RNA 
6000 Nano Ladder at 70°C for 2 minutes before use and keep on ice. 
 Ensure chip priming station, IKA vortex mixer, 2100 Bioanalyzer and 
2100 Expert Software are set up and ready to be used. 





1. Pipette 550µl RNA 6000 Nano Gel Matrix into a spin filter. 
2. Centrifuge at 1500g at room temperature for 10 minutes. 
3. Aliquot 65µl filtered gel into 0.5ml RNase-free microfuge tubes included 
in the kit. Store at 4°C and use within 1 month. 
 
Preparing gel-dye mix 
4. Protect RNA 6000 Nano Dye Concentrate from light when thawing to 
room temperature. 
5. Vortex RNA 6000 Nano Dye Concentrate for 10 seconds and spin down. 
6. Add 1µl RNA 6000 Nano Dye Concentrate to the 65µl filtered gel aliquot. 
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7. Vortex mixture thoroughly and centrifuge at 13000g at room temperature 
for 10 minutes. Protect gel-dye mix from light before use. 
 
Loading gel-dye mix 
8. Place a new RNA 6000 Nano Chip on the chip priming station. 
9. Pipette 9µl gel-dye mix at the bottom of the well marked . 
10. Ensure the plunger is positioned at 1ml and then close the chip priming 
station.  
11. Press the plunger down until it is held by the clip. 
12. Wait for exactly 30 seconds before releasing the clip. 
13. Wait for 5 seconds and then slowly pull back the plunger to the 1ml 
position. 
14. Open the chip priming station, and pipette 9µl gel-dye mix in each of the 
wells marked . 
 
Loading RNA 6000 Nano Marker 
15. Pipette 5µl RNA 6000 Nano Marker in all the 12 sample wells and in the 
well marked . 
 
Loading ladder and samples 
16. Pipette 1µl heat-denatured RNA ladder into the well marked . 
17. Pipette 1µl heat-denatured sample into each of the 12 sample wells. 
Unused wells are to be filled with 1µl RNA 6000 Nano Marker to allow 
the chip to run properly. 
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18. Place the chip horizontally in the adapter of the IKA vortex mixer and 
vortex at 2400rpm for 1 minute. 




Major features of a successful ladder run should resemble Figure 1, 
displaying: 
 1 marker peak 
 6 RNA peaks (2100 Expert Software calls for 5 first ladder peaks only) 
 All 7 peaks are well resolved 
 Correct peak size assignment 
 
Major features of a successful eukaryotic total RNA run should resemble 
Figure 2, displaying: 
 1 marker peak 





Figure 1: An electropherogram of a successful ladder run. 
 
 
Figure 2: An electropherogram of a successful eukaryotic total RNA run. 
 
By selecting the Results sub-tab in the 2100 Expert Software version B.02.02 
or higher, values for the calculated RNA concentration, the ribosomal ratio 




Appendix 2.4: Protocol for cRNA hybridization and array scanning 
(Illumina Whole-Genome Gene Expression for BeadStation) 
 
Mix with Hyb reagents 
1. Preheat the oven (with rocking platform) to 58°C. 
2. To 750ng of cRNA, add RNase-free water up to 5µl and mix. 
3. Incubate at room temperature for 10 minutes to resuspend cRNA. 
4. Incubate GEX-HYB and GEX-HCB bottles in the 58°C oven for 10 
minutes to dissolve any salt precipitation. If salt precipitation persists, 
incubate at 58°C for another 10 minutes. 
5. Cool to room temperature and mix thoroughly before using. 
6. Add 10µl GEX-HYB to each cRNA sample. 
 
Set up hybridization 
7. Place Hyb Chamber Gaskets into Hyb Chamber. 
8. Dispense 200μl GEX-HCB into each of the 2 humidifying buffer 
reservoirs in each Hyb Chamber. Only add buffer to chambers that will be 
used. 
9. Seal Hyb Chamber with lid and keep on bench at room temperature until 
ready to load BeadChips into Hyb Chamber. 
10. Remove all BeadChips from their packages, using 3 fingers at the notches 
to release. 
11. Holding BeadChip by cover seal tab with tweezers using powder-free 
gloved hands, slide BeadChip into Hyb Chamber Insert such that the 
barcode lines up with barcode symbol on the Hyb Chamber Insert. 
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12. Preheat cRNA sample at 65°C for 5 minutes. 
13. Briefly vortex and then briefly centrifuge to collect liquid at the bottom of 
the tube. Allow sample to cool to room temperature before using.  
14. Dispense 15μl sample immediately after cooling to room temperature onto 
the large sample port of each array, ensuring pipette tip does not touch 
array. 
15. Load Hyb Chamber Inserts containing BeadChips into the Hyb Chamber 
with rocker speed at 5. 
16. Seal lid onto the Hyb Chamber by applying the back of the lid first and 
then bringing it down to the front to avoid dislodging the Hyb Chamber 
Insert. 
17. Incubate at 58°C for 18 hours. 
 
Prepare 1X High-Temp Wash buffer with overnight incubation 
18. Prepare 1X High-Temp Wash buffer by adding 50ml 10X High-Temp 
Wash buffer to 450ml RNase-free water. 
19. Place Hybex Waterbath insert into heat block and add 500ml 1X High-
Temp Wash buffer. 
20. Set heat block temperature to 55°C and pre-warm High-Temp Wash buffer 
to that temperature. 
21. Close heat block lid and leave overnight. 
 
Prepare reagents 




23. Pre-warm Block E1 buffer (4ml/chip) to room temperature.  
 
Room-Temp incubation 
24. Remove Hyb Chamber from oven and disassemble. 
25. Using powder-free gloved hands, remove BeadChips from Hyb Chamber 
and submerge them face up at the bottom of a container with 1000ml 
Wash E1BC solution. Observe for bubbles on BeadChips, and if any, 
locate them on the tracking sheet. 
26. Using powder-free gloved hands, remove the cover seal from BeadChip in 
a zigzag manner, ensuring the entire BeadChip remains submerged during 
removal. 
27. Using tweezers or powder-free gloved hands, transfer the peeled BeadChip 
into the slide rack submerged in the staining dish containing 250ml Wash 
E1BC solution. 
28. Using the slide rack handle, transfer the slide rack into the Hybex 




29. Incubate static for 10 minutes with the Hybex lid closed. 
 
First Room-Temp wash 
30. During the 10-minute High-Temp Wash buffer incubation, add fresh 
250ml Wash E1BC solution to a clean staining dish. 
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31. After the 10-minute High-Temp Wash buffer incubation is complete, 
immediately transfer the slide rack into the above prepared staining dish. 
32. Briefly agitate using rack handle, then shake on orbital shaker at 110rpm 
for 5 minutes. 
 
Ethanol wash 
33. Transfer slide rack to a clean staining dish containing 250ml 100% 
ethanol. 
34. Briefly agitate using rack handle, then shake on orbital shaker at 110rpm 
for 10 minutes. 
 
Second Room-Temp wash 
35. Transfer slide rack to a clean staining dish containing fresh 250ml Wash 
E1BC solution. 
36. Briefly agitate using rack handle, then shake on orbital shaker at 110rpm 
for 2 minutes. 
 
Block 
37. Pipette 4ml Block E1 buffer into a BeadChip Wash Tray. 
38. Transfer the BeadChip face up into BeadChip Wash Tray on rocker. 
39. Rock at medium speed for 10 minutes. 
40. Prepare Block E1 buffer (2ml/chip) with streptavidin-Cy3 (2µl of 1mg/ml 
stock per chip). Use a single conical tube for all BeadChips. Store in dark 





41. Pipette 2ml mixture of Block E1 buffer and streptavidin-Cy3 into a clean 
BeadChip Wash Tray. 
42. Transfer the BeadChip face up into BeadChip Wash Tray on rocker. 
43. Place BeadChip Tray Cover on BeadChip Wash Tray and rock at medium 
speed for 10 minutes. 
 
Third Room-Temp wash 
44. Add 250ml Wash E1BC solution to a clean staining dish. 
45. Transfer the BeadChip into the slide rack submerged in the staining dish. 
46. Briefly agitate using rack handle, and then shake at room temperature on 
orbital shaker for 5 minutes. 
 
Dry 
47. Prepare centrifuge with plateholders, paper towels and balance rack. Set 
speed to 270 rcf. 
48. Transfer BeadChips in slide rack from staining dish to centrifuge and spin 
at room temperature for 4 minutes. 
49. Store dry BeadChips in slide box until scanned. 
 
Scanning 
50. Scan the BeadChips with scan factor 1.5, PMT 531 using BeadArray™ 
Reader. Ensure the signal is strong enough, by looking out for the green 
color on the slot instead of red. Check that all the housekeeping genes and 
other parameters are normal.  
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Appendix 3.1: Profile of control and IL-13 transfected nephrotic rats used 





















(3)C1 C1 0 37.9 1.81 89.5 398 12.5 
(3)C2 C2 0 41.0 1.94 88.2 218 12.0 
(3)C4 C4 0 56.9 1.63 67.2 194 12.4 
(3)J2 J2 1578 27.9 7.80 69.7 2331 16.5 
(3)J4 J4 376 29.3 5.83 89.5 3098 19.3 
(4)J2 J8 232 28.3 4.82 53.1 7590 18.6 
(4)J5 J11 28 29.0 4.30 70.5 2996 16.8 
(4)J9 J15 336 29.3 4.45 67.6 6846 18.1 
(4)J13 J19 1753 18.9 8.78 79.3 12087 9.0 




Appendix 3.2: List of downregulated DEGs 
 
List of downregulated genes with fold change ≥ 1.5 and FDR < 0.05 
differentially expressed in the livers of IL-13 transfected nephrotic rats versus 
control rats. 
 




Gene description Fold change 
ILMN_1354422 Tor3a NM_001009683 torsin family 3, member A -7.39 
ILMN_1651179 Hhip NM_001191817 Hedgehog-interacting protein -6.88 
ILMN_1361259 Fabp7 NM_030832 fatty acid binding protein 7, brain -6.37 
ILMN_1361194 Rab30 NM_001015012 RAB30, member RAS oncogene family -6.17 
ILMN_1358631 Abcg5 NM_053754 ATP-binding cassette, sub-family G (WHITE), member 5 -6.00 
ILMN_1350232 Hacl1 NM_053493 2-hydroxyacyl-CoA lyase 1 -5.39 
ILMN_1360828 Acot5 NM_001079709 acyl-CoA thioesterase 5 -5.00 
ILMN_1376848 Adh6 NM_001012084 alcohol dehydrogenase 6 (class V) -4.60 
ILMN_1369012 Mgll NM_138502 monoglyceride lipase -4.47 
ILMN_1530388 Tor3a NM_001009683 torsin family 3, member A -4.21 
ILMN_1350398 Lin7a NM_053514 lin-7 homolog a (C. elegans) -3.96 
ILMN_1352829 Apol9a NM_001025066 apolipoprotein L 9a -3.66 
ILMN_1360753 Umps NM_001025402 uridine monophosphate synthetase -3.57 
ILMN_1367748 Plekhb1 NM_172033 pleckstrin homology domain containing, family B (evectins) member 1 -3.54 
ILMN_1366852 Ifi47 NM_172019 interferon gamma inducible protein 47 -3.25 
ILMN_1349962 Wasf1 NM_001025114 WAS protein family, member 1 -3.18 
ILMN_1372579 Slc22a5 NM_019269 solute carrier family 22 (organic cation/carnitine transporter), member 5 -3.15 
ILMN_1365923 Rbm48 NM_001024246 RNA binding motif protein 48 -3.09 
ILMN_1362381 Gbp2 NM_133624 guanylate nucleotide binding protein 2 -3.01 
ILMN_1351993 Cobll1 XM_001056368 Cobl-like 1 -2.96 
ILMN_1370450 Decr1 NM_057197 2,4-dienoyl CoA reductase 1, mitochondrial, nuclear gene encoding mitochondrial protein -2.95 
ILMN_1372159 Stat1 NM_032612 signal transducer and activator of transcription 1, transcript variant alpha -2.80 
ILMN_1359709 RGD1562178 XM_575395 adenylate kinase 2, mitochondrial-like -2.77 
ILMN_1650864 Ak6 NM_001012463 adenylate kinase 6 -2.77 
ILMN_1376733 Krt23 NM_001008753 keratin 23 (histone deacetylase inducible) -2.76 
ILMN_1349803 Shisa3 NM_001109087 shisa family member 3 -2.74 
ILMN_1376951 Aco1 NM_017321 aconitase 1, soluble -2.73 
ILMN_1364915 LOC300760 XM_236308 similar to H3 histone, family 3B -2.72 
ILMN_1371397 Ptgds2 NM_031644 prostaglandin D2 synthase 2, hematopoietic -2.71 
ILMN_1366138 LOC306428 XM_224824 similar to Chain A, T13s Mutant Of Bovine 70 kDa Heat Shock Protein -2.68 
ILMN_1373487 RGD1562373 XM_001062085 similar to 3-ketoacyl-CoA thiolase B, peroxisomal precursor (Beta-ketothiolase B) -2.65 
168 
 
ILMN_1361581 Sod3 NM_012880 superoxide dismutase 3, extracellular -2.60 
ILMN_1376900 Oas1i NM_001009680 2' -5' oligoadenylate synthetase 1I -2.57 
ILMN_1375888 Coro2a XM_575819 coronin, actin binding protein 2A -2.54 
ILMN_1349211 Fcn1 NM_031348 ficolin (collagen/fibrinogen domain containing) 1 -2.49 
ILMN_1650649 LOC366608 XM_345665 similar to mKIAA0716 protein -2.43 
ILMN_1371171 Ppih XM_001073803 peptidylprolyl isomerase H (cyclophilin H), transcript variant 1 -2.42 
ILMN_1363976 Ak2 NM_030986 adenylate kinase 2, transcript variant 1 -2.42 
ILMN_1355623 S100g NM_012521 S100 calcium binding protein G -2.41 
ILMN_1650501 Ptgr2 NM_001015009 prostaglandin reductase 2 -2.41 
ILMN_1361712 Lifr NM_031048 leukemia inhibitory factor receptor alpha -2.41 
ILMN_1355010 Gemin6 NM_001009466 gem (nuclear organelle) associated protein 6 -2.41 
ILMN_1370689 Peci NM_001006966 peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase -2.40 
ILMN_1650465 Sectm1a NM_001013043 secreted and transmembrane 1A -2.40 
ILMN_1356675 Pank1 NM_001106373 pantothenate kinase 1 -2.37 
ILMN_1362465 LOC290964 XM_214409 similar to RIKEN cDNA 8430426H19 -2.36 
ILMN_1368814 Adi1 NM_199097 acireductone dioxygenase 1 -2.36 
ILMN_1359094 Yc2 NM_001009920 glutathione S-transferase Yc2 subunit -2.35 
ILMN_1362365 Scml4 NM_001107638 sex comb on midleg-like 4 (Drosophila) -2.34 
ILMN_1360177 Ly6c NM_020103 Ly6-C antigen -2.34 
ILMN_1367724 RGD1561455 XR_008037 similar to Ras GTPase-activating-like protein IQGAP2 -2.33 
ILMN_1360549 Dyrk2 NM_001108100 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 -2.33 
ILMN_1365281 Sh3gl3 NM_031238 SH3-domain GRB2-like 3 -2.33 
ILMN_1364273 Nceh1 NM_001127524 neutral cholesterol ester hydrolase 1 -2.32 
ILMN_1352135 Ceacam10 NM_173339 carcinoembryonic antigen-related cell adhesion molecule 10 -2.29 
ILMN_1376808 Pdlim5 NM_053326 PDZ and LIM domain 5 -2.28 
ILMN_1355553 Ddx6 XM_236192 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 -2.28 
ILMN_1351495 LOC686213 XM_001072911 similar to DnaJ homolog subfamily B member 6 (Heat shock protein J2) (HSJ-2) (MRJ) (mDj4) -2.28 
ILMN_1364820 MGC108776 NM_001017466 Snf7 homologue associated with Alix 3 -2.27 
ILMN_1351247 Ube2d1 NM_001108530 ubiquitin-conjugating enzyme E2D 1 -2.25 
ILMN_1363239 Slc25a46 NM_001100515 solute carrier family 25, member 46 -2.25 
ILMN_1360301 LOC497693 XM_579635 similar to P11 protein -2.25 
ILMN_1362787 Dnajc21 NM_138856 DnaJ (Hsp40) homolog, subfamily C, member 21 -2.21 
ILMN_1350303 RGD1565165 XR_007875 similar to 60S ribosomal protein L7a -2.20 
ILMN_1369636 Cdk2ap1 NM_001113751 cyclin-dependent kinase 2 associated protein 1 -2.19 
ILMN_1357234 Nrep NM_178096 neuronal regeneration related protein -2.18 
ILMN_1366128 RGD1562311 XR_008266 similar to PIRA5 -2.17 
ILMN_1363828 Pck1 NM_198780 phosphoenolpyruvate carboxykinase 1, cytosolic -2.17 
ILMN_1357078 Spred1 NM_001047089 sprouty-related, EVH1 domain containing 1 -2.15 
ILMN_1369055 Disp1 NM_001105983 dispatched homolog 1 (Drosophila) -2.15 
ILMN_1351996 Hadhb NM_133618 
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
hydratase (trifunctional protein), beta subunit, 
nuclear gene encoding mitochondrial protein 
-2.15 
ILMN_1374127 RGD1563348 NM_001114939 similar to Selenoprotein H -2.14 
ILMN_1360795 Slc11a1 NM_001031658 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 -2.14 




ILMN_1354480 Tusc2 NM_001109297 tumor suppressor candidate 2 -2.13 
ILMN_1359983 Hist1h2bd NM_001108414 histone cluster 1, H2bd -2.13 
ILMN_1357008 Fn3k NM_001109051 fructosamine 3 kinase -2.12 
ILMN_1350981 Ripk1 NM_001107350 receptor (TNFRSF)-interacting serine-threonine kinase 1 -2.12 
ILMN_1352627 LOC367191 XR_009207 poly(rC)-binding protein 2-like -2.12 
ILMN_1360891 Spin1 NM_001024796 spindlin 1 -2.12 
ILMN_1372765 Nat1 NM_053853 N-acetyltransferase 1 (arylamine N-acetyltransferase) -2.12 
ILMN_1358768 LOC503192 XM_578715 zinc finger protein ZFP -2.10 
ILMN_1356825 Hrsp12 NM_031714 heat-responsive protein 12 -2.08 
ILMN_1364518 Klhl25 NM_001039006 kelch-like 25 (Drosophila) -2.08 
ILMN_1350943 Cd163 NM_001107887 CD163 molecule -2.08 
ILMN_1350992 LOC498452 XM_573711 
similar to ORF2 consensus sequence encoding 
endonuclease and reverse transcriptase minus 
RNaseH 
-2.08 
ILMN_1360060 Pla2g4a NM_133551 phospholipase A2, group IVA (cytosolic, calcium-dependent) -2.07 
ILMN_1358826 Nudt15 NM_001106049 nudix (nucleoside diphosphate linked moiety X)-type motif 15 -2.07 
ILMN_1374947 Bpnt1 NM_171990 bisphosphate 3'-nucleotidase 1 -2.06 
ILMN_1371927 Srp54a NM_053871 signal recognition particle 54A -2.05 
ILMN_2039303 Pelo NM_001007634 pelota homolog (Drosophila) -2.05 
ILMN_1357590 Ascl2 NM_031503 achaete-scute complex homolog 2 (Drosophila) -2.05 
ILMN_1352469 Irf7 NM_001033691 interferon regulatory factor 7 -2.05 
ILMN_1366496 Slc25a32 NM_001173334 solute carrier family 25 (mitochondrial folate carrier) , member 32 -2.04 
ILMN_1363052 Pcgf6 NM_001013154 polycomb group ring finger 6 -2.04 
ILMN_1372153 Lactb2 NM_001024247 lactamase, beta 2 -2.04 
ILMN_1366226 Rbm47 NM_001005882 RNA binding motif protein 47 -2.03 
ILMN_1366337 RGD1560687 XM_576192 ferritin light chain 1-like -2.03 
ILMN_1374066 Acot2 NM_138907 acyl-CoA thioesterase 2, nuclear gene encoding mitochondrial protein -2.03 
ILMN_1357358 Med4 NM_001024256 mediator complex subunit 4 -2.02 
ILMN_1356599 Isg20l2 NM_001007741 interferon stimulated exonuclease gene 20-like 2 -2.02 
ILMN_1356300 Nrbf2 NM_022186 nuclear receptor binding factor 2 -2.00 
ILMN_1367993 Abcd2 NM_033352 ATP-binding cassette, sub-family D (ALD), member 2 -2.00 
ILMN_1370477 Cdc40 NM_001108538 cell division cycle 40 -1.99 
ILMN_1366288 March5 NM_001106372 membrane-associated ring finger (C3HC4) 5 -1.99 
ILMN_1354725 LOC500490 XM_575855 similar to Retrovirus-related POL polyprotein -1.98 
ILMN_1651174 RGD1565965 XM_237746 hypothetical gene supported by NM_021262; AF171072 -1.98 
ILMN_1357104 LOC498786 XM_574071 similar to GTP-binding protein NGB -1.98 
ILMN_1350310 Mecr NM_017209 mitochondrial trans-2-enoyl-CoA reductase, nuclear gene encoding mitochondrial protein -1.97 
ILMN_1370862 Upp1 NM_001030025 uridine phosphorylase 1 -1.96 
ILMN_1366946 LOC299262 XM_238465 hypothetical LOC299262 -1.95 
ILMN_1376954 Uchl5 NM_001012149 ubiquitin carboxyl-terminal hydrolase L5 -1.95 
ILMN_1372790 Scfd2 NM_001017499 sec1 family domain containing 2 -1.95 
ILMN_1376652 Sh3glb1 NM_001011929 SH3-domain GRB2-like B1 (endophilin) -1.93 
ILMN_1358408 Xcl1 NM_134361 chemokine (C motif) ligand 1 -1.93 
ILMN_1372785 MGC105647 XM_001079820 similar to Nur77 downstream protein 2 -1.92 
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ILMN_1351513 Asf1a NM_001106389 anti-silencing function 1A histone chaperone -1.92 
ILMN_1364990 Nkrf XM_233308 NFKB repressing factor -1.91 
ILMN_1372465 Trex1 NM_001024989 three prime repair exonuclease 1 -1.91 
ILMN_1354716 Nupr1l NM_001134570 nuclear protein, transcriptional regulator, 1-like -1.91 
ILMN_1376412 Gphn NM_022865 gephyrin -1.90 
ILMN_1358752 Ndn NM_001008558 necdin homolog (mouse) -1.90 
ILMN_1353110 Tmem167b NM_001135260 transmembrane protein 167B -1.90 
ILMN_1350714 Oxr1 NM_057153 oxidation resistance 1, transcript variant 2 -1.90 
ILMN_1363212 LOC498424 XM_573673 similar to 5330440M15Rik protein -1.89 
ILMN_1364624 LOC501605 XM_577005 similar to 40S ribosomal protein S2 -1.88 
ILMN_1355426 Ppp1r10 NM_022951 protein phosphatase 1, regulatory subunit 10 -1.88 
ILMN_1650500 Ccdc91 NM_001014061 coiled-coil domain containing 91 -1.88 
ILMN_1364166 Prr16 NM_001108432 proline rich 16 -1.87 
ILMN_1376472 Irgm NM_001012007 immunity-related GTPase family, M -1.87 
ILMN_1367105 Cbr1 NM_019170 carbonyl reductase 1 -1.85 
ILMN_1364885 Zdhhc6 NM_001037652 zinc finger, DHHC domain containing 6 -1.83 
ILMN_1371910 Ube2e3 NM_001047857 ubiquitin-conjugating enzyme E2E 3 -1.83 
ILMN_1352241 RGD1562392 XM_346007 similar to Sulfotransferase K1 (rSULT1C2) -1.82 
ILMN_1366967 RGD1562699 NM_001106141 RGD1562699 -1.82 
ILMN_1355930 LOC497782 XM_579621 hypothetical gene supported by NM_133401 -1.81 
ILMN_1367580 RGD1564026 XR_007667 similar to L-lactate dehydrogenase A chain (LDH-A) (LDH muscle subunit) (LDH-M) -1.81 
ILMN_1371172 LOC500734 XM_576113 similar to immunoglobulin heavy chain variable region -1.80 
ILMN_1360968 Arl5a NM_053979 ADP-ribosylation factor-like 5A -1.80 
ILMN_1360638 LOC500903 XM_576305 similar to RIKEN cDNA 2210421G13 -1.80 
ILMN_1372614 Ncald NM_001024371 neurocalcin delta -1.80 
ILMN_1375936 Rangap1 XM_576313 RAN GTPase activating protein 1 -1.79 
ILMN_1356037 LOC501413 XM_576825 similar to hypothetical protein -1.79 
ILMN_1350607 Siah2 NM_134457 seven in absentia 2 -1.79 
ILMN_1650512 RGD1566244 XR_007720 similar to TatD DNase domain containing 1 -1.79 
ILMN_1362688 Zfp191 NM_182955 zinc finger protein 191 -1.79 
ILMN_1373470 Ctr9 XM_238127 Ctr9, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) -1.78 
ILMN_1366773 Sord NM_017052 sorbitol dehydrogenase -1.78 
ILMN_1355396 Txndc17 NM_001105805 thioredoxin domain containing 17 -1.78 
ILMN_1374122 LOC364763 XM_344621 similar to GTP-binding protein NGB -1.78 
ILMN_1354166 LOC687840 XM_001080312 
similar to Glutathione S-transferase alpha-4 
(Glutathione S-transferase Yk) (GST Yk) (GST 8-8) 
(GST K) (GST A4-4) 
-1.78 
ILMN_1373384 Dmn XM_001055724 desmuslin, transcript variant 2 -1.78 
ILMN_1376437 Zfand3 NM_001012175 zinc finger, AN1-type domain 3 -1.78 
ILMN_1361429 Arih1 NM_001013108 ariadne ubiquitin-conjugating enzyme E2 binding protein homolog 1 (Drosophila) -1.77 
ILMN_1352032 Decr2 NM_171996 2,4-dienoyl CoA reductase 2, peroxisomal -1.77 
ILMN_1357381 Bet1 NM_019251 blocked early in transport 1 homolog (S. cerevisiae) -1.77 
ILMN_1358738 Ly86 NM_001106128 lymphocyte antigen 86 -1.76 
ILMN_1355124 Galnt2 NM_001106196 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2) -1.76 
ILMN_1354435 Hnf4a NM_022180 hepatocyte nuclear factor 4, alpha -1.76 
ILMN_1366222 LOC501416 XM_576827 similar to glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A -1.75 
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ILMN_1372464 Mb21d2 NM_001109056 Mab-21 domain containing 2 -1.75 
ILMN_1369812 Zfp36l2 NM_001036626 zinc finger protein 36, C3H type-like 2 -1.75 
ILMN_1357813 RGD1564594 XM_001055954 similar to pellino protein -1.75 
ILMN_1368635 Dst NM_001108208 dystonin -1.74 
ILMN_1355986 Rab1 NM_031090 RAB1, member RAS oncogene family -1.74 
ILMN_1354213 Adh4 NM_017270 alcohol dehydrogenase 4 (class II), pi polypeptide -1.74 
ILMN_1651079 LOC500436 XM_575798 similar to heat shock protein 8 -1.74 
ILMN_1376386 Pycrl NM_001011993 pyrroline-5-carboxylate reductase-like -1.74 
ILMN_1349967 RGD1559924 XR_007622 similar to Eukaryotic translation initiation factor 1 (eIF1) -1.74 
ILMN_1374957 Mtfmt NM_001009697 mitochondrial methionyl-tRNA formyltransferase, nuclear gene encoding mitochondrial protein -1.73 
ILMN_1376331 Hadha NM_130826 
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
hydratase (trifunctional protein), alpha subunit 
-1.73 
ILMN_1374922 LOC499898 XM_575244 LOC499898 -1.73 
ILMN_1351237 Txnrd1 NM_031614 thioredoxin reductase 1 -1.73 
ILMN_2039089 Adh1 NM_019286 alcohol dehydrogenase 1 (class I) -1.73 
ILMN_1376965 Btbd1 XM_001067480 BTB (POZ) domain containing 1 -1.73 
ILMN_1376462 Fxr1 NM_001012179 fragile X mental retardation, autosomal homolog 1 -1.72 
ILMN_1363156 LOC684318 XM_001069848 similar to ubiquitin specific protease 12 -1.72 
ILMN_1362861 Rwdd2b NM_001100559 RWD domain containing 2B -1.71 
ILMN_1350341 Dnajc28 NM_001014124 DnaJ (Hsp40) homolog, subfamily C, member 28 -1.71 
ILMN_1349542 Ssbp2 XM_342171 single-stranded DNA binding protein 2 -1.70 
ILMN_1375183 Slc16a13 NM_001005530 solute carrier family 16, member 13 (monocarboxylic acid transporter 13) -1.70 
ILMN_1367476 LOC501326 XR_009028 similar to glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A -1.70 
ILMN_1361326 Dhrs4 NM_153315 dehydrogenase/reductase (SDR family) member 4 -1.70 
ILMN_1351249 Spast NM_001108702 spastin -1.70 
ILMN_1366889 Timm21 NM_001008343 translocase of inner mitochondrial membrane 21 homolog (yeast) -1.69 
ILMN_1360190 Cd8a NM_031538 CD8a molecule -1.69 
ILMN_1372394 Unc119 NM_017188 UNC-119 homolog (C. elegans) -1.69 
ILMN_1375869 Fbxo8 XM_573904 F-box only protein 8 -1.68 
ILMN_1364233 Chfr NM_001009258 checkpoint with forkhead and ring finger domains -1.68 
ILMN_1366519 Cdip1 NM_001008360 cell death-inducing p53 target 1 -1.68 
ILMN_1359655 LOC683919 XM_001068058 similar to nudix-type motif 8 -1.68 
ILMN_1355225 Rac1 NM_134366 ras-related C3 botulinum toxin substrate 1 -1.68 
ILMN_1366255 Abca6 XM_001081607 ATP-binding cassette, subfamily A (ABC1), member 6 -1.68 
ILMN_1363211 Cs NM_130755 citrate synthase, nuclear gene encoding mitochondrial protein -1.68 
ILMN_1374215 Gpr89b NM_001139486 G protein-coupled receptor 89B -1.68 
ILMN_1354598 Dexi NM_001109026 dexamethasone-induced transcript -1.67 
ILMN_1376941 rnf141 NM_001001800 ring finger protein 141 -1.67 
ILMN_1357860 Rpf1 NM_001100794 ribosome production factor 1 homolog (S. cerevisiae) -1.67 
ILMN_1361564 LOC501187 XM_576615 similar to putative RNA binding protein 1 -1.66 
ILMN_1365812 Kbtbd4 NM_001107746 kelch repeat and BTB (POZ) domain containing 4 -1.66 
ILMN_1365910 Etfa NM_001009668 electron-transfer-flavoprotein, alpha polypeptide, nuclear gene encoding mitochondrial protein -1.66 
ILMN_1365109 LOC500343 XM_575695 similar to LRRGT00176 -1.65 
ILMN_1357474 Ahcy NM_017201 S-adenosylhomocysteine hydrolase -1.65 
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ILMN_1373959 Map3k3 NM_001107058 mitogen activated protein kinase kinase kinase 3 -1.65 
ILMN_1650897 Dnaaf2 NM_001014197 dynein, axonemal, assembly factor 2 -1.65 
ILMN_1650940 Snrnp200 NM_001037766 small nuclear ribonucleoprotein 200 (U5) -1.65 
ILMN_1358108 Srm NM_053464 spermidine synthase -1.65 
ILMN_1364242 Nanp NM_001009409 N-acetylneuraminic acid phosphatase -1.64 
ILMN_1360282 Yars2 NM_001009627 tyrosyl-tRNA synthetase 2 (mitochondrial), nuclear gene encoding mitochondrial protein -1.64 
ILMN_1371034 Acsl4 NM_053623 acyl-CoA synthetase long-chain family member 4 -1.64 
ILMN_1373367 Aar2 NM_001106535 AAR2 splicing factor homolog (S. cerevisiae) -1.64 
ILMN_2038784 Txn1 NM_053800 thioredoxin 1 -1.64 
ILMN_1369091 Slc35e3 NM_001134687 solute carrier family 35, member E3 -1.63 
ILMN_1359331 LOC687248 XR_009164 hypothetical protein LOC687248 -1.63 
ILMN_1351590 Erich1 NM_001127680 glutamate-rich 1 -1.63 
ILMN_1372726 Nub1 NM_001013925 negative regulator of ubiquitin-like proteins 1 -1.63 
ILMN_1355168 Coa4 NM_001127655 cytochrome c oxidase assembly factor 4 -1.63 
ILMN_1369530 Cat NM_012520 catalase -1.63 
ILMN_1365458 Gtpbp10 NM_001100815 GTP-binding protein 10 (putative) -1.62 
ILMN_1366845 Auh NM_001108407 AU RNA binding protein/enoyl-CoA hydratase -1.62 
ILMN_1371924 Utp14a NM_001014113 UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) -1.62 
ILMN_1354803 Arcn1 NM_001007662 archain 1 -1.62 
ILMN_1354808 Ncf4 NM_001127304 neutrophil cytosolic factor 4 -1.61 
ILMN_1369424 Napg NM_001107384 N-ethylmaleimide-sensitive factor attachment protein, gamma -1.61 
ILMN_1365599 Bphl NM_001037206 biphenyl hydrolase-like (serine hydrolase) -1.61 
ILMN_1356247 RGD1564894 NM_001126278 similar to glycine-N-acyltransferase isoform a -1.61 
ILMN_1374995 Srp19 NM_001106157 signal recognition particle 19 -1.61 
ILMN_1371355 RGD1309188 NM_001108129 similar to hypothetical protein BC011833 -1.60 
ILMN_1360216 Id3 NM_013058 inhibitor of DNA binding 3 -1.60 
ILMN_1366625 Slc17a5 NM_001009713 solute carrier family 17 (anion/sugar transporter), member 5 -1.60 
ILMN_1361722 Rbm8a XM_001059872 RNA binding motif protein 8A -1.60 
ILMN_1354675 Chrac1 NM_001134880 chromatin accessibility complex 1 -1.60 
ILMN_1363823 Ccdc58 NM_001105875 coiled-coil domain containing 58 -1.60 
ILMN_1368767 Polg NM_053528 polymerase (DNA directed), gamma -1.60 
ILMN_1369087 RGD1304567 NM_001009711 similar to RIKEN cDNA A430005L14 -1.60 
ILMN_1373798 Plcb1 NM_001077641 phospholipase C, beta 1 (phosphoinositide-specific) -1.59 
ILMN_1363987 Cndp1 NM_001007687 carnosine dipeptidase 1 (metallopeptidase M20 family) -1.59 
ILMN_1350248 Ryk NM_080402 receptor-like tyrosine kinase -1.59 
ILMN_1353438 Mrps9 NM_001100549 mitochondrial ribosomal protein S9 -1.59 
ILMN_1371849 Ccdc59 NM_001108090 coiled-coil domain containing 59 -1.59 
ILMN_1364217 Isy1 NM_001014188 ISY1 splicing factor homolog (S. cerevisiae) -1.58 
ILMN_1353995 Mcee NM_001106341 methylmalonyl CoA epimerase -1.58 
ILMN_1355224 Stk35 NM_001107773 serine/threonine kinase 35 -1.58 
ILMN_1362897 Acadm NM_016986 
acyl-Coenzyme A dehydrogenase, C-4 to C-12 
straight chain, nuclear gene encoding mitochondrial 
protein 
-1.58 
ILMN_1351976 Ifi44l XM_227820 interferon-induced protein 44-like -1.58 
ILMN_1367456 C1qbp NM_019259 
complement component 1, q subcomponent binding 





ILMN_1365423 Mpc2 NM_001077643 mitochondrial pyruvate carrier 2 -1.58 
ILMN_1354759 Fxn NM_001191952 frataxin, nuclear gene encoding mitochondrial protein -1.57 
ILMN_1352941 Dusp12 NM_022248 dual specificity phosphatase 12 -1.57 
ILMN_1374010 RGD1561310 XM_001068169 60S ribosomal protein L37-like -1.57 
ILMN_1362835 Rpain NM_001033060 RPA interacting protein -1.57 
ILMN_1354159 LOC500420 XM_575783 similar to CG12279-PA -1.56 
ILMN_1358897 Glud1 NM_012570 glutamate dehydrogenase 1 -1.56 
ILMN_1376836 Fut8 NM_001002289 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) -1.55 
ILMN_1360039 Pafah1b3 NM_053654 platelet-activating factor acetylhydrolase, isoform 1b, alpha1 subunit -1.55 
ILMN_1650955 Ifi27 NM_203410 interferon, alpha-inducible protein 27 -1.55 
ILMN_1349065 Iqcf6 NM_001109362 IQ motif containing F6 -1.55 
ILMN_1353223 Nudt19 NM_001004258 nudix (nucleoside diphosphate linked moiety X)-type motif 19 -1.55 
ILMN_1370151 Cdk7 XM_215467 cyclin-dependent kinase 7 -1.54 
ILMN_1353778 RGD1564492 XM_574204 similar to hypothetical protein, 2-6 -1.54 
ILMN_1353814 LOC689226 NM_001127573 similar to ubiquitin-conjugating enzyme E2R 2 -1.54 
ILMN_1351644 LOC501311 XM_576724 hypothetical gene supported by BC088860 -1.53 
ILMN_1353960 Idh1 NM_031510 isocitrate dehydrogenase 1 (NADP+), soluble -1.53 
ILMN_1373451 Slc37a2 XM_001061125 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 -1.53 
ILMN_1366497 Yipf6 NM_001025747 Yip1 domain family, member 6 -1.53 
ILMN_1369440 Tinf2 NM_001006962 TERF1 (TRF1)-interacting nuclear factor 2 -1.53 
ILMN_1362225 LOC497934 NM_001017474 similar to hypothetical protein FLJ20014 -1.52 
ILMN_2040058 Chchd3 NM_001106588 coiled-coil-helix-coiled-coil-helix domain containing 3 -1.52 
ILMN_1357565 Hdac1 NM_001025409 histone deacetylase 1 -1.52 
ILMN_1373709 Trpm6 XM_219747 transient receptor potential cation channel, subfamily M, member 6 -1.52 
ILMN_1359694 Lgals8 NM_053862 lectin, galactose binding, soluble 8 -1.51 
ILMN_1375247 Fxyd2 NM_145717 FXYD domain-containing ion transport regulator 2, transcript variant a -1.51 
ILMN_1364467 RGD1561886 XR_008939 similar to ribosomal protein L27 -1.51 





Appendix 3.3: List of upregulated DEGs 
 
List of upregulated genes with fold change ≥ 1.5 and FDR < 0.05 differentially 
expressed in the livers of IL-13 transfected nephrotic rats versus control rats. 
 




Gene description Fold change 
ILMN_1359586 Scd NM_031841 stearoyl-CoA desaturase (delta-9-desaturase) 18.01 
ILMN_1360317 Smoc2 NM_001106215 SPARC related modular calcium binding 2 15.01 
ILMN_1360645 Gck NM_012565 glucokinase 8.56 
ILMN_1369135 Hsd11b1 NM_017080 hydroxysteroid 11-beta dehydrogenase 1 7.39 
ILMN_1372932 LOC500504 XM_580077 LOC500504 6.11 
ILMN_1360285 Mocos NM_001108425 molybdenum cofactor sulfurase 5.79 
ILMN_1373783 LOC360228 NM_001003706 WDNM1 homolog 5.75 
ILMN_1373045 Cyp2c22 NM_138512 cytochrome P450, family 2, subfamily c, polypeptide 22 5.35 
ILMN_1364575 Pfkfb1 NM_012621 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 5.20 
ILMN_1357139 Ikbke NM_001108854 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon 5.16 
ILMN_1353346 Ltbp4 NM_001170336 latent transforming growth factor beta binding protein 4 5.03 
ILMN_1365415 Prss8 NM_138836 protease, serine, 8 (prostasin) 5.00 
ILMN_1352807 Vwf NM_053889 von Willebrand factor 4.61 
ILMN_1352810 Arhgef19 NM_001108692 Rho guanine nucleotide exchange factor (GEF) 19 4.36 
ILMN_1367162 Gpm6a NM_178105 glycoprotein m6a 3.97 
ILMN_1365485 Pdgfa NM_012801 platelet-derived growth factor alpha polypeptide 3.81 
ILMN_1363044 C1qtnf2 XM_001067870 C1q and tumor necrosis factor related protein 2 3.78 
ILMN_1366328 Nipal2 NM_001130559 NIPA-like domain containing 2 3.71 
ILMN_1650259 Plod2 NM_175869 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 3.71 
ILMN_1364908 Pmepa1 NM_001107807 prostate transmembrane protein, androgen induced 1 3.69 
ILMN_1359113 Kifc3 NM_001103352 kinesin family member C3 3.69 
ILMN_1359487 Mapk8ip3 NM_001100673 mitogen-activated protein kinase 8 interacting protein 3 3.67 
ILMN_1366030 Cacna2d1 NM_012919 calcium channel, voltage-dependent, alpha2/delta subunit 1, transcript variant 1 3.62 
ILMN_1365447 Cryab NM_012935 crystallin, alpha B 3.60 
ILMN_1366910 Acly NM_016987 ATP citrate lyase 3.56 
ILMN_1351428 Abcc3 NM_080581 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 3.45 
ILMN_1350619 Pdia5 NM_001014125 protein disulfide isomerase family A, member 5 3.40 
ILMN_1355412 Olfml2b NM_001107195 olfactomedin-like 2B 3.40 
ILMN_1366054 Abcc8 NM_013039 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 3.38 
ILMN_1361494 LOC498901 XM_574188 similar to LRRGT00176 3.36 
ILMN_1373203 Kif12 XM_001058042 kinesin family member 12 3.36 
ILMN_1353477 LOC498907 XM_574196 similar to LRRGT00004 3.24 
ILMN_1361779 Tcea3 NM_001015008 transcription elongation factor A (SII), 3 3.23 
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ILMN_1360221 Tacstd1 NM_138541 tumor-associated calcium signal transducer 1 3.17 
ILMN_1367467 Per2 NM_031678 period homolog 2 (Drosophila) 3.14 
ILMN_1355237 Cxcl1 NM_030845 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 3.13 
ILMN_1373157 Wfdc2 NM_173109 WAP four-disulfide core domain 2 3.12 
ILMN_1358074 Npdc1 NM_001004231 neural proliferation, differentiation and control, 1 3.02 
ILMN_1376846 Loxl1 NM_001012125 lysyl oxidase-like 1 3.01 
ILMN_1359236 Adamdec1 NM_001106046 ADAM-like, decysin 1 2.90 
ILMN_1359468 Dhcr24 NM_001080148 24-dehydrocholesterol reductase 2.90 
ILMN_1355149 Manba NM_001031655 mannosidase, beta A, lysosomal 2.86 
ILMN_1530405 Loxl1 NM_001012125 lysyl oxidase-like 1 2.81 
ILMN_1364423 Synpo2 NM_001191963 synaptopodin 2 2.81 
ILMN_1361143 Suv420h2 NM_001107475 suppressor of variegation 4-20 homolog 2 (Drosophila) 2.81 
ILMN_1355110 Fbxl20 NM_022272 F-box and leucine-rich repeat protein 20 2.77 
ILMN_1650719 Tmem106a NM_001024967 transmembrane protein 106A 2.75 
ILMN_1368538 Gria3 NM_032990 glutamate receptor, ionotropic, AMPA3 (alpha 3) 2.74 
ILMN_1371681 Rcn3 NM_001008694 reticulocalbin 3, EF-hand calcium binding domain 2.73 
ILMN_1354646 Tmem98 NM_001007672 transmembrane protein 98 2.71 
ILMN_1374494 MGC116197 NM_001025755 similar to RIKEN cDNA 1700001E04 2.70 
ILMN_1358691 Myadm NM_183332 myeloid-associated differentiation marker 2.70 
ILMN_1361132 Map2k6 NM_053703 mitogen-activated protein kinase kinase 6 2.69 
ILMN_1365374 LOC295167 XM_227324 similar to CG13990-PA 2.62 
ILMN_1360353 LOC500617 XM_575991 similar to LRRGT00014 2.54 
ILMN_1368890 Wfikkn1 NM_001129776 WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1 2.52 
ILMN_1354506 Icam1 NM_012967 intercellular adhesion molecule 1 2.50 
ILMN_1365488 Cyp4f37 NM_001271352 cytochrome P450, family 4, subfamily f, polypeptide 37 2.45 
ILMN_1354101 Dazap1 NM_001025742 DAZ associated protein 1 2.43 
ILMN_1375844 Tia1 XM_575591 cytotoxic granule-associated RNA binding protein 1 2.43 
ILMN_1355240 Pnoc NM_013007 prepronociceptin 2.42 
ILMN_1374674 LOC362882 XM_343210 similar to Lysozyme C, type 2 precursor (1,4-beta-N-acetylmuramidase C) 2.40 
ILMN_1370728 Dctn1 NM_024130 dynactin 1 2.39 
ILMN_1360715 LOC360303 XM_346531 hypothetical LOC360303 2.37 
ILMN_1364747 Jub NM_053503 jub, ajuba homolog (Xenopus laevis) 2.35 
ILMN_1359746 Prpf38b NM_001024305 pre-mRNA processing factor 38B 2.30 
ILMN_1351912 RGD1304868 XR_009138 similar to RIKEN cDNA 2810443J12 2.28 
ILMN_1360884 Arl13b NM_001107101 ADP-ribosylation factor-like 13B 2.27 
ILMN_1374266 Mgl1 NM_022393 macrophage galactose N-acetyl-galactosamine specific lectin 1 2.25 
ILMN_1355272 Akap8 NM_053855 A kinase (PRKA) anchor protein 8 2.25 
ILMN_1373875 Sparcl1 NM_012946 SPARC-like 1 (hevin) 2.23 
ILMN_1352063 LOC499416 XM_574732 similar to transient receptor potential cation channel subfamily M member 2 2.22 
ILMN_1370711 Plekha4 NM_199101 pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4 2.21 
ILMN_1351742 Abcb9 NM_022238 ATP-binding cassette, sub-family B (MDR/TAP), member 9 2.21 
ILMN_1364291 Spbc24 XM_001077474 spindle pole body component 24 homolog (S. cerevisiae) 2.21 
ILMN_1357348 Nrg1 NM_031588 neuregulin 1 2.19 
ILMN_1365562 LOC500974 XR_009636 similar to CDNA sequence BC024479 2.19 
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ILMN_1360746 Dmxl1 NM_001107388 Dmx-like 1 2.19 
ILMN_1360523 Shroom1 XM_213289 shroom family member 1 2.19 
ILMN_1350429 Setdb2 XM_224248 SET domain, bifurcated 2 2.19 
ILMN_1375236 Pvrl2 XM_574380 poliovirus receptor-related 2 (herpesvirus entry mediator B) 2.18 
ILMN_1355909 Tmem176b NM_134390 transmembrane protein 176B 2.17 
ILMN_1375690 Sept4 XM_001081164 septin 4 2.16 
ILMN_1353007 Vtcn1 NM_001024244 V-set domain containing T cell activation inhibitor 1 2.16 
ILMN_1368854 Gpx2 NM_183403 glutathione peroxidase 2 2.16 
ILMN_1351420 RGD1305807 NM_001025276 hypothetical LOC298077 2.16 
ILMN_1356327 Scarf1 NM_001107022 scavenger receptor class F, member 1 2.15 
ILMN_1357400 Glt8d1 NM_001007683 glycosyltransferase 8 domain containing 1 2.14 
ILMN_1356318 Cdc42ep5 NM_001108469 CDC42 effector protein (Rho GTPase binding) 5 2.11 
ILMN_1372296 Zmym6 NM_001108681 zinc finger, MYM-type 6 2.11 
ILMN_1368776 LOC498674 XM_579847 LOC498674 2.10 
ILMN_1360376 App NM_019288 amyloid beta (A4) precursor protein 2.09 
ILMN_1350349 Sox4 NM_001271205 SRY (sex determining region Y)-box 4 2.09 
ILMN_1352802 Cxadr NM_053570 coxsackie virus and adenovirus receptor 2.08 
ILMN_1366115 Cd151 NM_022523 CD151 molecule (Raph blood group) 2.07 
ILMN_1651198 Zmynd11 NM_203366 zinc finger, MYND domain containing 11, transcript variant 1 2.02 
ILMN_1355561 Cst3 NM_012837 cystatin C 2.01 
ILMN_1376819 Sept4 XM_001081164 septin 4 2.01 
ILMN_1356895 Ttc13 NM_001136162 tetratricopeptide repeat domain 13 2.00 
ILMN_1369717 LOC682323 XM_001059807 
similar to Splicing factor, arginine/serine-rich 3 
(Pre-mRNA splicing factor SRP20) (X16 protein), 
transcript variant 1 
2.00 
ILMN_1374155 Nfkb2 NM_001008349 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 2.00 
ILMN_1350234 Fbxw4 NM_001107600 F-box and WD repeat domain containing 4 1.98 
ILMN_1364755 Snrpa NM_001008303 small nuclear ribonucleoprotein polypeptide A 1.98 
ILMN_1371901 Clk4 NM_001013041 CDC like kinase 4 1.97 
ILMN_1351902 Abcg3 NM_001128311 ATP-binding cassette, subfamily G (WHITE), member 3 1.97 
ILMN_1372684 Ppip5k2 NM_001025775 diphosphoinositol pentakisphosphate kinase 2 1.96 
ILMN_1360455 Tmem110 NM_198774 transmembrane protein 110 1.95 
ILMN_1355371 Jak3 NM_012855 Janus kinase 3 1.93 
ILMN_1372351 Chrnb1 NM_012528 cholinergic receptor, nicotinic, beta 1 (muscle) 1.93 
ILMN_1372737 Sfrs11 NM_001035255 splicing factor, arginine/serine-rich 11 1.93 
ILMN_1352832 Slc39a13 NM_001039196 solute carrier family 39 (metal ion transporter), member 13 1.93 
ILMN_1349593 Srrm2 NM_001277154 serine/arginine repetitive matrix 2 1.92 
ILMN_1363056 Camta2 NM_001105801 calmodulin binding transcription activator 2 1.92 
ILMN_1358401 Cygb NM_130744 cytoglobin 1.92 
ILMN_1365170 LOC689253 XM_001070133 similar to neurobeachin-like 1 1.91 
ILMN_1361128 Acat2 NM_001006995 acetyl-Coenzyme A acetyltransferase 2 1.91 
ILMN_1353902 Dennd1c NM_001126289 DENN/MADD domain containing 1C 1.90 
ILMN_1373158 Clec2l NM_001044233 C-type lectin domain family 2, member L 1.90 
ILMN_1363209 Efemp2 XM_001070338 EGF-containing fibulin-like extracellular matrix protein 2 1.89 
ILMN_1360749 Aplf NM_001173382 aprataxin and PNKP like factor 1.89 
ILMN_1373978 Pcolce NM_019237 procollagen C-endopeptidase enhancer 1.88 
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ILMN_1356806 Serpinh1 NM_017173 serine (or cysteine) peptidase inhibitor, clade H, member 1 1.87 
ILMN_1375001 Col27a1 NM_198747 collagen, type XXVII, alpha 1 1.87 
ILMN_1356512 Ap1g2 XM_214197 adaptor protein complex AP-1, gamma 2 subunit 1.87 
ILMN_1349654 Crebl1 NM_001002809 cAMP responsive element binding protein-like 1 1.86 
ILMN_1357732 Armc5 NM_001009455 armadillo repeat containing 5 1.86 
ILMN_1359476 Nbeal2 XM_236649 neurobeachin-like 2 1.85 
ILMN_1371992 Arv1 NM_001106197 ARV1 homolog (S. cerevisiae) 1.85 
ILMN_1350517 Sfrs11 NM_001035255 splicing factor, arginine/serine-rich 11 1.84 
ILMN_1368941 RGD1561145 NM_001134605 similar to novel protein 1.84 
ILMN_1374618 Crb3 NM_001025661 crumbs homolog 3 (Drosophila) 1.84 
ILMN_1353885 Zfp219 NM_001007681 zinc finger protein 219 1.84 
ILMN_1367641 Git2 NM_001005553 G protein-coupled receptor kinase interacting ArfGAP 2 1.83 
ILMN_1356069 Clk1 NM_001106913 CDC-like kinase 1 1.83 
ILMN_1353448 LOC362725 XM_343047 similar to Retrovirus-related POL polyprotein 1.82 
ILMN_1364845 RGD1305147 XR_009392 similar to RIKEN cDNA 1810048J11 1.82 
ILMN_1374238 LOC690312 XM_001074055 similar to Fc receptor-like and mucin-like 1 1.82 
ILMN_1362740 RGD1565059 NM_001127562 similar to hypothetical protein E130311K13 1.81 
ILMN_1371331 Fnbp4 NM_001013159 formin binding protein 4 1.81 
ILMN_1374027 Ppt1 NM_022502 palmitoyl-protein thioesterase 1 1.80 
ILMN_1349485 LOC503197 XM_578721 
similar to ATP synthase lipid-binding protein, 
mitochondrial precursor (ATP synthase proteolipid 
P1) (ATPase protein 9) (ATPase subunit C) 
1.80 
ILMN_1361731 Pabpn1 NM_001135008 poly(A) binding protein, nuclear 1 1.79 
ILMN_1360269 Sfrs5 NM_019257 splicing factor, arginine/serine-rich 5 1.79 
ILMN_1354884 Fstl1 NM_024369 follistatin-like 1 1.78 
ILMN_1369730 Sidt2 NM_001108142 SID1 transmembrane family, member 2 1.78 
ILMN_1360442 Yt521 NM_133423 splicing factor YT521-B 1.78 
ILMN_1358403 Adcy4 NM_019285 adenylate cyclase 4 1.76 
ILMN_1361299 Itgb1 NM_017022 integrin beta 1 (fibronectin receptor beta) 1.76 
ILMN_1372853 LOC362985 XM_347091 similar to mKIAA3020 protein 1.76 
ILMN_1366346 Emp3 NM_030847 epithelial membrane protein 3 1.75 
ILMN_1357740 RGD1560636 XM_001063601 similar to novel protein 1.75 
ILMN_1353961 Prpf3 NM_001108559 pre-mRNA processing factor 3 1.75 
ILMN_1360410 U2surp XM_001065014 U2 snRNP-associated SURP domain containing, transcript variant 2 1.75 
ILMN_1349906 Casp2 NM_022522 caspase 2 1.75 
ILMN_1368127 Tatdn3 NM_001105987 TatD DNase domain containing 3 1.74 
ILMN_1376945 Tmem180 NM_001014030 transmembrane protein 180 1.74 
ILMN_1373032 RGD1561715 XR_007960 similar to complement component 1, s subcomponent 1.74 
ILMN_1354816 LOC497674 XM_579401 hypothetical gene supported by NM_017212 1.73 
ILMN_1373348 Fas NM_139194 Fas (TNF receptor superfamily, member 6) 1.73 
ILMN_1351435 Anapc4 NM_001107220 anaphase promoting complex subunit 4 1.73 
ILMN_1376672 Dync1h1 NM_019226 dynein cytoplasmic 1 heavy chain 1 1.72 
ILMN_1373398 Tnfrsf4 NM_013049 tumor necrosis factor receptor superfamily, member 4 1.72 
ILMN_1367561 LOC497794 XM_579477 hypothetical gene supported by NM_023103 1.72 
ILMN_1364535 Rbm39 NM_001013207 RNA binding motif protein 39 1.72 
ILMN_1355583 Bclaf1 NM_001047852 BCL2-associated transcription factor 1 1.71 
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ILMN_1361932 Kmt2e NM_001100851 lysine (K)-specific methyltransferase 2E 1.71 
ILMN_1375706 Rxrb NM_206849 retinoid X receptor beta 1.71 
ILMN_1370471 Cdc91l1 NM_181637 CDC91 cell division cycle 91-like 1 (S. cerevisiae) 1.71 
ILMN_1352273 Klc1 NM_001081972 kinesin light chain 1, transcript variant A 1.70 
ILMN_1369703 Naglu XM_001081442 N-acetylglucosaminidase, alpha 1.70 
ILMN_1376540 Spata7 NM_138862 spermatogenesis associated 7 1.69 
ILMN_1368008 Mcoln1 NM_001105903 mucolipin 1 1.68 
ILMN_1355376 Ercc5 NM_001106910 excision repair cross-complementing rodent repair deficiency, complementation group 5 1.68 
ILMN_1373773 Pot1 NM_001024322 protection of telomeres 1 1.68 
ILMN_1370484 Alms1 NM_001106604 Alstrom syndrome 1 1.67 
ILMN_1352630 Sigirr NM_001024887 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 1.66 
ILMN_1375146 Cspp1 XM_001060285 centrosome and spindle pole associated protein 1 1.66 
ILMN_1374672 Nol5 NM_021754 nucleolar protein 5 1.66 
ILMN_1370339 Rarres2 NM_001013427 retinoic acid receptor responder (tazarotene induced) 2 1.64 
ILMN_1358945 Kank3 NM_001108989 KN motif and ankyrin repeat domains 3 1.64 
ILMN_1374578 RGD1307395 XM_001060221 similar to SR rich protein 1.64 
ILMN_1363067 Slc9a1 NM_012652 solute carrier family 9 (sodium/hydrogen exchanger), member 1 1.63 
ILMN_1352116 Ogt NM_017107 




ILMN_1649927 Tmem106c NM_001008358 transmembrane protein 106C 1.62 
ILMN_2039973 Bhmt NM_030850 betaine-homocysteine methyltransferase 1.62 
ILMN_1370376 LOC499031 XM_574321 similar to kinesin family member 25 isoform 1 1.61 
ILMN_1355555 Taf1c NM_001014155 TATA box binding protein (Tbp)-associated factor, RNA polymerase I, C 1.61 
ILMN_1650076 Chtop NM_001014175 similar to DKFZP547E1010 protein 1.61 
ILMN_1650323 Vps33b NM_022286 vacuolar protein sorting 33 homolog B (yeast) 1.60 
ILMN_1352678 Knop1 NM_001134611 lysine-rich nucleolar protein 1 1.60 
ILMN_1376513 Ctsb NM_022597 cathepsin B 1.60 
ILMN_1371937 LOC501139 XM_576559 similar to Ormdl1 protein 1.60 
ILMN_1371416 Slc50a1 NM_001106445 solute carrier family 50 (sugar efflux transporter), member 1 1.59 
ILMN_1376866 Znf18 NM_001012008 zinc finger protein 18 1.59 
ILMN_1371270 Gpr56 NM_152242 G protein-coupled receptor 56 1.59 
ILMN_1374214 Thoc1 XM_214625 THO complex 1 1.59 
ILMN_1370972 Dtx2 NM_001107157 deltex homolog 2 (Drosophila) 1.59 
ILMN_1367911 Abcg4 NM_001106816 ATP-binding cassette, subfamily G (WHITE), member 4 1.58 
ILMN_1357995 RGD1559841 XR_009077 similar to expressed sequence AW413431 1.58 
ILMN_1368568 Golga2 NM_022596 golgi autoantigen, golgin subfamily a, 2 1.58 
ILMN_1376336 Mboat5 NM_001012189 membrane bound O-acyltransferase domain containing 5 1.58 
ILMN_1359384 Topbp1 XM_236578 topoisomerase (DNA) II binding protein 1 1.58 
ILMN_1362616 LOC497740 XM_579710 hypothetical gene supported by NM_178021 1.57 
ILMN_1361040 Ostc NM_001108566 oligosaccharyltransferase complex subunit (non-catalytic) 1.57 
ILMN_1355605 Vkorc1 NM_203335 vitamin K epoxide reductase complex, subunit 1 1.56 
ILMN_1362080 Klf6 NM_031642 Kruppel-like factor 6 1.56 
ILMN_2040330 Tmed9 NM_001009703 transmembrane emp24 protein transport domain containing 9 1.56 
ILMN_1353756 RGD1562094 XM_001080227 similar to RIKEN cDNA 2810426N06 1.56 
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ILMN_1368320 Tsc22d2 NM_001191960 TSC22 domain family, member 2 1.55 
ILMN_1361346 RGD1564940 XM_575773 similar to RIKEN cDNA 3000004N20 1.55 
ILMN_1371277 Pigq NM_001007607 phosphatidylinositol glycan anchor biosynthesis, class Q 1.54 
ILMN_1354877 LOC362587 XM_001055153 similar to microfilament and actin filament cross-linker protein isoform a 1.54 
ILMN_1356051 RGD1560633 XM_218078 60S ribosomal protein L27a-like 1.54 
ILMN_1358278 Tyro3 NM_017092 TYRO3 protein tyrosine kinase 1.54 
ILMN_1364187 Tmem111 NM_001008355 transmembrane protein 111 1.54 
ILMN_1374872 LOC499760 XM_575096 similar to serologically defined colon cancer antigen 3 1.53 
ILMN_1349787 Tspo NM_012515 translocator protein 1.53 
ILMN_1357075 Myg1 NM_001005545 melanocyte proliferating gene 1 1.53 
ILMN_1374816 Appl2 NM_001108741 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 1.53 
ILMN_1349757 Sirt5 NM_001004256 sirtuin (silent mating type information regulation 2 homolog) 5 (S. cerevisiae) 1.52 
ILMN_1360062 Fam207a NM_001008307 family with sequence similarity 207, member A 1.52 
ILMN_1359049 Ilkap NM_022606 integrin-linked kinase-associated serine/threonine phosphatase 2C 1.52 
ILMN_1351625 Zpbp2 NM_001007011 zona pellucida binding protein 2 1.52 
ILMN_1352750 Ccpg1 NM_001108770 cell cycle progression 1 1.51 








Appendix 4.1: Weekly profile of plasma IL-13 (pg/ml) in control and IL-
13 transfected rats 
 
Batch Rat W0 W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 
B6 C1 69 21 37 27 0 9 30 19 24 26 44 
B6 C2 91 29 36 47 76 27 34 27 30 39 26 
B6 C3 42 71 27 16 24 8 17 16 28 22 30 
B7 C1 47 18 45 84 47 21 41 0 15 22 20 
B7 C2 28 31 25 26 22 26 22 18 19 15 32 
B8 C1 83 70 13 40 20 50 42 44 47 22 D 
B8 C2 38 97 34 92 111 66 D D D D D 
B8 C3 50 43 42 D D D D D D D D 
B9 C1 43 NA 58 40 50 NA 41 12 NA 12 13 
B9 C2 49 NA 55 31 115 NA 45 23 NA 18 18 
B9 C3 71 NA 85 47 61 NA 46 23 NA 24 27 
B10 C1 40 NA 44 36 34 NA 19 16 NA 20 13 
B10 C2 41 NA 27 37 38 NA 31 31 NA 27 21 
B10 C3 66 NA 25 49 48 NA 43 29 NA 32 13 
B11 C1 52 19 27 31 D D D D D D D 
B11 C2 14 18 10 NA 21 D D D D D D 
B11 C3 39 19 36 D D D D D D D D 
B11 C4 57 13 15 NA 13 NA 9 9 D D D 
B12 C1 40 50 14 11 NA 10 13 9 NA NA 19 
B12 C2 16 13 13 10 NA 9 13 10 NA NA 9 
B12 C3 50 39 27 25 NA 49 10 16 NA NA 15 
B12 C4 35 42 19 11 NA 12 27 11 NA NA 12 
B12 C5 41 40 32 25 NA 11 10 24 NA NA 15 
B12 C6 71 61 40 46 26 D D D D D D 
B13 C1 29 11 NA 18 NA 10 8 D D D D 
B13 C2 24 14 NA 17 NA 10 17 NA 0 10 13 
B13 C3 11 53 NA 11 NA 13 11 D D D D 
B13 C4 18 12 NA 16 NA 11 9 NA 10 11 10 
B13 C5 33 40 NA 41 NA 48 31 D D D D 
B13 C6 10 27 NA 26 D D D D D D D 
B14 C1 11 10 NA 28 NA 1 17 D D D D 
B14 C2 9 20 NA 31 29 D D D D D D 
B14 C3 12 13 NA 20 NA 19 24 D D D D 
B14 C4 18 14 NA 22 29 D D D D D D 
B14 C5 13 19 33 D D D D D D D D 
B14 C6 31 12 NA 42 NA 17 17 D D D D 
B15 C1 55 NA 55 88 55 NA 59 44 48 NA 49 
B15 C2 45 NA 47 59 50 NA 51 29 15 NA 26 
B15 C3 51 NA 44 92 55 D D D D D D 
B6 T1 61 62 43 37 21 319 99 97 D D D 
B6 T2 62 77 530 548 389 294 398 137 D D D 
B6 T3 38 43 36 48 41 282 232 250 D D D 
B6 T4 54 23 36 31 65 362 921 912 560 395 788 
B6 T5 47 205 81 50 69 111 26 82 52 39 29 
B6 T6 61 35 65 40 51 809 393 272 110 91 155 
B6 T7 47 43 229 278 195 136 422 874 399 556 536 
B6 T8 248 71 51 40 47 214 763 655 370 546 447 
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B6 T9 72 65 383 202 280 266 70 508 66 112 81 
B6 T10 103 73 28 33 4 188 588 165 57 62 137 
B6 T11 67 56 87 56 101 209 153 81 30 27 39 
B6 T12 47 58 72 106 167 147 128 68 124 68 187 
B6 T13 40 39 21 25 65 84 40 364 152 524 725 
B6 T14 65 65 55 55 30 199 80 54 46 305 361 
B6 T15 35 28 210 172 99 74 41 90 71 43 708 
B7 T1 15 995 266 114 612 1351 1881 1554 350 99 112 
B7 T2 44 307 163 307 62 19 39 37 67 35 36 
B7 T3 98 391 485 52 26 18 41 38 460 39 58 
B7 T4 33 1145 714 317 127 87 156 47 66 44 63 
B7 T5 29 950 998 101 869 464 100 44 43 67 74 
B7 T6 26 3864 1263 879 3242 697 203 58 46 82 71 
B7 T7 40 1497 1360 606 1387 250 111 39 50 66 61 
B7 T8 81 1127 876 1418 935 602 114 64 112 82 79 
B7 T9 140 1640 695 499 1812 D D D D D D 
B7 T10 30 729 2354 1067 1187 1646 5257 D D D D 
B8 T1 455 864 1414 D D D D D D D D 
B8 T2 43 877 992 170 83 518 D D D D D 
B8 T3 21 273 136 759 983 958 767 829 841 606 1904 
B8 T4 169 1021 911 805 614 167 94 898 113 113 74 
B8 T5 12 845 478 368 1478 871 D D D D D 
B8 T6 36 887 536 742 964 959 963 839 840 684 494 
B8 T7 53 469 839 791 469 347 409 585 707 264 212 
B8 T8 59 869 448 D D D D D D D D 
B8 T9 60 412 315 325 414 353 418 248 539 107 102 
B9 T1 52 NA 571 773 94 NA 60 25 NA 10 33 
B9 T2 52 NA 148 482 42 NA 41 32 NA 22 37 
B9 T3 38 NA 184 704 634 NA 643 626 NA 170 316 
B9 T4 86 NA 364 717 154 NA 86 78 NA 26 42 
B9 T5 37 NA 121 673 848 NA 482 642 NA 493 1028 
B9 T6 51 NA 480 977 735 NA 572 303 NA 153 210 
B9 T7 84 NA 475 314 213 NA 85 261 NA 58 56 
B9 T8 70 NA 129 1234 508 NA 151 510 NA 68 53 
B9 T9 50 NA 116 449 92 NA 51 65 NA 14 25 
B9 T10 37 NA 73 1214 558 NA 617 83 NA 997 374 
B10 T1 30 NA 84 144 32 NA 32 26 NA 16 14 
B10 T2 26 NA 47 72 43 NA 84 48 NA 544 612 
B10 T3 34 NA 75 583 96 NA 45 35 NA 70 39 
B10 T4 31 NA 621 182 79 NA 138 70 NA 162 63 
B10 T5 49 NA 910 897 217 NA 223 259 NA 193 244 
B10 T6 41 NA 386 65 66 NA 163 28 NA 51 28 
B11 T1 13 491 1298 811 D D D D D D D 
B11 T2 10 OVER 2040 D D D D D D D D 
B11 T3 25 906 479 NA 142 D D D D D D 
B11 T4 29 851 362 225 D D D D D D D 
B11 T5 55 241 51 NA 55 NA UNDER 85 D D D 
B11 T6 27 54 672 NA 52 NA 219 292 D D D 
B11 T7 36 UNDER UNDER NA UNDER D D D D D D 
B11 T8 17 2239 2161 D D D D D D D D 
B11 T9 43 1995 1170 D D D D D D D D 
B11 T10 83 369 128 1323 D D D D D D D 
B11 T11 46 1115 363 NA 87 D D D D D D 
B11 T12 28 274 382 NA 61 NA 64 205 D D D 
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B12 T1 56 936 2032 592 NA 227 937 408 NA NA 553 
B12 T2 56 1176 1173 50 NA 43 23 33 NA NA 71 
B12 T3 54 887 273 69 413 D D D D D D 
B12 T4 53 175 57 387 NA 50 611 196 NA NA 93 
B12 T5 28 74 469 273 NA 216 76 43 NA NA 188 
B12 T6 53 1133 708 421 NA 157 257 104 NA NA 170 
B13 T1 16 214 NA 4420 D D D D D D D 
B13 T2 19 106 NA 36 NA 258 56 NA 21 24 795 
B13 T3 41 14970 NA 4853 D D D D D D D 
B13 T4 37 57 NA 1154 NA 1028 1301 D D D D 
B13 T5 43 962 NA 279 NA 633 273 NA 778 808 302 
B13 T6 35 452 NA 563 NA 150 304 NA 101 224 193 
B14 T1 19 254 NA 4362 1742 D D D D D D 
B14 T2 12 1052 NA 235 NA 77 77 D D D D 
B14 T3 11 234 NA 165 NA 60 88 D D D D 
B14 T4 37 721 NA 582 NA 226 680 D D D D 
B14 T5 34 7186 1218 D D D D D D D D 
B14 T6 32 49 NA 155 NA 6 138 D D D D 
B15 T1 24 NA 591 306 339 NA 2401 290 77 NA 151 
B15 T2 44 NA 13285 3074 1140 D D D D D D 
B15 T3 31 NA 604 199 338 NA 57 2233 558 NA 335 
B15 T4 31 NA 388 393 69 NA 50 25 16 NA 60 
B15 T5 34 NA 637 349 64 NA 44 22 20 NA 56 
B15 T6 52 NA 94 105 543 NA 264 2244 832 NA 668 
B15 T7 42 NA 147 10 15 NA 631 43 16 NA 70 
B15 T8 25 NA 176 51 12 NA 43 11 9 NA 13 
B15 T9 46 NA 209 45 51 NA 18 43 11 NA 45 
‘W’ denotes week, ‘C’ denotes control rat, ‘T’ denotes IL-13 transfected rat, ‘NA’ denotes not 
applicable and ‘D’ denotes dead. ‘UNDER’ denotes that IL-13 could not be detected in the 




Appendix 4.2: Weekly profile of plasma cholesterol (mmol/l) in control 
and IL-13 transfected rats 
 
Batch Rat W0 W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 
B6 C1 2.50 1.99 2.71 2.77 2.98 2.63 3.15 3.02 2.47 2.93 2.65 
B6 C2 2.27 1.43 2.31 2.59 3.43 2.64 3.02 2.99 2.43 2.77 2.87 
B6 C3 2.53 1.71 2.21 2.82 2.93 2.19 2.66 2.43 1.91 2.07 2.05 
B7 C1 2.02 2.07 2.14 2.67 2.12 2.39 2.67 2.49 2.35 1.98 1.89 
B7 C2 2.02 1.76 2.10 2.07 1.74 2.12 2.05 1.29 1.69 1.79 1.65 
B8 C1 1.75 2.09 2.31 2.18 2.56 2.50 2.61 2.09 2.52 2.21 1.82 
B8 C2 1.95 2.10 2.51 2.67 2.40 2.35 D D D D D 
B8 C3 2.10 1.98 2.27 D D D D D D D D 
B9 C1 2.10 NA 2.00 1.45 2.00 NA 2.05 2.10 NA 2.29 1.74 
B9 C2 2.53 NA 2.12 1.82 2.48 NA 2.48 2.79 NA 3.23 2.41 
B9 C3 2.10 NA 1.96 2.04 2.04 NA 1.75 1.87 NA 2.12 1.67 
B10 C1 2.21 NA 2.16 2.07 2.55 NA 2.58 2.77 NA 2.49 2.88 
B10 C2 2.04 NA 1.82 1.92 1.83 NA 1.96 1.86 NA 1.79 1.79 
B10 C3 2.09 NA 1.33 2.06 2.06 NA 2.23 2.08 NA 2.01 2.03 
B11 C1 1.95 1.67 1.72 NA D NA D D D D D 
B11 C2 1.74 1.28 1.57 NA 1.35 NA D D D D D 
B11 C3 2.07 1.92 1.65 NA D NA D D D D D 
B11 C4 1.82 1.60 1.67 NA 1.62 NA 1.71 1.85 D D D 
B12 C1 1.57 1.48 1.64 1.97 NA 2.00 1.91 1.87 NA 1.91 1.87 
B12 C2 1.90 1.86 1.97 2.29 NA 2.06 1.83 1.77 NA 2.20 1.96 
B12 C3 1.99 2.07 1.82 2.04 NA 2.22 2.33 1.95 NA 2.18 2.00 
B12 C4 2.02 1.70 1.67 1.93 NA 1.91 1.94 1.94 NA 2.10 1.93 
B12 C5 1.86 1.54 1.79 1.88 NA 2.14 1.93 1.85 NA 1.73 1.63 
B12 C6 1.83 1.66 1.73 1.87 1.88 D D D D D D 
B13 C1 1.92 1.83 NA 1.45 NA 2.36 1.94 D D D D 
B13 C2 1.32 1.38 NA 1.22 NA 1.48 1.54 NA 1.94 1.72 1.60 
B13 C3 1.87 1.57 NA 1.45 NA 1.68 1.76 D D D D 
B13 C4 1.71 1.52 NA 1.63 NA 1.97 1.90 NA 2.37 2.10 2.03 
B13 C5 1.61 1.20 NA 1.15 NA 1.65 1.51 D D D D 
B13 C6 1.36 1.26 NA 0.99 D D D D D D D 
B14 C1 1.62 1.95 NA 1.81 NA 2.08 2.81 D D D D 
B14 C2 1.48 1.39 NA 1.35 1.73 D D D D D D 
B14 C3 1.97 1.76 NA 2.04 NA 2.09 2.13 D D D D 
B14 C4 1.44 1.60 NA 2.25 1.37 D D D D D D 
B14 C5 1.68 1.62 1.07 D D D D D D D D 
B14 C6 1.36 1.46 NA 1.37 NA 1.74 2.33 D D D D 
B15 C1 2.25 NA 2.03 1.87 1.76 NA 2.09 2.05 1.73 NA 2.01 
B15 C2 2.15 NA 2.05 1.91 1.84 NA 2.10 2.10 1.83 NA 1.89 
B15 C3 2.94 NA 3.20 2.74 2.93 D D D D D D 
B6 T1 2.73 2.01 2.84 2.93 3.55 2.60 3.09 2.40 D D D 
B6 T2 2.39 1.87 2.52 2.15 3.84 2.99 3.08 2.77 D D D 
B6 T3 2.12 1.80 2.17 2.28 2.96 2.34 2.43 2.40 D D D 
B6 T4 1.93 1.68 2.12 2.00 3.15 2.30 3.12 3.64 3.53 3.21 3.54 
B6 T5 2.82 1.55 2.26 3.02 3.53 2.66 2.90 2.77 2.16 2.39 2.09 
B6 T6 1.79 1.61 1.88 2.54 2.16 2.16 2.41 2.27 2.09 2.32 1.96 
B6 T7 2.77 1.91 2.58 3.49 2.98 2.63 2.82 2.77 2.35 3.03 3.00 
B6 T8 2.04 1.58 2.30 2.13 3.20 2.60 3.09 2.92 2.87 2.73 2.94 
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B6 T9 1.77 0.84 1.76 2.26 2.32 2.28 2.54 2.71 2.36 2.16 2.31 
B6 T10 2.03 1.51 1.95 2.32 2.89 2.79 3.11 2.81 2.31 2.23 2.29 
B6 T11 1.85 1.15 2.29 2.33 3.15 2.77 3.53 2.72 2.62 2.45 2.42 
B6 T12 1.89 1.29 2.09 2.34 3.14 2.19 2.41 2.82 2.25 2.28 2.33 
B6 T13 2.50 1.74 2.34 2.34 3.01 2.17 2.45 2.60 2.30 2.45 2.80 
B6 T14 2.29 1.89 2.20 2.37 2.87 2.17 2.45 2.51 2.16 2.51 1.92 
B6 T15 1.95 1.65 1.98 2.21 2.87 2.56 3.33 2.91 2.36 2.48 2.52 
B7 T1 1.19 2.00 2.08 1.87 2.26 2.23 2.73 2.49 2.29 2.51 2.61 
B7 T2 2.35 2.11 2.57 2.32 2.41 2.30 2.77 2.27 2.26 2.35 2.72 
B7 T3 2.59 2.20 3.05 3.00 2.79 2.76 2.76 2.41 3.24 2.79 3.26 
B7 T4 2.46 2.48 2.18 2.83 2.22 2.33 2.64 2.15 1.90 2.25 1.28 
B7 T5 2.70 2.75 3.05 2.91 2.61 3.44 4.22 2.99 3.06 3.41 2.97 
B7 T6 2.26 3.01 3.14 2.83 4.10 3.64 4.50 3.75 3.48 3.87 3.51 
B7 T7 1.67 2.49 4.33 4.50 5.81 5.92 5.60 6.93 6.60 6.60 6.37 
B7 T8 2.13 2.33 2.75 2.58 3.09 3.65 3.34 3.04 3.01 2.86 2.54 
B7 T9 2.24 2.70 3.53 2.94 6.34 D D D D D D 
B7 T10 2.57 2.13 3.07 2.93 2.93 3.03 3.54 D D D D 
B8 T1 1.76 2.90 2.67 D D D D D D D D 
B8 T2 1.01 1.43 2.47 2.72 2.32 2.53 D D D D D 
B8 T3 1.38 1.78 2.62 2.51 2.14 2.06 2.31 2.08 2.93 2.35 2.27 
B8 T4 1.88 2.16 2.43 1.69 2.56 2.78 2.38 2.99 3.32 2.75 2.46 
B8 T5 2.25 2.49 2.86 2.44 3.18 3.40 D D D D D 
B8 T6 1.59 2.17 2.51 1.95 2.43 2.21 2.36 2.27 2.78 2.55 2.22 
B8 T7 1.92 1.98 2.56 2.50 2.89 2.85 1.76 2.59 3.25 2.09 2.82 
B8 T8 1.95 3.05 3.02 D D D D D D D D 
B8 T9 2.04 2.42 2.88 2.64 2.60 2.62 1.85 3.22 3.61 2.55 2.93 
B9 T1 2.77 NA 4.69 6.03 6.30 NA 6.09 6.63 NA 6.55 4.75 
B9 T2 2.42 NA 1.78 1.81 2.11 NA 2.32 2.13 NA 2.35 1.52 
B9 T3 1.81 NA 1.96 1.28 1.87 NA 1.82 1.94 NA 2.18 1.39 
B9 T4 1.90 NA 1.90 0.82 2.11 NA 1.79 2.06 NA 2.27 1.16 
B9 T5 2.89 NA 2.77 2.25 5.00 NA 4.70 4.99 NA 5.52 5.52 
B9 T6 2.22 NA 2.23 1.81 2.11 NA 2.88 2.62 NA 2.26 1.98 
B9 T7 2.35 NA 2.30 1.96 2.06 NA 1.94 2.36 NA 2.16 1.71 
B9 T8 2.07 NA 2.40 2.43 2.43 NA 2.67 3.13 NA 2.62 1.46 
B9 T9 2.58 NA 2.41 2.37 2.83 NA 2.58 2.74 NA 3.23 2.31 
B9 T10 1.57 NA 1.90 2.78 3.24 NA 2.61 2.23 NA 3.71 2.41 
B10 T1 2.50 NA 2.40 2.50 2.62 NA 3.02 3.04 NA 3.14 3.10 
B10 T2 2.14 NA 1.90 2.22 2.33 NA 2.51 2.59 NA 2.24 2.47 
B10 T3 1.77 NA 1.85 1.73 2.60 NA 1.82 2.22 NA 1.77 2.26 
B10 T4 2.12 NA 2.17 3.24 3.03 NA 3.03 3.28 NA 2.88 3.13 
B10 T5 2.04 NA 2.09 3.34 2.41 NA 2.72 2.49 NA 2.58 2.21 
B10 T6 2.38 NA 2.14 3.74 2.55 NA 2.76 2.95 NA 3.10 2.83 
B11 T1 1.57 1.78 1.89 NA D NA D D D D D 
B11 T2 2.17 3.88 5.07 NA D NA D D D D D 
B11 T3 2.10 2.24 2.08 NA 2.12 NA D D D D D 
B11 T4 1.81 1.50 1.44 NA D NA D D D D D 
B11 T5 2.43 1.87 1.72 NA 2.11 NA 1.99 1.93 D D D 
B11 T6 2.43 2.01 2.09 NA 2.25 NA 2.41 2.50 D D D 
B11 T7 2.04 1.91 1.87 NA 2.06 NA D D D D D 
B11 T8 2.20 4.23 4.63 NA D NA D D D D D 
B11 T9 1.79 3.31 3.05 NA D NA D D D D D 
B11 T10 2.42 1.84 1.79 NA D NA D D D D D 
B11 T11 3.37 3.96 3.27 NA 3.43 NA D D D D D 
B11 T12 2.03 1.67 1.45 NA 1.71 NA 1.87 1.79 D D D 
185 
 
B12 T1 2.05 1.79 1.78 2.11 NA 2.06 2.19 1.84 NA 2.25 1.84 
B12 T2 1.77 1.56 1.34 2.13 NA 1.93 2.48 2.07 NA 1.92 1.64 
B12 T3 2.19 1.94 2.06 2.42 2.37 D D D D D D 
B12 T4 1.62 1.58 1.58 1.88 NA 2.12 1.83 2.02 NA 2.27 1.72 
B12 T5 1.76 1.82 1.72 2.01 NA 2.25 2.42 2.20 NA 2.47 2.08 
B12 T6 1.52 1.67 1.58 2.01 NA 1.85 1.86 1.92 NA 1.88 1.56 
B13 T1 1.44 1.31 NA 2.14 D D D D D D D 
B13 T2 1.57 1.55 NA 1.45 NA 1.61 1.64 NA 1.76 1.76 1.80 
B13 T3 1.68 1.78 NA 2.25 D D D D D D D 
B13 T4 1.54 1.66 NA 1.63 NA 1.97 1.73 D D D D 
B13 T5 1.57 1.68 NA 1.54 NA 1.83 2.10 NA 2.45 2.63 2.15 
B13 T6 1.61 1.52 NA 1.36 NA 1.60 1.65 NA 1.49 1.89 1.93 
B14 T1 1.60 1.57 NA 3.05 3.04 D D D D D D 
B14 T2 2.10 2.48 NA 1.99 NA 2.76 3.45 D D D D 
B14 T3 1.71 1.60 NA 0.82 NA 2.20 2.36 D D D D 
B14 T4 1.61 1.81 NA 1.65 NA 1.87 2.36 D D D D 
B14 T5 1.83 2.72 3.30 D D D D D D D D 
B14 T6 1.48 1.78 NA 1.24 NA 1.91 1.79 D D D D 
B15 T1 1.97 NA 2.12 1.68 1.76 NA 2.12 2.12 1.92 NA 1.90 
B15 T2 2.34 NA 3.54 6.74 11.71 D D D D D D 
B15 T3 2.06 NA 2.14 1.64 1.79 NA 2.00 2.63 1.93 NA 2.13 
B15 T4 1.84 NA 2.21 2.30 2.23 NA 2.39 2.21 2.12 NA 2.17 
B15 T5 2.18 NA 2.50 1.97 2.07 NA 2.04 1.89 2.01 NA 2.22 
B15 T6 2.22 NA 2.86 2.61 2.65 NA 2.70 2.46 2.37 NA 2.53 
B15 T7 1.94 NA 2.08 2.04 2.15 NA 2.34 2.25 2.30 NA 2.43 
B15 T8 0.95 NA 1.67 1.58 2.03 NA 1.75 1.92 1.72 NA 1.89 
B15 T9 3.24 NA 3.06 3.06 2.84 NA 2.76 2.95 2.67 NA 2.83 
‘W’ denotes week, ‘C’ denotes control rat, ‘T’ denotes IL-13 transfected rat, ‘NA’ denotes not 




Appendix 4.3: Weekly profile of urine albumin excretion (μg/24hour) in 
control and IL-13 transfected rats 
 
Batch Rat W0 W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 
B6 C1 363 644 396 610 1271 692 862 929 786 824 745 
B6 C2 206 583 258 347 291 383 388 499 741 418 552 
B6 C3 227 195 232 201 168 224 321 235 365 273 454 
B7 C1 115 119 243 128 115 191 88 115 294 124 142 
B7 C2 119 970 150 314 287 211 199 166 213 237 246 
B8 C1 289 320 298 701 270 NA 118 182 140 167 NA 
B8 C2 362 666 776 252 456 NA D D D D D 
B8 C3 745 404 436 D D D D D D D D 
B9 C1 261 NA 270 671 281 NA 183 287 NA 375 493 
B9 C2 281 NA 698 2254 567 NA 553 508 NA 673 901 
B9 C3 453 NA 547 1326 627 NA 499 548 NA 740 753 
B10 C1 146 NA 261 224 563 NA 524 653 NA 344 566 
B10 C2 693 NA 1081 1361 1047 NA 1153 712 NA 1364 615 
B10 C3 1101 NA 448 718 494 NA 405 368 NA 359 591 
B11 C1 916 233 226 NA D NA D D D D D 
B11 C2 364 277 621 NA 1233 NA D D D D D 
B11 C3 143 278 D NA D NA D D D D D 
B11 C4 285 640 594 NA 362 NA 1005 324 D D D 
B12 C1 149 147 154 NA 357 211 203 359 NA 194 133 
B12 C2 146 236 248 NA 889 711 779 1188 NA 969 779 
B12 C3 115 147 185 NA 457 425 397 489 NA 459 234 
B12 C4 108 232 222 NA 173 382 412 445 NA 334 143 
B12 C5 77 113 145 NA 270 355 731 99 NA 220 218 
B12 C6 169 211 314 NA 353 D D D NA D D 
B13 C1 632 614 NA 549 NA 1036 1268 D D D D 
B13 C2 225 200 NA 292 NA 243 275 NA 450 342 162 
B13 C3 255 241 NA 980 NA 259 605 D D D D 
B13 C4 90 196 NA 247 NA 163 142 NA 160 124 148 
B13 C5 400 1012 NA 821 NA 2026 1566 D D D D 
B13 C6 253 333 NA 534 D D D D D D D 
B14 C1 486 635 NA 1098 NA 865 1307 D D D D 
B14 C2 323 245 NA 479 396 D D D D D D 
B14 C3 386 699 NA 624 NA 1024 1539 D D D D 
B14 C4 552 652 NA 1510 922 D D D D D D 
B14 C5 242 308 575 D D D D D D D D 
B14 C6 349 188 NA 609 NA 693 1520 D D D D 
B15 C1 469 NA 258 527 331 NA 535 436 256 NA 250 
B15 C2 453 NA 367 398 215 NA 264 363 354 NA 436 
B15 C3 243 NA 463 554 510 D D D D D D 
B6 T1 364 346 365 620 584 394 540 445 D D D 
B6 T2 3874 3443 2250 3540 705 1005 1466 1483 D D D 
B6 T3 551 510 182 176 206 171 171 152 D D D 
B6 T4 475 481 529 930 1603 2193 1462 785 674 687 1542 
B6 T5 220 404 439 153 160 158 201 116 123 116 176 
B6 T6 387 108 151 356 379 534 1147 1015 629 974 1718 
B6 T7 409 474 630 307 299 224 205 191 162 130 180 
B6 T8 2928 505 504 763 386 756 497 510 587 1107 868 
187 
 
B6 T9 282 402 311 600 714 334 601 713 747 550 1563 
B6 T10 1196 292 210 247 207 243 246 165 163 132 170 
B6 T11 6388 807 671 508 736 891 480 618 489 404 369 
B6 T12 175 277 197 149 151 144 137 109 134 110 146 
B6 T13 125 139 168 149 323 254 560 642 627 809 524 
B6 T14 360 236 208 238 280 203 183 187 187 172 87 
B6 T15 822 431 805 1393 480 940 1101 1185 826 881 3041 
B7 T1 78 231 535 524 117 199 240 153 209 240 312 
B7 T2 148 166 268 213 95 201 132 124 113 278 247 
B7 T3 139 98 143 129 98 107 106 154 73 96 128 
B7 T4 359 704 1006 248 326 284 238 185 162 289 213 
B7 T5 311 1843 3618 5833 15053 1882 5792 9484 21357 37381 21015 
B7 T6 125 238 293 103 126 177 173 138 208 249 1095 
B7 T7 182 125 333 276 107 234 1273 391 637 1333 1067 
B7 T8 86 114 149 94 92 126 120 148 144 140 165 
B7 T9 129 77 110 5292 10042 D D D D D D 
B7 T10 216 369 451 719 484 281 520 D D D D 
B8 T1 1276 655 986 D D D D D D D D 
B8 T2 373 191 252 95 158 313 D D D D D 
B8 T3 129 78 88 157 101 84 124 101 109 91 119 
B8 T4 292 226 303 388 1608 737 833 1716 1757 4165 1378 
B8 T5 163 131 149 167 197 178 D D D D D 
B8 T6 826 307 415 227 274 125 290 329 176 147 190 
B8 T7 226 323 196 329 286 98 164 407 230 222 516 
B8 T8 400 329 645 D D D D D D D D 
B8 T9 346 398 597 866 348 346 283 1255 405 457 1015 
B9 T1 157 NA 108 103 165 NA 249 327 NA 418 510 
B9 T2 505 NA 270 329 209 NA 192 148 NA 179 179 
B9 T3 164 NA 164 136 47 NA 65 118 NA 133 136 
B9 T4 193 NA 295 203 925 NA 314 580 NA 559 465 
B9 T5 188 NA 205 111 109 NA 190 145 NA 437 245 
B9 T6 668 NA 886 907 1166 NA 1878 980 NA 1594 2206 
B9 T7 215 NA 167 123 153 NA 117 113 NA 258 521 
B9 T8 236 NA 606 535 901 NA 1355 1225 NA 2408 2211 
B9 T9 168 NA 156 293 220 NA 268 242 NA 310 664 
B9 T10 245 NA 197 70 72 NA 101 106 NA 200 197 
B10 T1 251 NA 214 276 392 NA 639 600 NA 673 602 
B10 T2 249 NA 241 196 312 NA 454 613 NA 854 652 
B10 T3 434 NA 956 468 648 NA 520 355 NA 170 226 
B10 T4 736 NA 593 158 385 NA 504 545 NA 576 546 
B10 T5 368 NA 581 353 373 NA 558 322 NA 341 609 
B10 T6 318 NA 606 1751 1883 NA 3281 6263 NA 3597 24487 
B11 T1 165 268 199 NA D NA D D D D D 
B11 T2 484 202 D NA D NA D D D D D 
B11 T3 293 197 225 NA 285 NA D D D D D 
B11 T4 237 452 544 NA D NA D D D D D 
B11 T5 182 198 244 NA 226 NA 607 548 D D D 
B11 T6 516 440 337 NA 690 NA 2230 2576 D D D 
B11 T7 211 232 226 NA 496 NA D D D D D 
B11 T8 242 275 D NA D NA D D D D D 
B11 T9 380 269 D NA D NA D D D D D 
B11 T10 352 191 232 NA D NA D D D D D 
B11 T11 237 427 522 NA 891 NA D D D D D 
B11 T12 229 340 180 NA 457 NA 311 1028 D D D 
188 
 
B12 T1 120 144 143 NA 210 257 341 316 NA 330 292 
B12 T2 100 152 155 NA 291 307 1240 542 NA 479 459 
B12 T3 193 197 215 NA 308 D D D NA D D 
B12 T4 155 356 355 NA 713 2021 2349 2013 NA 1997 1564 
B12 T5 135 515 308 NA 487 1724 1380 1393 NA 7584 1729 
B12 T6 177 451 577 NA 904 731 1059 1375 NA 1268 660 
B13 T1 170 129 NA 104 D D D D D D D 
B13 T2 512 1335 NA 2895 NA 1909 2548 NA 2946 1688 1050 
B13 T3 452 270 NA 2633 D D D D D D D 
B13 T4 250 323 NA 333 NA 808 176 D D D D 
B13 T5 331 264 NA 377 NA 348 145 NA 977 554 472 
B13 T6 399 312 NA 495 NA 224 333 NA NA 533 400 
B14 T1 233 344 NA 308 268 D D D D D D 
B14 T2 179 200 NA 551 NA 1002 2322 D D D D 
B14 T3 544 1359 NA 555 NA 1577 1665 D D D D 
B14 T4 235 262 NA 213 NA 614 470 D D D D 
B14 T5 572 134 290 D D D D D D D D 
B14 T6 447 319 NA 1390 NA 719 302 D D D D 
B15 T1 251 NA 308 236 464 NA 784 1304 1956 NA 2318 
B15 T2 216 NA 1234 1877 10239 D D D D D D 
B15 T3 343 NA 363 705 6064 NA 930 673 1235 NA 2502 
B15 T4 203 NA 581 964 463 NA 679 1517 601 NA 1173 
B15 T5 323 NA 377 579 327 NA 580 438 492 NA 656 
B15 T6 229 NA 495 928 199 NA 486 630 1030 NA 935 
B15 T7 1072 NA 1175 2638 1766 NA 2830 2823 2802 NA 2500 
B15 T8 233 NA 1899 2342 5062 NA 2171 3277 2059 NA 3478 
B15 T9 455 NA 176 352 353 NA 397 515 613 NA 613 
‘W’ denotes week, ‘C’ denotes control rat, ‘T’ denotes IL-13 transfected rat, ‘NA’ denotes not 






























B11 C3 36 1.65 31.0 81.1 278 196 8.4 
B12 C1 19 1.87 44.1 70.5 133 241 10.0 
B12 C3 15 2.00 36.3 96.4 234 284 10.1 
B12 C4 12 1.93 35.6 114.1 143 300 9.9 
B12 C6 26 1.88 44.2 95.2 353 241 8.8 
B13 C2 13 1.60 35.0 91.1 162 311 10.3 
B13 C4 10 2.03 36.0 91.1 148 251 7.4 
B14 C2 29 1.73 34.3 116.9 396 222 7.7 
B15 C2 26 1.89 37.8 106.8 436 270 10.5 
B7 T1 112 2.61 44.2 94.0 312 278 13.6 
B8 T2 518 2.53 42.3 83.5 313 259 11.1 
B8 T3 1904 2.27 41.7 87.6 119 264 10.8 
B8 T5 871 3.40 43.1 65.7 178 248 12.6 
B8 T6 494 2.22 39.9 91.5 190 285 10.9 
B8 T7 212 2.82 46.0 96.2 516 284 11.8 
B8 T8 448 3.02 48.5 74.0 645 223 10.6 
B11 T2 2040 5.07 46.6 89.3 202 221 14.0 
B11 T8 2161 4.63 37.1 105.7 275 232 17.2 
B11 T9 1170 3.05 36.0 88.6 269 214 11.5 
B13 T1 4420 2.14 32.8 85.8 104 239 14.0 
B13 T5 302 2.15 31.8 76.6 472 289 9.0 
B14 T1 1742 3.04 37.1 61.8 268 245 11.8 
B14 T4 680 2.36 38.1 65.8 470 236 9.0 
B14 T5 1218 3.30 36.3 55.3 290 208 11.4 






Appendix 4.5: Plasma lipid profile of control and HC rats after overnight 
fasting 
 







B12 C6 1.88 1.23 0.43 0.49 
B12 C1 1.87 0.81 0.52 1.18 
B12 C3 2.00 1.41 0.33 0.55 
B13 C2 1.60 0.86 0.56 0.39 
B13 C4 2.03 1.18 0.64 0.45 
B14 C2 1.73 1.19 0.32 0.48 
B13 T1 2.14 1.33 0.52 0.62 
B13 T5 2.15 1.41 0.53 0.44 
B14 T5 3.30 2.30 0.71 0.62 
B14 T1 3.04 1.89 0.90 0.56 
B14 T4 2.36 1.46 0.76 0.31 




Appendix 4.6: Liver cholesterol profile of control and HC rats 
 





B11 C3 1.46 1.19 0.28 
B12 C1 0.77 0.66 0.11 
B12 C3 0.82 0.68 0.14 
B12 C4 1.07 0.79 0.27 
B12 C6 0.93 0.70 0.23 
B13 C2 1.05 0.93 0.12 
B13 C4 1.12 0.97 0.15 
B14 C2 0.91 0.74 0.17 
B15 C2 0.83 0.74 0.10 
B7 T1 0.79 0.69 0.11 
B8 T2 0.86 0.68 0.19 
B8 T3 0.87 0.74 0.14 
B8 T5 0.92 0.72 0.20 
B8 T6 0.84 0.72 0.12 
B8 T7 0.88 0.74 0.14 
B8 T8 0.95 0.67 0.28 
B11 T2 1.17 0.94 0.23 
B11 T8 1.14 0.92 0.21 
B11 T9 0.89 0.69 0.21 
B13 T1 0.71 0.62 0.10 
B13 T5 1.11 0.89 0.22 
B14 T1 0.83 0.69 0.15 
B14 T4 1.01 0.84 0.17 
B14 T5 0.82 0.64 0.19 






Appendix 4.7: Hepatic mRNA expression index was of IL-13 receptor subunits and cholesterol metabolic genes in control and HC rats 
Batch Rat IL-4Ra IL-13Ra1 IL-13Ra2 SREBF2 HMGCR ACAT2 LXRa RXRa CYP7A1 LDLR ABCA1 ABCG5 
B11 C3 4.07E-01 1.16E-01 6.22E-03 1.90E-02 1.26E-01 2.43E-02 1.84E-01 8.80E-02 7.63E-02 2.03E-03 4.68E-02 1.40E-01 
B12 C1 2.57E-01 2.85E-01 2.56E-03 3.57E-02 7.34E-02 3.93E-02 2.13E-01 1.79E-01 2.61E-02 4.34E-03 8.28E-02 2.62E-02 
B12 C3 2.94E-01 3.33E-01 3.76E-03 5.01E-02 1.33E-01 3.15E-02 2.63E-01 2.13E-01 2.40E-02 6.98E-03 8.90E-02 3.80E-02 
B12 C4 2.43E-01 3.03E-01 4.36E-03 4.74E-02 1.19E-01 4.06E-02 2.02E-01 1.49E-01 1.16E-02 5.43E-03 8.91E-02 1.29E-01 
B12 C6 4.63E-01 4.94E-01 1.98E-02 5.16E-02 1.61E-01 3.90E-02 2.60E-01 2.44E-01 1.33E-01 5.70E-03 1.21E-01 2.01E-01 
B13 C2 3.95E-01 5.14E-01 3.20E-02 3.75E-02 1.76E-01 3.81E-02 3.32E-01 2.01E-01 8.36E-02 4.29E-03 1.16E-01 3.40E-02 
B13 C4 5.72E-01 4.48E-01 2.10E-02 3.11E-02 1.42E-01 4.51E-02 3.15E-01 1.79E-01 5.14E-02 2.80E-03 1.05E-01 1.03E-01 
B14 C2 7.34E-01 6.60E-01 2.20E-02 4.68E-02 1.13E-01 4.69E-02 4.50E-01 2.47E-01 7.45E-02 1.47E-03 1.01E-01 1.41E-01 
B15 C2 5.69E-01 5.40E-01 6.03E-03 5.40E-02 1.11E-01 5.50E-02 3.75E-01 2.32E-01 5.68E-02 7.08E-03 9.77E-02 7.18E-03 
B7 T1 3.17E-01 3.34E-01 2.35E-02 3.29E-02 5.64E-02 2.96E-02 2.62E-01 1.07E-01 9.20E-02 3.14E-03 5.59E-02 1.50E-02 
B8 T2 2.98E-01 2.81E-01 2.95E-02 3.57E-02 6.14E-02 3.22E-02 1.74E-01 1.19E-01 1.41E-02 4.87E-03 5.79E-02 2.92E-02 
B8 T3 2.56E-01 3.10E-01 8.75E-02 3.70E-02 8.01E-02 2.19E-02 2.06E-01 1.20E-01 6.92E-02 5.81E-03 6.32E-02 1.26E-02 
B8 T5 9.55E-01 2.37E-01 9.70E-02 3.67E-02 1.02E-01 2.22E-02 1.34E-01 9.71E-02 2.43E-02 6.64E-03 6.64E-02 6.40E-02 
B8 T6 4.16E-01 3.68E-01 5.96E-02 7.06E-02 1.58E-01 3.82E-02 1.98E-01 1.38E-01 1.52E-01 8.78E-03 7.47E-02 1.55E-01 
B8 T7 1.34E+00 3.61E-01 5.24E-02 4.28E-02 1.35E-01 3.55E-02 2.40E-01 1.73E-01 1.77E-01 8.25E-03 9.38E-02 5.50E-02 
B8 T8 4.38E-01 2.54E-01 2.92E-02 2.52E-02 1.14E-01 2.58E-02 2.07E-01 1.49E-01 1.38E-02 3.23E-03 5.49E-02 9.37E-02 
B11 T2 6.98E-01 2.23E-01 7.83E-02 2.95E-02 1.04E-01 3.51E-02 1.66E-01 9.85E-02 9.26E-02 2.92E-03 5.23E-02 2.25E-03 
B11 T8 2.87E-01 1.33E-01 3.98E-02 2.28E-02 7.27E-02 2.22E-02 1.52E-01 8.50E-02 3.90E-02 1.79E-03 5.34E-02 7.73E-04 
B11 T9 5.12E-01 1.69E-01 7.37E-02 2.13E-02 5.75E-02 2.29E-02 1.69E-01 1.19E-01 3.85E-02 1.24E-03 6.16E-02 1.75E-02 
B13 T1 2.10E-01 3.39E-01 4.03E-01 2.81E-02 1.33E-01 2.99E-02 1.95E-01 1.17E-01 1.63E-01 3.00E-03 7.54E-02 9.99E-03 
B13 T5 3.81E-01 3.04E-01 1.38E-01 1.67E-02 4.99E-02 2.26E-02 2.36E-01 1.36E-01 8.14E-03 1.51E-03 7.61E-02 1.39E-02 
B14 T1 5.42E-01 4.79E-01 2.17E-01 3.22E-02 1.27E-01 3.43E-02 2.38E-01 1.96E-01 1.80E-01 1.67E-03 8.97E-02 2.47E-03 
B14 T4 6.08E-01 6.03E-01 1.17E-01 3.12E-02 6.35E-02 2.92E-02 3.33E-01 2.87E-01 9.57E-02 2.03E-03 1.14E-01 7.51E-03 
B14 T5 4.97E-01 6.62E-01 2.37E-01 3.80E-02 1.56E-01 3.25E-02 2.66E-01 2.10E-01 1.51E-01 2.48E-03 9.69E-02 9.19E-03 





Appendix 4.8: Hepatic protein concentration of ABCG5 in control and 
HC rats 
 
Batch Rat Concentration of liver ABCG5 (ng/ml) 
B11 C3 340 
B12 C1 299 
B12 C3 258 
B12 C4 365 
B12 C6 426 
B13 C2 334 
B13 C4 499 
B14 C2 484 
B15 C2 306 
B7 T1 192 
B8 T2 237 
B8 T3 301 
B8 T5 265 
B8 T6 251 
B8 T7 260 
B8 T8 245 
B11 T2 270 
B11 T8 264 
B11 T9 254 
B13 T1 218 
B13 T5 494 
B14 T1 359 
B14 T4 448 
B14 T5 290 




Appendix 4.9: Hepatic protein expression index was of IL-4Ra, IL-13Ra2, 
ABCA1 and LXRa in control and HC rats 
 
Batch Rat IL-4Ra IL-13Ra2 ABCA1 LXRa 
B11 C3 0.68 0.45 2.24 0.57 
B12 C1 0.50 0.61 NA 0.95 
B12 C3 0.55 0.52 3.31 0.65 
B12 C4 0.61 0.29 3.16 0.60 
B12 C6 0.54 0.83 2.01 0.93 
B13 C2 0.92 0.40 1.32 1.08 
B13 C4 1.08 0.18 1.72 0.85 
B14 C2 0.73 1.07 1.79 1.07 
B15 C2 0.42 0.63 0.95 0.66 
B7 T1 NA NA 0.99 0.97 
B8 T2 NA NA 1.08 0.87 
B8 T3 0.40 0.77 1.00 1.14 
B8 T5 0.25 0.31 1.33 0.50 
B8 T6 0.62 1.58 1.43 1.17 
B8 T7 0.44 0.68 0.75 1.00 
B8 T8 0.43 0.55 1.29 0.46 
B11 T2 0.48 0.41 1.84 0.41 
B11 T8 0.29 0.86 1.27 0.29 
B11 T9 0.42 0.72 0.98 0.73 
B13 T1 0.70 0.64 1.50 0.74 
B13 T5 2.64 1.09 1.06 1.02 
B14 T1 0.42 0.45 1.83 1.33 
B14 T4 0.81 0.73 1.46 1.07 
B14 T5 0.43 0.57 1.68 0.67 
Protein expression index was normalized against GAPDH. Rat column starting with ‘C’ 





Appendix 4:10: Correlation values for hepatic protein expression of 
LXRa and plasma total cholesterol in HC rats 
 
Batch Rat Protein expression index was of LXRa Plasma total cholesterol (mmol/l) 
B7 T1 0.97 2.61 
B8 T2 0.87 2.53 
B8 T3 1.14 2.27 
B8 T5 0.50 3.40 
B8 T6 1.17 2.22 
B8 T7 1.00 2.82 
B8 T8 0.46 3.02 
B11 T2 0.41 5.07 
B11 T8 0.29 4.63 
B11 T9 0.73 3.05 
B13 T1 0.74 2.14 
B13 T5 1.02 2.15 
B14 T1 1.33 3.04 
B14 T4 1.07 2.36 





Appendix 5.1: mRNA expression index was of IL-13 receptor subunits 




Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 1.98E-01 1.98E-01 3.96E-02 2.99E-02 
H38 2.12E-01 2.47E-01 3.88E-02 3.15E-02 
H39 2.17E-01 2.17E-01 3.85E-02 3.00E-02 
H42 2.42E-01 3.28E-01 3.33E-02 3.26E-02 
H43 3.04E-01 3.38E-01 2.71E-02 2.79E-02 
 
SREBF2 HMGCR ACAT2 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 8.13E-03 7.45E-03 8.83E-02 4.40E-02 6.97E-03 8.43E-03 
H38 7.40E-03 8.23E-03 5.66E-02 3.43E-02 5.81E-03 7.96E-03 
H39 6.84E-03 6.85E-03 6.51E-02 3.47E-02 6.04E-03 7.19E-03 
H42 7.93E-03 8.65E-03 6.25E-02 4.18E-02 7.18E-03 8.73E-03 
H43 1.01E-02 9.95E-03 5.55E-02 3.51E-02 8.55E-03 1.02E-02 
 
LXRa RXRa CYP7A1 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 9.48E-03 6.97E-03 2.56E-02 1.83E-02 5.63E-05 1.50E-05 
H38 8.72E-03 4.93E-03 1.84E-02 1.35E-02 1.34E-04 9.68E-06 
H39 5.36E-03 3.06E-03 1.79E-02 1.31E-02 1.16E-04 2.85E-05 
H42 6.39E-03 4.80E-03 1.89E-02 1.43E-02 1.28E-05 4.21E-06 
H43 1.05E-02 7.31E-03 3.54E-02 2.61E-02 2.03E-05 7.37E-06 
 
LDLR ABCA1 ABCG5 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 1.19E-03 1.29E-03 3.65E-02 1.96E-02 1.45E-04 4.49E-04 
H38 1.60E-03 1.74E-03 1.47E-02 9.20E-03 1.04E-04 4.18E-04 
H39 2.64E-03 2.60E-03 2.52E-02 1.73E-02 5.40E-05 2.13E-04 
H42 3.02E-03 2.83E-03 1.63E-02 1.13E-02 5.98E-05 2.22E-04 
H43 3.51E-03 3.25E-03 4.09E-02 1.90E-02 4.61E-05 9.37E-05 
 




Appendix 5.2: Protein expression index was of LXRa and ABCA1, and 




Batch Unstimulated IL-13-stimulated 
H16 0.72 0.47 
H18 0.52 0.79 
H20 0.81 0.94 
H21 0.35 0.43 
H29 0.66 0.68 
H36 0.51 0.36 
 
ABCA1 
Batch Unstimulated IL-13-stimulated 
H16 1.68 1.16 
H18 0.69 0.81 
H20 0.74 0.57 
H21 0.71 0.50 
H29 0.67 0.54 
H36 0.69 0.41 
 
ABCG5 (ng/ml) 
Batch Unstimulated IL-13-stimulated 
H76 87 105 
H79 140 82 
H81 95 76 
H82 66 77 
H87 87 92 
H89 50 54 
 





Appendix 5.3: Temporal mRNA expression index was of LXRa, RXRa, ABCA1, ABCG5 and CYP7A1 in unstimulated and IL-13-
stimulated hepatocytes 
LXRa 2H 4H 6H 8H 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 9.55E-03 7.37E-03 9.53E-03 8.86E-03 9.67E-03 8.82E-03 1.27E-02 1.08E-02 
H38 6.88E-03 6.07E-03 8.09E-03 7.01E-03 9.19E-03 8.96E-03 9.20E-03 8.39E-03 
H39 5.64E-03 4.81E-03 6.15E-03 5.23E-03 7.03E-03 6.06E-03 7.24E-03 5.57E-03 
H41 4.58E-03 3.86E-03 5.28E-03 4.50E-03 6.08E-03 4.38E-03 5.31E-03 5.20E-03 
H42 3.67E-03 3.64E-03 4.35E-03 3.49E-03 4.24E-03 3.13E-03 5.26E-03 3.39E-03 
 
RXRa 2H 4H 6H 8H 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 2.85E-02 2.13E-02 2.37E-02 1.97E-02 2.33E-02 2.25E-02 2.68E-02 2.21E-02 
H38 1.94E-02 1.86E-02 2.00E-02 1.84E-02 2.14E-02 1.95E-02 2.23E-02 1.97E-02 
H39 1.88E-02 1.66E-02 1.78E-02 1.68E-02 1.74E-02 1.67E-02 1.90E-02 1.69E-02 
H41 1.83E-02 1.75E-02 1.53E-02 1.51E-02 1.68E-02 1.27E-02 1.65E-02 1.42E-02 
H42 2.04E-02 1.98E-02 1.76E-02 1.40E-02 1.62E-02 1.33E-02 1.59E-02 1.41E-02 
 
ABCA1 2H 4H 6H 8H 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 5.60E-02 4.95E-02 5.38E-02 5.27E-02 5.40E-02 5.23E-02 4.71E-02 4.33E-02 
H38 3.33E-02 3.42E-02 3.61E-02 3.72E-02 3.61E-02 3.07E-02 2.66E-02 2.16E-02 
H39 4.61E-02 4.38E-02 4.54E-02 4.41E-02 4.06E-02 3.86E-02 3.45E-02 3.21E-02 
H41 4.67E-02 4.57E-02 4.43E-02 4.62E-02 4.20E-02 3.62E-02 3.11E-02 2.84E-02 





ABCG5 2H 4H 6H 8H 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 6.71E-04 1.30E-03 5.98E-04 1.04E-03 4.41E-04 1.11E-03 3.36E-04 9.16E-04 
H38 8.63E-04 1.38E-03 6.49E-04 1.42E-03 4.25E-04 1.33E-03 3.07E-04 1.12E-03 
H39 3.50E-04 5.29E-04 2.42E-04 3.90E-04 1.63E-04 4.54E-04 1.10E-04 3.39E-04 
H41 6.87E-04 1.22E-03 3.46E-04 8.91E-04 2.88E-04 6.05E-04 2.92E-04 7.02E-04 
H42 5.22E-04 9.03E-04 3.67E-04 5.03E-04 2.28E-04 3.85E-04 1.96E-04 3.41E-04 
 
CYP7A1 2H 4H 6H 8H 
Batch Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated Unstimulated IL-13-stimulated 
H35 2.91E-04 4.41E-04 3.80E-04 3.27E-04 4.30E-04 2.53E-04 2.37E-04 2.06E-04 
H38 1.45E-04 2.38E-04 1.28E-04 1.69E-04 8.23E-05 1.06E-04 5.91E-05 4.94E-05 
H39 3.46E-04 4.62E-04 3.38E-04 3.05E-04 2.94E-04 2.16E-04 2.93E-04 1.57E-04 
H41 5.66E-05 5.50E-05 2.18E-05 4.72E-05 3.07E-05 2.79E-05 2.67E-05 3.70E-05 
H42 5.04E-05 2.58E-05 2.68E-05 1.75E-05 1.78E-05 1.32E-05 1.86E-05 1.12E-05 
 




Appendix 5.4: Percentage of [3H]-cholesterol efflux using apoA-I and 
taurocholate, and intracellular cholesterol level in unstimulated and IL-
13-stimulated hepatocytes 
 
5µg/ml ApoA-I-mediated [3H]-cholesterol efflux (%) 
Batch Unstimulated IL-13-stimulated 
H100a 8.38 7.53 
H100b 8.02 6.78 
H102 8.02 5.49 
H104 6.95 6.09 
H105 7.88 5.37 
H107 7.52 6.63 
 
10mM Taurocholate-mediated [3H]-cholesterol efflux (%) 
Batch Unstimulated IL-13-stimulated 
H76 13.51 12.02 
H77 13.50 11.51 
H78 14.99 11.19 
H80 16.34 13.91 
H81 17.97 16.32 
H82 8.32 6.51 
H83 13.71 12.99 
H86 8.10 8.00 
H90 15.30 14.92 
H92 17.76 17.17 
 
Intracellular cholesterol level (µg/mg) 
Batch Unstimulated IL-13-stimulated 
H1 188 187 
H2 218 201 
H3 308 257 
H4 172 201 





Appendix 5.5: mRNA and protein expression index was of LXRa in NTC-
transfected and LXRa-knockdown hepatocytes under unstimulated and 
T0901317-stimulated conditions 
 
LXRa gene expression 
Batch NTC LXRa siRNA NTC +T LXRa siRNA +T 
H103a 3.90E-02 9.90E-03 2.13E-02 4.50E-03 
H103b 3.31E-02 9.00E-03 2.29E-02 6.00E-03 
H107 7.14E-02 2.31E-02 6.58E-02 1.89E-02 
H116a 2.75E-02 2.70E-03 2.08E-02 2.90E-03 
H116b 2.89E-02 5.40E-03 1.92E-02 3.20E-03 
Gene expression index was normalized against b-actin. 
 
LXRa protein expression 
Batch NTC LXRa siRNA NTC +T LXRa siRNA +T 
H101 6.37E-01 3.17E-01 NA NA 
H103a 6.91E-01 5.41E-01 4.22E-01 3.35E-01 
H103b 5.51E-01 5.64E-01 4.22E-01 3.68E-01 









Appendix 5.6: mRNA and protein expression index was of ABCA1 and 
ABCG5 in NTC-transfected and LXRa-knockdown hepatocytes under 
unstimulated and T0901317-stimulated conditions 
 
ABCA1 gene expression 
Batch NTC LXRa siRNA NTC +T LXRa siRNA +T 
H103a 1.69E-02 1.22E-02 8.69E-02 6.08E-02 
H103b 1.34E-02 1.26E-02 8.40E-02 6.71E-02 
H107 4.42E-02 4.66E-02 1.44E-01 9.37E-02 
H116a 2.21E-02 9.30E-03 2.04E-01 1.47E-01 
H116b 2.06E-02 1.29E-02 1.98E-01 1.26E-01 
 
ABCG5 gene expression 
Batch NTC LXRa siRNA NTC +T LXRa siRNA +T 
H103a 1.35E-04 5.70E-05 4.33E-03 8.99E-04 
H103b 6.00E-05 6.70E-05 5.92E-03 1.37E-03 
H107 5.20E-04 6.76E-04 1.91E-02 5.56E-03 
H116a 1.35E-04 2.60E-05 2.00E-03 6.40E-05 
H116b 2.49E-04 7.60E-05 2.37E-03 3.00E-04 
 
Gene expression index was normalized against b-actin. 
 
ABCA1 protein expression 
Batch NTC LXRa siRNA NTC +T LXRa siRNA +T 
H101 1.27E+00 9.37E-01 NA NA 
H103a 2.78E-01 2.55E-01 7.11E-01 6.12E-01 
H103b 2.27E-01 1.62E-01 8.48E-01 4.80E-01 
Protein expression index was normalized against GAPDH. ‘NA’ denotes not applicable. 
 
